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EXECUTIVE SUMMARY 
Investment in medical research is vital to the continuing improvement of the UK‟s 
health and wealth. It is through research that we expand our understanding of 
disease and develop new treatments for patients. Medical research charities 
currently contribute over £1 billion annually to medical research in the UK, of 
which over £350 million is provided by Cancer Research UK. Many charities, 
including Cancer Research UK, receive no government funding for their research 
activity. 
Cancer Research UK is engaged in a programme of work in order to better 
understand the medical research funding environment and demonstrate the 
importance of sustained investment. A key part of that is the Office of Health 
Economics‟ (OHE) 2011 report “Exploring the interdependency between public 
and charitable medical research”. This study found that there are substantial 
benefits, both financial and qualitative, from the existence of a variety of funders 
and that reductions in the level of government financial support for medical 
research are likely to have broader negative effects. 
This contributed to other evidence which found that the activities and funding of 
the charity, public and private sectors respectively are complementary, i.e. 
mutually reinforcing, rather than duplicative or merely substituting for one 
another.  
“Exploring the interdependencies of research funders in the UK” by the Office of 
Health Economics (OHE) and SPRU: Science and Technology Policy Research at 
the University of Sussex, represents a continued effort to build the evidence base 
around the funding of medical research.  
This report uncovers the extent to which funders of cancer research are 
interdependent, nationally and internationally. Key figures show that two 
thirds of publications acknowledging external support have relied on 
multiple funders, while just under half benefited from overseas funding, 
and almost a fifth are also supported by industry. In addition the analysis 
shows that the general public would not want tax funding of cancer 
research to be reduced, but would not donate enough to charities to 
compensate for any such reduction. 
Exploring the interdependencies between different medical research funders, 
particularly in cancer, provides us with a striking picture of the extent to which 
research funders contribute together to produce world class research. The 
findings provide a compelling case for why investment - by all sectors - is needed 
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KEY FINDINGS 
ECONOMIES OF SCALE IN MEDICAL RESEARCH 
A cut in research funding by a research funder might cause a slightly 
disproportionate fall in research activity, demonstrating a small effect of 
economies of scale.  
 However, beyond the short term, economies of scale appear to be 
exhausted at small sizes of research teams and research projects. 
 There are exceptions of a few projects that entail expensive and highly 
specific equipment, IT systems or buildings that demonstrate the 
existence of economies of scale. 
 
FUNDING COMPLEMENTARITIES AND INTERDEPENDENCIES IN 
NEOPLASMS RESEARCH 
The UK produced almost 7% of global research publications on 
neoplasms1 in 2011. To achieve this, scientists’ host organisations and 
their funders worked in an interdependent and complementary way. 
 Over 1,000 UK organisations contributed to neoplasms research papers, 
and in doing so collaborated with co-authors in over 5,000 non-UK 
organisations.  
 Funding acknowledgements appear in half of all publications and reveal 
that these papers by UK researchers benefited from the support of over 
650 distinct UK funders and over 1,500 non-UK funders, as well as over 
300 private organisations (many of them multinational). 
 These publications were supported by an average of more than three 
funders per publication.     
 Major funders strongly focus on pathology and genetics while surgery is 
relatively neglected. 
 Minor UK funders are complementary to major UK funders as they focus 
on distinct neoplasm types.  
 
COMPLEMENTARITY/SUBSTITUTABILITY OF GOVERNMENT AND CHARITY 
FUNDING OF CANCER RESEARCH IN THE UK 
Most of the public’s decisions about how much to donate to cancer 
research or other medical research charities are unaffected by 
government decisions on funding cancer or other medical research. 
 The vast majority of respondents stated that their out-of-pocket donations 
to cancer research and other medical research charities would not be 
affected by changes in government funding levels or by being given the 
opportunity to allocate £100 of their income tax to these charities.  
                                           
1 Neoplasms are abnormal masses of tissue arising from an abnormal proliferation of cells. 
This term covers all forms of cancer research. 
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1. INTRODUCTION AND CONTEXT 
The UK makes a disproportionately strong and successful contribution to the 
global medical research effort. An important element of this is the role of medical 
research charities alongside the public sector and private industry. Charities 
currently contribute over £1 billion annually to medical research in the UK (AMRC, 
2013), about one third of which is provided by Cancer Research UK. 
The public, charity and private sectors bring different strengths and emphases. 
The evidence is that the three sectors‟ activities and funding are complementary, 
i.e. mutually reinforcing, rather than duplicative or merely substituting for one 
another (Cancer Research UK, 2011; HERG et al., 2008; OHE, 2009; OHE, 2011). 
Taken together, this combined medical research effort generates not only health 
benefits to people all over the world, but also important economic gains to the UK 
(HERG et al., 2008). 
The Government‟s June 2013 Spending Round maintained public funding of 
science research, including medical research, in cash terms until 2015/16, 
implying a gradual squeeze in real terms given expected inflation (as measured 
by the GDP deflator) of 2% per year (HM Treasury, 2013). The period of austerity 
and consequent pressure to constrain public expenditure is likely to continue 
beyond then. 
Cancer Research UK was interested in gaining further understanding of the 
following: 
a) What is the difference between the diverse research activities supported 
by funders in the UK? Do these research activities complement one 
another? How interdependent are these research activities? 
b) If there was a cut in government funding for life sciences would other 
funders (private and public) be able to continue to support research 
activities? What would be the impact on the life sciences output in the UK? 
In March 2013 Cancer Research UK awarded a grant to the Office of Health 
Economics (OHE) and SPRU: Science and Technology Policy Research at the 
University of Sussex to help answer these questions. This report sets out our 
work and has the following main elements: 
 A high level investigation of the likely extent of economies of scale in 
charity- and publicly-funded medical research in the UK. It is based on a 
review of academic and grey literature on economies of scale in medical 
research, and a programme of interviews with major UK medical research 
funders plus analysis of cost data provided by them. This part of our work 
is reported in Chapter 2. 
 Scientometric analysis (that is the science of measuring scientific 
research) was undertaken to establish the interdependencies and the 
differences between the diverse research activities supported by different 
funders of cancer research in the UK. This is reported in Chapter 3. We 
looked at research publications and tracked back to the funders identified 
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through these outputs. Our strategy made no a priori judgements on 
where UK researchers obtain funding and the results show the relative 
importance of all funders named or acknowledged in papers, including 
non-UK funders and industry. 
 A study of the complementarity or substitutability of government and 
charity funding of cancer research in the UK, including a literature review. 
The main focus of this strand of our research is an internet survey of a 
sample of the UK general population. We use a stated preference design, 
informed by a prior focus group workshop, to assess how a change in 
Government funding of cancer research might affect public willingness to 
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The impact on the output of medical research in the UK of a hypothetical cut in 
government funding depends on the answers to two questions: 
 would changes in government funding affect the general public‟s donations 
to medical research charities? 
 to what extent are there economies of scale in medical research? If 
economies of scale are significant then a 1% cut in medical research 
spending would reduce the outputs from that research by more than 1%. 
We address the first of these questions in Chapter 4. Answering the second 
question is the subject of the remainder of the present chapter. 
The presence (or not) of economies of scale is detected by measuring marginal 
costs relative to average costs. If marginal costs are below average costs then 
there are economies of scale: increasing the amount of activity would reduce the 
average cost of that activity; and conversely, reducing the amount of activity 
would raise the average cost of that activity. 
Economies of scale are generated by the existence of fixed costs. In the short 
run, e.g. within a year, many costs may be „fixed‟: not only the costs of buildings 
and equipment used but also overhead costs such as those of IT and information 
services, finance, personnel and general management staff. Over time many of 
the costs that are fixed in the short term become variable: overheads can be 
Key Points 
 There is some evidence in the literature of the existence of economies of 
scale in research but it is from a nearly 20-year old US study and is not 
specific to medical research. 
 In the short term, cost data from UK medical research funders suggests a 
hypothetical 1% cut in research funding might initially cause an 
approximately 1.3% fall in research activity, but in the medium to long term 
the impact would be more proportionate. 
 Beyond the short term, economies of scale appear to be exhausted at small 
sizes of research teams and research projects, with the exception of a few 
projects that entail expensive and highly specific equipment, IT systems or 
buildings. 
 But even temporary cuts in funding can have long lasting consequences: 
reduced funding means less work for researchers in the UK, meaning that 
some will either leave the country or change careers, and not all would return 
to the UK or to research were funding to be increased again later. 
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scaled down or up; buildings and equipment can be turned to other uses, sold off, 
or simply not replaced when they wear out. Some costs may never be variable 
though. These are the „sunk costs‟ associated with highly specific capital: physical 
capital such as specialised buildings or equipment (e.g. a synchrotron may have 
no other use than medical research, or no use that is nearly as valuable as 
medical research); and human capital, i.e. the specialised training and experience 
embodied in researchers that would not be nearly so valuable if those people had 
to find other employments. 
Thus the existence and magnitude of economies of scale is dependent on the 
timescale under consideration. In the absence of sunk costs, all costs are 
ultimately variable and in that case economies of scale are a short to medium 
term phenomenon. We have attempted, therefore, to distinguish between short 
and long term effects. 
To quantify precisely the magnitude of economies of scale in medical research 
would require access to, and detailed discussion and analysis of, disaggregated 
cost data from a representative range of organisations and individuals 
undertaking medical research in the UK. It is not clear that such data are 
currently available. RCUK and UUK noted in their review of the impact of „full 
economic costing‟ of research that “The absence of robust cost data had led many 
institutions to underestimate the costs of research” (RCUK and UUK, 2009). 
Separately identifying the costs of medical research is far from straightforward 
given that research is usually jointly produced (in higher education institutions) 
with teaching undergraduate and graduate students, and (in hospitals) with 
provision of health care services to patients. Allocating costs, e.g. between 
undergraduate education, postgraduate education and research at a university, is 
to some extent arbitrary. Plus there are very many different areas of research, 
which may share costs. Thus in a „multi-product enterprise‟ such as a university 
there is a distinction between „ray economies of scale‟ and „product-specific 
economies of scale‟. Ray economies of scale assume that the composition of 
output remains constant, while its scale is allowed to expand or contract. This 
gets round the multi-product nature of the enterprise by assuming that the 
quantity of teaching, say, is increased pro rata with the quantity of research. But 
a multi-product enterprise may expand outputs of different products non-
proportionally, in which case ray economies of scale are not applicable. In such 
an environment, estimation of product-specific economies of scale allows a better 
understanding of the organisation‟s cost structure. 
A further complication is that empirical studies of economies of scale need to 
measure not only the quantity of research outputs (which is itself not 
straightforward but is commonly proxied by numbers of research publications), 
but also should allow for the quality of those outputs (which is very difficult in 
practice), as a 1% cut in finding might lead to lower quality research as corners 
are cut, not just to less research. 
2.2 Method 
Thus, an empirical analysis of economies of scale in medical research would be a 
major undertaking. It would, furthermore, depend on the willingness of research 
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organisations (i.e. the recipients of research funding) to open their books to 
scrutiny of their costs. Such a study would have been well beyond the scope of 
the budget available for the current project. We therefore agreed with Cancer 
Research UK to undertake instead a high level assessment of the magnitude of 
economies of scale in medical research, based on: 
 a review of economic and grey literature on economies of scale in medical 
research outside industry. There is a considerable literature on R&D in 
industry, especially in pharmaceutical companies, but our focus was rather 
on that research which is funded by the Government and/or charities. The 
review comprised: (a) a search (as at 6th August 2013) by title and (if 
warranted by the title) abstract of the first 100 hits found via Google 
Scholar and Google respectively using the search terms “economies of 
scale” AND (“medical” AND “research”); (b) obtaining grey literature on 
the subject of medical research funding in the UK, including literature 
recommended by interviewees; and (c) checking apparently relevant 
references in the bibliographies of relevant publications; 
 interviews with senior representatives of the MRC, NIHR and OSCHR, the 
Wellcome Trust and Arthritis Research UK. The interviewees provided an 
overview of the fixed versus variable costs of the research funded by their 
organisations and indicated how their organisations might be expected to 
respond to reduced or increased funds for medical research; 
 a group interview with five managers at Cancer Research UK with 
responsibilities related to allocation of funds to different types of research 
activity; 
 analysis of cost data provided by interviewees on the balance between 
fixed and variable costs in medical research. 
2.3 Literature review findings 
All of the handful of relevant references found among the first 100 hits of the 
Google Scholar search were summarised in a book chapter by Cohn and Cooper 
(2004). These references discuss economies of scale in the production of 
university research, including medical research, in the context of empirical 
studies of economies of scale in higher education institutions. They are all 
econometric analyses and have as their main focus the measurement of 
economies of scale in university teaching but they also offer evidence (or appear 
to) on economies of scale in research as one of the products of universities seen 
as multi-product enterprises. 
Dundar and Lewis (1995) examined econometrically the production of hours of 
student teaching and the number of research publications of 118 departments of 
18 public research universities in the USA. They report finding, at the department 
level, both ray and product-specific economies of scale in undergraduate 
teaching, graduate teaching and research publications. In other words, the cost 
per research publication fell the larger the scale/funding of the university 
department, both when teaching and research are increased together in constant 
proportions and when research is increased by itself. 
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The only UK studies were by Johnes (1997 and 1998) and Izadi et al. (2002). 
Johnes (1997 and 1998) used academic year 1994/95 data for 99 UK universities 
to estimate a multi-product cost function with research as one of the products. 
„Research‟ was not limited to medical or natural sciences research but covered all 
areas including humanities and social sciences. „Research‟ was measured as the 
value of research grants. The results appear to show significant unexploited 
economies of scale in research overall at the then current average scale of UK 
universities. Izadi et al. (2002) analysed the same data as Johnes but used a 
different econometric approach. They also appeared to find economies of scale in 
research. Each of the UK studies concerns „product-specific‟ economies of scale 
where the „product‟ is the value of research grants won. In other words, larger 
universities win disproportionately more research grants, and smaller universities 
disproportionately few. Unfortunately, however, these UK studies say nothing 
about the outputs of the research carried out with those grants and hence 
nothing about what happens to the cost per research output as research funding 
is increased or reduced.  
The Google review revealed two references of interest from the grey literature. 
Vonortas and colleagues (2011) undertook an analysis for DG Research and 
Information of the European Commission of the economies of scale and scope at 
the project level in European Commission funded research. They analysed 
econometrically survey data from 1,172 organisations participating in 676 
research projects funded by the 5th and 6th Framework Programmes for Research 
and Technological Development of the EU. This includes medical research but 
along with much non-medical research. The complex econometric analysis 
showed no statistically significant relationships between project size and outputs 
for publicly and charity funded research. Economies of scale were exhausted at 
small project sizes “well below the … average project sizes that we observe”. In 
summary they found that: “Taken overall, the econometric results indicate that 
increasing scale does not seem to improve project performance, with the notable 
exception of firms which seem to benefit from increasing scale in terms of their 
own funding, showing a positive effect mainly on commercial impacts.” (Vonortas 
et al., 2011; both quotes taken from page 4). 
In a review for the UK Government Office of Science and Technology, von 
Tunzelmann et al. (2003) looked at the impact of the size of research units on 
their research performance. The review was not limited to medical research. The 
studies they reviewed included the Dundar and Lewis (1995) and Johnes (1997) 
articles discussed above. Von Tunzelmann and colleagues concluded overall that: 
“the key unit would appear to be the group or team, rather than the 
department or the university” 
and 
“there is reasonably convincing evidence of a size effect in the form [of] a 
„critical mass‟ threshold. In many scientific fields, productivity seems to 
rise as the team size increases to about six or eight persons, above which 
there is usually little or no extra gain per capita.” 
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This suggests that if a hypothetical cut in research funding were met by cutting 
discrete small teams rather than shaving resources from many more of them, the 
loss of research output would be proportionate to the funding cut rather than 
disproportionate. 
Finally, one of the interviewees identified a 2009 report by the management 
consultants McKinsey (2009) of being of some relevance to the discussion of 
economies of scale. McKinsey sought to identify the distinguishing characteristics 
of high productivity medical research laboratories, based on interviews with “12 
world-class academic innovators” and their own analysis of practices in 15 
research laboratories in industry with different levels of performance and “several 
more academic laboratories”. They identified five areas that distinguished high 
productivity labs: strategy decisions, talent management, portfolio and project 
management, problem solving, collaboration. The inclusion of portfolio and 
project management in the list implies a possible role for economies of scale, 
though more so for economies of scope: “The top labs design their portfolios of 
projects to be interlinked, so that they are both additive, in that the lab reaps 
benefits from their intellectual scale, and synergistic, in that each project might 
uncover insights that prove valuable to another.” (McKinsey & Company, 2009). 
Overall the literature is largely unhelpful about identifying the existence or not of 
economies of scale in medical research, in terms of research output per research 
pound spent. Such economies of scale as there are appear to be exhausted at 
small scales of research units. Consequently, if a hypothetical cut in medical 
research spending were met by closing down whole, albeit small, research teams 
rather than by squeezing across the board, the loss of research output might only 
be proportionate to the funding cut, rather than disproportionately damaging. 
2.4 Cost data 
Medical research in the UK is funded, indirectly as well as directly, from a variety 
of sources. This, plus the previously noted tendency for research to be conducted 
in institutions that are jointly producing research and teaching (and sometimes 
health care), from some or all of the same people and facilities, makes it 
problematic to determine the balance between variable and fixed costs incurred 
in the production of medical research. However, a review of literature on UK 
research funding arrangements, combined with information obtained in the 
interview programme, allows the following impressionistic picture to be 
constructed. 
Some of the infrastructure necessary for universities to conduct medical research 
is paid for by “Quality Related (QR)” funding that UK universities receive from the 
higher education funding councils of the four countries of the UK in recognition of 
the quality and quantity of the research they achieve across all subject areas 
(UKCRC, 2012). Some of the infrastructure, including some staff costs, is also in 
effect paid for out of non-research funding streams received by universities. The 
2010 Wakeham Report found that UK higher education institutions were reporting 
in 2008/09 a deficit of £2.187billion (24%) of research funding versus research 
costs. 
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The funding arrangements currently in place in the UK assume that 20% of full 
economic costs of research (whether medical research or any other kind) are met 
from QR and other underlying funding streams. The remaining 80% of full 
economic costs are supposed to be funded by research council and NIHR grants, 
and by grants from charities topped up by the tax-funded Charity Research 
Support Fund. Charities generally fund around 60% of full economic costs of 
research at universities. The interviewees from MRC and NIHR confirmed that this 
20/80 split of funding of full economic costs was not based on any assessment of 
the split between fixed and variable costs of research, but was rather a political 
agreement. 
The Wakeham Report recommended incentivising universities to improve 
efficiency in indirect costs, which are essentially overhead costs and which across 
all research councils (not just the Medical Research Council) were estimated to 
represent 30% of total research project costs. Direct costs were estimated at 
61% of total research project costs, with estates costs making up the remaining 
9%. (Estates costs are more usually included under the heading of indirect or 
overhead costs, but the Wakeham Report treated them separately as it explicitly 
did not propose cutting spending on that part of total research costs). 
Information provided by Cancer Research UK implies a rather higher percentage 
of medical research costs are direct, i.e. short-term variable, costs than the 
Wakeham Report states for all (not just medical) research councils. An analysis of 
data provided by Cancer Research UK, of £155million of research grants (110 
grants) awarded by them with start dates between June 2012 and May 2013 
inclusive, shows that the costs of those projects have the following average split: 
 directly incurred costs = 54% (min 20%; max 93%) 
 directly allocated costs = 22% (5%; 56%) 
 indirect costs = 24% (2%; 45%) 
Thus there is wide variation from project to project but overall, short term 
variable costs (i.e. the direct costs) appear to average 76% of the total and 
indirect costs (overheads etc.) 24%. 
Other data provided by Cancer Research UK shows the annual budgets of the five 
research institutes they fund. Out of total costs of £122million, 78% are identified 
as research staff costs and other research running expenses, which may be 
thought of as broadly equivalent to „variable‟ costs. The other 22% were 
overhead costs, including administrative and support staff (e.g. information 
systems staff) and corresponding operating expenses, plus the annuitised costs of 
property and capital equipment. 
Data provided by the MRC showed that of the total of £372million that the MRC 
committed in 2012/13 to fund grants and fellowships, 78% went on „direct costs‟ 
(including „exceptions‟, which are direct costs funded at 100% of „full economic 
costs‟) and 22% on „indirect costs‟. 
In summary, the 78/22 direct/indirect cost split for the MRC grants and 
fellowships matches the 78/22 direct/indirect split for Cancer Research UK‟s 
institutes, and is similar to the 76/24 direct/indirect split for Cancer Research 
UK‟s grants. 
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Taking a 78/22 or 76/24 split to represent the balance of variable versus short 
term fixed costs: a hypothetical 1% cut in research funding falling entirely on 
direct/variable costs would imply an approximately 1.3% cut in the short term in 
the amount of research activity. 
However, in the medium to long term it would be possible to reduce the scale of 
infrastructure slightly so that research capacity and use of that capacity are once 
more brought into balance. To the extent that resources have been invested in 
highly specific human capital – specialist trained and experienced researchers – 
and highly specific fixed capital, meaning that the specialised skills/experience 
and equipment have much higher value in their current uses than in their next 
best alternative uses, then those economies of scale will persist even in the long 
run. Those costs are „sunk‟, meaning that if that human and physical capacity is 
used less than fully then there will be irrecoverable waste. However, it is not 
possible on the basis of the information we found to determine what percentage 
of costs fall into the „sunk‟ category. 
2.5 Additional findings from the interviews 
We asked the interviewees at Arthritis Research UK, MRC, NIHR, OSCHR and the 
Wellcome Trust how significant, if at all, they would expect short run and longer 
run economies of scale to be, and how they would expect a marginal reduction or 
increase in funds available for medical research to be allocated.  
Three of the four interviewees who felt able to comment considered that although 
there might be economies of scale in medical research in the short run – because 
research capacity and overhead support functions cannot be created or 
abandoned immediately – in the longer run capacity could and would be adjusted 
in response to sustained increases or cuts in funding. The fourth interviewee 
largely agreed with this view but with the qualification that a minority of medical 
research in the UK is capital intensive, and furthermore that the physical capital 
involved was highly specific, implying substantial sunk costs and hence some long 
lasting economies of scale. Examples are: the Diamond Light Source synchrotron 
at Harwell; cancer biobanking; and research requiring high cost IT and imaging 
equipment. 
When considering the likely impact of marginal reductions or increases in funding, 
an essential distinction is whether the changed funding level is expected to be a 
temporary aberration or a permanent feature. Temporary increases in funding 
would be expended on short duration projects, to avoid creating commitments 
that might not be sustainable beyond the current year. Temporary reductions 
would be met by delaying the starts of new projects or by attempting to squeeze 
efficiencies out of research activity already under way. 
One particular issue, raised by two of the interviewees, was that temporary cuts 
in funding can have long lasting negative consequences. The fixed costs of 
educating and training researchers, combined with the international nature of 
labour markets for highly trained and expert people, mean that the funding „tap‟ 
causes problems immediately it is turned off and these problems take time to be 
overcome even if the tap is turned back on again subsequently. When reduced 
funding means less work for researchers to do, they leave the country or leave 
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research for other careers. If funding were then to be increased again, not all of 
them would return to the UK or to research. Thus even temporary funding cuts 
cause long term damage. In general, planned cuts with advance warning (giving 
time to plan for them) are less damaging than sudden unexpected cuts. 
Changes to funding levels that are expected to persist would generally prompt 
qualitatively different responses by research funders. The initial response to a cut 
in funds available might still involve attempting to squeeze efficiencies from 
research units and projects already being funded. One interviewee said that their 
organisation would not push too hard for further efficiencies for fear of the 
damage that might cause. A more general short term response would be to raise 
the quality „bar‟ for funding new projects: i.e. fewer projects would be initiated. 
This would in effect mean less research produced from the existing research 
capacity. Given the earlier discussion of fixed/indirect and variable/direct costs, a 
1% cut in funds might in the short term therefore be expected to have the effect 
of a greater than 1% cut in the amount of research activity funded. 
However, over the medium to longer term a sustained cut in funds would lead to 
reduced capacity too, bringing research capacity and use of that capacity back 
into balance. In other words, capital would be sold off or not replaced and 
overhead staff and costs would also be cut. Thus over a period of a few years a 
1% cut in funding would imply, broadly speaking, a 1% reduction of research 
activity. This view is borne out by the literature on economies of scale in medical 
research, as discussed earlier. 
The response to a sustained increase in funds available might, even in the short 
term, be to increase research capacity as well as to make more use of such 
capacity. A common theme in the interviews was that capacity for medical 
research is issue/field specific. Consequently, funders‟ decisions about how much 
of any increase to invest in capacity would depend on which fields were 
considered to be the highest priorities for more research and whether they 
already had sufficient capacity or whether they were high priorities to build up. 
2.6 Summary of economies of scale 
The published academic literature offers little evidence on whether there are 
economies of scale in medical research outside industry. A study of 18 public 
research universities in the USA found that the cost per research publication 
produced (not specifically medical research, but all types of research) fell as the 
scale/funding of the university department increased, both when teaching and 
research are increased in step together and when research is increased by itself 
(Dundar and Lewis, 1995). Studies using data for 99 UK universities for the 
academic year 1994/95 also appeared to find economies of scale in research 
(again not specifically medical research), but they used research grants won as 
their measure of „research‟, which begs the question what happened to the scale 
of outputs from research (Johnes, 1997 and 1998; and Izadi et al., 2002). An EU 
study found economies of scale in research projects (again, not specifically 
medical research) to be exhausted at small project scales (Vonortas et al., 2011) 
and von Tunzelmann and colleagues concluded that further economies of scale 
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would not be realised once research teams went beyond eight or so members 
(von Tunzelmann et al., 2003). 
Data from Cancer Research UK and the MRC show direct (arguably short term 
variable) costs to be around 76%-78% of total costs, and indirect costs (arguably 
more fixed costs in the short term) around 22%-24% of total costs. This suggests 
that in the first year or so after a change in funding, when only direct costs can 
be varied, a hypothetical 1% cut in funding would lead to a 1.3% reduction in 
medical research activity. 
The views of the interviewees imply that this short term consequence would not 
last in the medium to longer term as over a period of a few years it would be 
possible to adjust research capacity too. Thus economies of scale appear to be 
only short term. The one exception to that is a minority of medical research that 
involves high cost and highly specialised equipment, IT or biobanks. Furthermore, 
temporary cuts in funding can have long lasting negative consequences: reduced 
funding means less work for researchers in the UK, meaning that some will either 
leave the country or change careers, and not all would return to the UK or to 
research if funding were to be increased again later. 
Thus, in summary, there is some evidence of the existence of economies of scale 
in research but it is from a nearly 20-year old US study and is not specific to 
medical research. Beyond the short term, economies of scale appear to be 
exhausted at small sizes of research teams and research projects, with the 
exception of the small number of projects that entail expensive and highly 
specific equipment, IT systems or buildings. 
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 The UK produced 6.9% of global research publications on neoplasms in 2011.  
 This research was produced by authors from 1,159 UK organisations and co-
authors from 5,077 non-UK research host organisations. 
 Publications by UK authors acknowledged financial support from 2,621 
organisations, of which 663 were UK based, excluding 307 private sector 
organisations. 
 26 host organisations (2% of the total) contribute to 72% of the publications 
output. 
 
Interdependency – Strong interdependencies exist among research hosts 
and among research funders   
 67% of publications relied on collaboration among research hosting institutions 
and 43% involved international collaborators.  
 The 113 leading UK research organisations collaborate in publications more with 
international partners than with their UK neighbours.  
 Where publications acknowledge funding, multiple funders are acknowledged 64% 
of the time, with a mean of 3.3 funders acknowledged per publication.  
 Industry contributed to over 14% of UK neoplasm publications in 2011 and 18% 
of those acknowledging funders acknowledge industry support. These papers were 
more highly cited than expected.  
 
Complementarity – The research funding of different organisations is 
complementary, particularly between large funders and small funders   
 The major funders of research on neoplasms support scientific publications that 
have co-authors across almost the entire UK, but centre their efforts in the 
Cambridge, London and Oxford areas. 
 Smaller funders focus primarily on London but often have a secondary and focus 
on other regions, which makes them complementary to the major funders in 
geographic terms. 
 The top-three UK funders of neoplasms research – Cancer Research UK, the UK 
Departments of Health and MRC – focused mainly on “Neoplasms, Glandular and 
Epithelial”, “Digestive System Neoplasms” and “Urogenital Neoplasms”, while 
smaller funders are complementary as they often focus on other neoplasm types. 
 Funding schemes provided by the major charity and government funders provide 
UK researchers with a broad choice of grants, making the UK an attractive funding 
environment for leading scientists who rely on multiple grants simultaneously to 
build their groups and sustain promising new research lines. 
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The UK biomedical research community benefits from a broad range of public 
sector, private sector and charitable funders that play a key role in supporting 
their work. Yet, the extent to which funders play complementary roles in this 
support is less understood. The analysis undertaken for this project provides 
evidence of a highly interdependent and complementary funding system, based 
on an in-depth study of the portion of the UK‟s research base focused on 
neoplasms.  
Prior studies that attempt to ascertain the nature of funding landscapes have 
often begun by exploring the stated funding activities of selected, large UK-based 
funders (e.g. HERG et al. 2008; Morgan-Jones and Grant 2011, OHE 2011). Our 
approach complements the established ones with an additional „search mode‟. 
Specifically, starting from the one of the main outputs of research activity, that is 
publications, we map the funders as they are acknowledged in publications. This 
empirical approach has an advantage in that it makes no a priori judgements on 
which funding bodies supported the UK researchers. It allows a comprehensive 
picture to be produced of the diverse and complex constellation of all funders that 
supported publications in the selected domain, i.e. the approach is not biased 
towards the large funding bodies. Publications and the relative databases 
containing the bibliographic data of these publications can be analysed to reveal 
much about the way researchers make use of their funding environment. 
Publications can be used as a starting point to explore questions such as:  
a) How interdependent are the research activities that funders support?  
b) How do funders support research activities in ways that complement one 
another? 
c) How is the broad and diverse range of research activities in the UK 
supported by the different funders? 
From an analytical perspective these are broad questions. Using scientometric 
analysis, terms such as interdependence, complementarity, and diversity can be 
Diversity – The major research funders and host organisations differ 
considerably in terms of supported scientific disciplines and research 
domains 
 Of the major funders, Cancer Research UK and the Departments of Health 
(including NHS and NIHR) BBSRC and EPSRC support the broadest range of 
research. 
 Major funders strongly focus on pathology and genetics, while surgery is 
relatively neglected. 
 
Additional Perspectives – Research quality and international collaborations 
 Major UK funders support a higher proportion of highly cited publications than 
minor UK funders. Papers with more funders also have higher citations. 
 Publications supported by industry are significantly more highly cited than those 
without industry support. 
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explored from a number of different informative perspectives (Rotolo et al. 2013). 
The analysis therefore has to begin by addressing even more fundamental 
questions concerning the involvement of funders in supporting biomedical 
research: 
 Which public and private bodies fund UK researchers in cancer and which 
support more publications? 
 What are the differences in the geographic and institutional coverage of 
each funder‟s investments? 
 Which funders support rapidly cited works, or works in high quality 
journals? 
 Which funders support international collaborations or public/private 
collaborations?  
 Which funders support more interdisciplinary research? 
 Which funders support particular approaches such as clinical trials of 
therapeutics and diagnostics? (These are derived from the Medical Subject 
Headings (MeSH) classifications). 
 What is the diseases focus (within cancer) of different funders? 
Additional insights into the complementarities of funders are provided by a 
qualitative analysis of the types of award schemes offered by grant funders and 
their characteristics. 
Finally, the interdependency of research funded through different means and 
complementarities between funders is explored using case studies drawn from 
interviews with four leading UK researchers to illustrate how researchers working 
in diverse areas of biomedicine have used funding schemes funding in order to 
achieve significant research milestones. 
The data analysis is arranged in sections according to address questions A, B and 
C above, with additional sections discussing further findings, distributed according 
to the following working definitions of key terms: 
 Research host organisations – Primarily undertake research 
 Major UK host organisations – UK research host organisations that 
contribute to at least 2% of the UK research output in neoplasms in 2011 
 External funding organisations – Primarily sponsor research 
undertaken externally 
 Major UK funders – UK funders that supported at least 2% of the UK 
research publications in neoplasms in 2011 
 Interdependency – Where two or more research hosts or external 
funders support a single output (i.e. publication) 
 Complementarity – Where different research hosts and external funders 
support activities that collectively address a wider range of activities than 
individual organisations contributing to more potential synergies across 
the research system.   
 Diversity – Variety in the characteristics, scope and balance of research 
activities that individual research hosts undertake or that individual 
external funders support  
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3.2 Research methods  
Two systematic approaches are possible to undertake a comprehensive analysis 
of a research funding landscape over a given time period. One starts upstream 
with the funders and then traces the research outputs they have supported (the 
„top down‟ approach). The other starts with the research outputs and traces the 
funders that supported these (the „bottom up‟ approach). Both approaches have 
limitations and so with limited resources, analysts must be aware of these and 
make pragmatic choices (McLean et al. 1998). 
Collection of data from funders requires that, inter alia, all relevant funders can 
be identified and that these organisations are transparent about the research 
they support, use common definitions and similar reporting styles to ensure 
relevant inputs, and their outputs, can be identified (Hopkins and Siepel 2013). 
Efforts to develop a „top down‟ approach have been advanced by UK research 
funders and are becoming increasingly sophisticated (for example see UKCRC 
2012). However many smaller funders are not included in such funding statistics, 
nor are international funders.  
The „bottom up‟ approach requires that all relevant research outputs can be 
identified and that authors of outputs are transparent about who has funded their 
research, with funding data reported in a style that is accessible and amenable to 
analysis. Although much research is published and accessible through highly 
indexed and structured databases which aids searching, some organisations, 
particularly in industry, do not publish all of their research (Rafols et al. 2012, 
Goldacre 2012). This is a substantial limitation because in the UK at least, 
estimates suggest industry funds the majority of biomedical research (Morgan-
Jones and Grant 2011) However this limitation is also likely to be a problem for 
the top down approach (Hopkins and Siepel 2013). 
This study develops a „bottom up‟ strategy to map all papers written by authors 
working in the UK and related to the neoplasms domain in order to map the 
funding landscape. The required information is not readily available from one 
database and so a multi-stage process is required to identify relevant papers and 
collect data across the required fields for a broad analysis. Full details of the 
steps undertaken to create the dataset are provided in the Appendix to this 
chapter. The following paragraphs provide just a summary of this more detailed 
account. 
For the purposes of identifying a sample of UK papers from which to generate a 
„snapshot‟ of the UK research system a search was undertaken of 
PubMed/MEDLINE using the Medical Subject Headings (MeSH) code „Neoplasms‟. 
This is a broad term encompassing cancerous and pre-cancerous growths. All 
papers with at least one UK author on neoplasms published in 2011 where 
identified. Of the 7,922 records identified, electronic access was possible for 
94.8% of the sample (7,510 publications).  
These 7,510 publications were scanned for acknowledgements to funders, with 
3,914 publications disclosing at least one funder. Robustness checks confirmed 
that those publications not acknowledging funders were more likely to be shorter, 
less cost intensive categories of publication (such as editorials or comments) and 
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that those not acknowledging funders were most often funded only by their 
employer (already captured for this analysis through identification of all author 
affiliated host organisations). These findings are consistent with prior research on 
UK biomedical publications data which found that 39% of papers did not 
acknowledge funders, with the primary reason being that the papers were funded 
by the organisation or organisations that the authors were affiliated with (Lewison 
et al. 1995).  
As discussed in Chapter 2, most grants by UK research councils and charities do 
not fully reimburse organisations hosting research for their costs. Therefore in 
identifying the funders of neoplasm research in the UK it is appropriate to discuss 
the research host organisations and their external funders. These are considered 
as two distinct perspectives in the analysis presented here – a single combined 
approach being problematic because of heterogeneity in the origin of funding 
supporting research host organisations that not externally grant funded.    
3.2.1 Limitations of the dataset construction for analysis and 
interpretation  
A key limitation is that although publications record author affiliations and in 
many cases report funding sources, it is frequently the case that publications do 
not disclose which authors or affiliated organisations have benefitted from specific 
funders. Figure 3.1 illustrates the structure of the data records under ideal and 
actual conditions, and shows how the resulting data analysis focuses on either the 
publications host organisations produce, or the publications funders support.    
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Figure 3.1: Ideal and actual funding disclosure reconstruction 
 
(ideal funding disclosure reconstruction) 
 
 
(actual funding disclosure reconstruction) 
 
 
3.2.2 Method for analysis of research funding schemes 
In order to understand how the major research funders provide complementary 
or overlapping funding schemes for the research community it was necessary to 
identify the leading funders, using the data from publication acknowledgements 
sections. Those funders contributing to >1% of publications were selected for 
investigation (10 UK-based funders and three non-UK based funders). Funders‟ 
websites and key documents such as annual reports for the most recent period 
were examined to determine whether these schemes were open to researchers 
working in the UK. A qualitative comparative analysis based on similarities and 
differences between the funders‟ different schemes was then undertaken. 
3.2.3 Method for case studies of leading researchers  
The scientometric analysis of publications in 2011 and the description of the top 
funders funding schemes both provide system-wide snapshots of the landscape of 
UK biomedicine in the neoplasms field. To explore how researchers navigate 
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schemes may be complementary or interdependent, case studies of leading 
researchers were undertaken.  
Case study subjects were selected from a sample of convenience provided by 
Cancer Research UK and so cannot be described as scientifically selected. Five 
individuals were approached in mid 2013 with four responding and contributing. 
The case study sample over-selects highly successful scientists funded by Cancer 
Research UK, but with this bias understood these cases can be used to inform the 
scientometric analysis by providing insight into the writing of acknowledgement 
sections and the role of international partners. These case studies also to provide 
some (non-comprehensive) illustrations of the ways in which different funding 
sources funding can be used over time to advance an avenue of research.  
3.3 Scientometric analysis results: Contextual descriptive 
statistics  
3.3.1 Publication numbers and outlets 
Of the 115,101 publications in 2011 classified as related to neoplasms according 
to the MeSH coding system, 7,922 had at least one UK-based author. The UK was 
therefore involved in the generation of 6.9% of the global output of publications 
on neoplasms in 2011. These papers are distributed across 1,480 journal titles. 
The analysis focuses on a sample of 94.8% of these papers, based on 7,510 
publications across 1,350 journal titles.  
Concentration is low with only 13 journals containing >1% of these publications 
and the top 17 journals accounting for just 20% of total publications (see Figure 
3.2). The most frequently targeted journals within the sample are the British 
Journal of Cancer (2.9%), highlighted in green, the European Journal of Cancer 
(1.6%), highlighted in blue, joint in third place, highlighted in orange, the 
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Figure 3.2: Leading journals of 2011 UK publications on neoplasms and 
distribution journal-number of publications 
 
 
3.3.2 Publications by UK research host organisations 
Table 3.1 reports the top-50 UK organisations publishing in neoplasms (62 host 
organisations are listed). It is notable that a large proportion of the organisations 
contributing to more than 100 publications per year are clusters of institutions 
linked by association to a university hospital or NHS Trust. This makes direct 
comparisons to smaller organisations somewhat problematic, but pragmatically is 
necessary as staff in these clusters will frequently work between sites and have 
dual affiliations. 
Figure 3.3 shows the distribution of publishing output in the field of neoplasms 
across the population of host organisations, dividing these into three groups 
according to their contribution to the publication output: (i) less than 0.1%, (ii) 
from 0.1% to 1%, and (iii) more than 1%. These three groups accounts for 951, 
182, and 26 organisations that contributed respectively to 1,433, 2,933, 5,394 
publications,. This suggests that although neoplasm research in the UK was 
undertaken in a large number of organisation (1,159 organisations), a core of 26 
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Table 3.1: Top-50 ranking of UK organisations (62 organisations listed) 
publishing on neoplasms research 
 Organisation Number of 
publications 
1) Institute of Cancer Research, London  
(including the following organisation or name variations: Royal Marsden NHS Foundation Trust) 
699 
2) University College London, London 
(including the following organisation or name variations: University College London Hospitals NHS 
Trust, UCL Cancer Institute, National Hospital for Neurology and Neurosurgery, Royal Free 
Hampstead NHS Trust) 
630 
3) Imperial College, London 
(including the following organisation or name variations: Imperial College Healthcare NHS Trust, 
Hammersmith Hospital, Charing Cross Hospital) 
567 
4) University of Cambridge, Cambridge 
(including the following organisation or name variations: Cancer Research UK Cambridge Research 
Institute, Hutchison/MRC Research Centre, Cambridge Biomedical Research Centre, Addenbrooke's 
University Hospital, Cambridge University Hospital NHS Trust) 
556 
5) Oxford University, Oxford 
(including the following organisation or name variations: Gray Institute, John Radcliffe Hospital, 
Oxford Radcliffe Hospitals NHS Trust, United Kingdom) 
548 
6) King's College London, London 
(including the following organisation or name variations: King's College Hospital NHS Trust, Guy's 
and St Thomas NHS Trust, Guy's Hospital, Western General Hospital) 
529 
7) University of Leeds, Leeds 
(including the following organisation or name variations: Leeds Cancer Research UK Centre, St 
James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary) 
395 
8) University of Manchester, Manchester 
(including the following organisation or name variations: Cancer Research UK Paterson Institute,  
Christie Hospital) 
389 
9) Queen Mary University of London, London 
(including the following organisation or name variations: St Bartholomew's Hospital) 
323 
10) University of Edinburgh, Edinburgh 
(including the following organisation or name variations: Edinburgh Cancer Research Centre, Western General Hospital) 
282 
11) University of Glasgow, Glasgow 
(including the following organisation or name variations: NHS Greater Glasgow and Clyde, Gartnaval 
General Hospital, Glasgow Royal Infirmary, Western Infirmary) 
278 
12) University of Newcastle, Newcastle Upon Tyne 
(including the following organisation or name variations: Northern Institute of Cancer Research, 
Newcastle upon Tyne Hospitals NHS Trust, Royal Victoria Infirmary, Freeman Hospital) 
243 
13) University of Birmingham, Birmingham 219 
14) University of Sheffield, Sheffield 
(including the following organisation or name variations: Weston Park Hospital, Sheffield Children's 
NHS Trust, Sheffield Teaching Hospitals NHS Trust) 
212 
15) Cardiff University, Cardiff 
(including the following organisation or name variations: Velindre NHS Trust) 
191 
16) University of Southampton, Southampton 
(including the following organisation or name variations: Southampton General Hospital) 
170 
17) University of Liverpool, Liverpool 166 
18) St George's Hospital NHS Trust, London 
(including the following organisation or name variations: St George's Hospital, St George's, 
University of London) 
132 
19) Queen's University, Belfast 
(including the following organisation or name variations: Belfast City Hospital) 
128 
20) University of Nottingham, Nottingham 115 
21) University of Aberdeen, Aberdeen 104 
22) University of Bristol, Bristol 100 
23) University of Leicester, Leicester 87 
24) Mount Vernon Hospital, Northwood 81 
25) London Research Institute, London 79 
26) Ninewells Hospital and Medical School, Dundee 77 
27) AstraZeneca, Macclesfield 75 
27) Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool 75 
28) Great Ormond Street Hospital for Children, London 72 
28) Queen's Medical Centre, Nottingham 72 
29) Churchill Hospital, Headington 70 
29) Nottingham University Hospitals NHS Trust, Nottingham 70 
30) London School of Hygiene and Tropical Medicine, London 69 
30) University of Dundee, Dundee 69 
31) Royal Surrey County Hospital, Guildford 58 
32) Queen Elizabeth Hospital, Birmingham 57 
33) Nottingham City Hospital, Nottingham 56 
34) University Hospital of Wales, Cardiff 54 
35) Leicester Royal Infirmary, Leicester 52 
35) University of Sussex, Brighton 52 
36) Medical Research Council, London 49 
37) University of Warwick, Warwick 48 
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 Organisation Number of 
publications 
38) University Hospital Southampton NHS Trust, Southampton 46 
39) Beatson Institute for Cancer Research, Glasgow 44 
40) University of York, York 42 
40) Welcome Trust Sanger Institute, Cambridge 42 
41) Aberdeen Royal Infirmary, Aberdeen 41 
41) St. Mary's Hospital, London 41 
42) Queen Alexandra Hospital, Portsmouth 40 
42) Royal Infirmary of Edinburgh, Edinburgh 40 
43) University of East Anglia, Norwich 39 
44) St Mary's Hospital, Manchester 38 
45) Birmingham Women's Hospital, Birmingham 36 
46) Birmingham Children's Hospital, Birmingham 35 
46) Royal Hallamshire Hospital, Sheffield 35 
46) Royal National Orthopaedic Hospital, London 35 
47) Norfolk and Norwich University Hospital, Norwich 34 
48) Royal Brompton Hospital, London 33 
48) University of Surrey, Guildford 33 
49) University Hospitals Bristol NHS Trust, Bristol 32 
50) Manchester Royal Infirmary, Manchester 31 
50) Royal Devon and Exeter Hospital, Exeter 31 
 
Figure 3.3: Number of organisation by contribution to the 2011 UK 
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3.4 Scientometric analysis: Interdependencies in Neoplasm 
Research 
This section aims to address the question „How interdependent are these research 
activities that funders support?‟. In this context, interdependency is understood 
as situations where two or more research hosts or external funders support a 
single research output (publication).  
Host organisations may therefore be seen as interdependent when they work with 
other host organisations to produce research publications. Funders can be 
described as interdependent on other funders when the publications that their 
mission depends on are produced in conjunction with those funders. Analysis of 
these two perspectives (illustrated in Figure 3.1) form the basis of this section 
with the analysis of the authors‟ affiliations on 7,510 publications and the analysis 
of external funders based on acknowledgements in 3,914 publications. It is a 
presumption that in most cases publications produced with charitable funding or 
funding from research councils are the result of interdependencies between hosts 
and external funders due to the practice of not funding 100% of full economic 
costs (as discussed in Chapter 2). However, the analysis presented here does not 
explore this third perspective.  
3.4.1 The interdependence of research host organisations 
Analysis of the sample of 7,510 publications reveals that neoplasms research is a 
highly collaborative enterprise between research host organisations. Figure 3.4 
shows the distribution of publications by authorship, revealing that very few 
(<6%) publications are sole authored, and of these fewer are cost intensive 
„articles‟. Figure 3.5 shows the distribution of publication by number of authors‟ 
affiliations per paper, revealing that 67% of publications result from cross-
organisational collaboration, indicating that research host organisations are highly 
interdependent on each other to produce research publications. 
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Table 3.2 shows that publications have a mean of 7.7 authors (although Figure 
3.5 shows the mode is 3 for all publications and 4 if considering just the more 
cost intensive articles) and involves a mean of 3.8 host organisations (although 
Figure 3.6 shows the mode is 1, even for the cost-intensive research articles, this 
is because of the wide distribution of the data). 
Overall, Table 3.2 shows that the sample of 7,510 publications has 1,159 UK host 
organisations publishing on neoplasms and co-authoring with researchers at 
5,077 non-UK host organisations. 
Research on neoplasms involves much international collaboration with 43.3% of 
publications having at least one co-author based outside the UK. This implies that 
over two fifths of the UK neoplasms publication output is dependent on 
international host organisations, with the average international „publication‟ 
relying on a mean of 2.1 non-UK organisations. Table 3.3 reveals the top-50 
ranking (containing 68 organisations) non-UK host organisations (excluding 
industry) that contribute co-authors to publications with UK co-authors. The high 
proportion of US collaborators in this list (18/68), implies that UK research on 
neoplasms is most interdependent on the US funding system for co-author 
funding. Other strong ties are evident with Italian and Dutch (both 8/68), 
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Table 3.2: Descriptive statistics on the publication sample (N=7,510) 
Number of author-publication pairs 57,988 
  
Number of authors per publication  
Mean 7.7 




Number of affiliation-publication pairs  
before names’ harmonisation process  34,732 
after names’ harmonisation process 28,834 
  




Number of affiliations per publication  
Mean 3.8 




Number of UK affiliations per publication  
Mean 1.7 




Number of publications involving   
at least one non-UK affiliation 3,253 
only UK affiliations 4,257 
  
  
Number of non-UK affiliations per publication  
Mean 2.1 
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Table 3.3: Top 50 Ranking of non-UK organisations (68 organisations 
listed) collaborating with UK organisations 
 Organisation Number of 
publications 
1) Karolinska Institutet, Sweden 164 
2) National Institutes of Health, United States 146 
3) University of California, United States 144 
4) University of Texas, United States 129 
5) Umea University, Sweden 124 
6) Fondazione IRCCS Istituto Nazionale dei Tumori, Italy 123 
7) Harvard University, United States 122 
8) International Agency for Research on Cancer, France 120 
9) Utrecht University, Netherlands 116 
10) University of Toronto, Canada 114 
11) German Cancer Research Center, Germany 113 
12) Erasmus University Medical Center, Netherlands 103 
13) Paris South University, France 98 
14) Mayo Clinic, United States 97 
15) Catalan Institute of Oncology (ICO), Spain 96 
16) AMC Amsterdam, Netherlands 91 
17) Leiden University Medical Center, Netherlands 89 
18) Lund University Hospital, Sweden 85 
19) Aahrus University, Denmark 83 
20) Danish Cancer Society, Denmark 82 
21) Katholieke Universiteit Leuven, Belgium 82 
21) Memorial Sloan-Kettering Cancer Center, United States 82 
21) Radboud University, Netherlands 82 
22) Dana Farber Cancer Institute, United States 81 
23) CIBER-BBN, Spain 76 
23) University of Montreal, Canada 76 
24) University of Copenhagen, Denmark 74 
25) Queensland Institute of Medical Research, Australia 72 
26) University of Melbourne, Australia 71 
27) University of Pennsylvania, United States 70 
28) Istituto Toscano Tumori, Italy 69 
28) University of Washington, United States 69 
29) University of Heidelberg, Germany 68 
30) University of Sydney, Australia 65 
31) Federico II University, Italy 64 
32) University of Athens, Greece 63 
33) Netherlands Cancer Institute, Netherlands 61 
34) University of Torino, Italy 60 
35) University of Southern California, United States 58 
35) Uppsala University, Sweden 58 
36) Azienda Ospedaliera Civile MP Arezzo, Italy 55 
37) National Institute for Public Health and the Environment, Netherlands 54 
37) University of Leuven, Belgium 54 
38) Johns Hopkins University, United States 53 
39) European Institute of Oncology, Italy 51 
40) Andalusian School of Public Health, Spain 50 
40) German Institute of Human Nutrition, Germany 50 
41) University of Padua, Italy 49 
42) University of Tromso, Norway 48 
43) Human Genetic Foundation (HuGeF), Italy 47 
43) Peter MacCallum Cancer Centre, Australia 47 
43) Stanford University, United States 47 
44) University of Michigan, United States 46 
45) Maastricht University Medical Center, Netherlands 45 
45) Mount Sinai Medical Centre, United States 45 
45) Health and Health Care Services Council, Spain 45 
45) University of Gotherburg, Sweden 45 
45) World Health Organisation, Worldwide 45 
46) Navarre Public Health Institute, Spain 44 
47) Charité Berlin, Germany 42 
47) Charles University, Czech Republic 42 
47) Fred Hutchinson Cancer Center, United States 42 
47) Ulm University, Germany 42 
48) Duke University, United States 41 
49) Massachusetts General Hospital, United States 40 
50) Universite Paris Descartes, France 39 
50) Hannover Medical School, Germany 39 
50) University of North Carolina, United States 39 
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Figures 3.6 and 3.7 explore the co-authorship network of host organisations. The 
complete network is a highly complex structure due to the large number of 
organisations and ties connecting those organisations. Specifically, the network 
involves >6,000 organisations connected by >95,000 co-authorships in 
publications. The complete network is depicted in Figure 3.6 (a).2 Despite this 
complexity the complete co-authorship network is informative for the analysis of 
interdependencies in neoplasms research. For example, the largest component – 
i.e. the largest set of connected nodes (Wassermann and Faust 1994) – includes 
97.4% of the nodes, which is notably high and suggests those organisations in 
the field are highly interdependent. Further evidence of the intensity of inter-
organisational research activities is provided by the degree centrality measure, 
that is the number of ties connecting a node to other nodes in the network 
(Freeman 1979). On average an organisation is connected to 30.8 other 
organisations (with the maximum being 1,286 organisations). 
The analysis of a core of the co-authorship network provides an additional 
informative perspective but can only be undertaken by subjectively imposing 
conditions (i.e. there is no objectively definable „core‟). We identify a core 
imposing the following conditions: 
a) Organisations that contributed to at least 0.1% (at least seven 
publications) of the UK research output are included in the set of nodes 
b) The strongest 5% of co-authorship ties are included as connections 
(connections are shown between two organisations if they are connected 
by co-authorship in at least five publications) 
This imposing of these conditions is necessary to visualise the most central 
organisations. The core network is depicted in Figure 3.6 (b). It involves 575 
organisations connected by 5,039 ties. We focus only on organisations in the 
largest component of the network. This reduces the network to 387 nodes, i.e. 
188 organisations are working in smaller clusters isolated by imposing the above 
mentioned conditions. The set of 387 organisations is composed of 113 (~29%) 
UK organisations, 263 (~69%) non-UK organisations, and 11 (~2%) 
organisations located in multiple countries including UK (where multinational 
firms are placed).  
Analysis of the core highlights one of the key features of UK research in 
neoplasms, which is the strong role international collaborations play. Despite the 
bias in sample collection created by focusing only on papers with UK authors (as 
defined by the sample strategy adopted to meet the main aims of this report) the 
centre of the network is dominated by international research host organisations. 
In the international core network, an organisation is on average connected with 
17.5 other organisations (degree centrality) up to a maximum of 197 
organisations. Figure 3.7 provides a more detailed picture of this core. The strong 
interdependency between UK organisations and international actors is also 
depicted in Figure 3.6 (c) which by removing the non-UK organisations from 
previous core networks, identifies the UK core network. In the UK core network 
an organisation is on average connected with 7.5 other organisations (degree 
centrality) up to 53 organisations.  
                                           
2 Gephi 0.8.2 was used to produce the network figures. 
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Figure 3.6: Co-authorship network. The nodes’ colours are assigned as in the followings: UK organisations (green), non-UK 
organisations (blue), organisation located in multiple countries including UK (yellow). The size of nodes is proportional to 
the log2 of the number of publications the given actors contributed to. 
 
  
(a) Complete network (b) Core network (c) UK core network 
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Figure 3.7: Focus on the core co-authorship network in neoplasms. The nodes’ colours are assigned as in the followings: UK 
organisations (green), non-UK organisations (blue), organisation located in multiple countries including UK (yellow). The 
size of nodes is proportional to the log2 of the number of publications the given actors contributed to. 
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3.4.2 The interdependence of funding organisations 
Publications in the sample acknowledged support from over 2,500 organisations. 
While 663 funders are based in the UK (excluding private sector organisations), 
1,591 non-UK funders are acknowledged, as well as a further 307 private sector 
organisations (see Table 3.4). 
Table 3.4: Funding data and publications (N= 3,914) 
Number of distinct funders  
UK 663 
Non-UK 1,579 
Industrial actors 307 
  
Number of funders per publication  
Mean 3.3 




Number of UK funders per publication 
(excluding industrial actors) 
 
Mean 1.4 




Number of industrial funders per publication  
Mean 0.3 
Standard Deviation 1.5 
Min 0 
Max 50 
Note. Industrial actors are considered as a separate category 
since they generally have multiple geographical locations. 
 
Where publications acknowledge funding, only in 36% (1,420/3,914) of the cases 
the research depended on a single funder. Those papers acknowledging financial 
support had a mean of 3.3 funders. 
To gain an insight into the reasons why papers acknowledge multiple funders, it 
is useful to draw on the case study interviews. Although only four individuals 
were interviewed, the resulting case studies follow research undertaken by 
Principal Investigators (PIs) over at least a decade each, thereby following 
multiple projects per investigator and giving an insight into the funding support 
behind several hundred papers. In a complex funding ecosystem, research is 
often not funded by a single organisation. The interviewees reveal three broad 
types of co-contribution: 
1. Host + external funder - UK funders will generally not support the full 
economic cost of research and will require the host organisation to make a 
financial contribution. Host organisations will often meet this cost through 
cross-subsidising activities, for example with teaching revenues supporting 
research infrastructure and/or staff costs.  
2. Sharing funding by cost type - funders contribute to different types of 
cost, perhaps at different times such as when one funder finances a facility 
(externally) and another provides for staff costs related to the particular 
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project. Additionally, others may provide significant support, as when 
industrial partners provide expensive drugs for a trial. 
3. Joint funding - researchers or funders can anticipate the need for joint 
funding of a project or scheme in advance with costs being shared in a 
number of ways, such as by geography, institution or overall contribution. 
In other cases once a project is established, researchers may be 
opportunistic by working with other groups as projects progress if this 
allows projects to advance more efficiently. Joint publications are therefore 
also jointly funded by the authors‟ financial supporters.  
These categories are not mutually exclusive, with some or all applying to a given 
publication. Interpreting the contribution of a given funder is challenging as 
publications often have multiple authors from multiple organisations, and 
acknowledge multiple funders. Indeed from the information provided in the 
acknowledgements sections of publications it is generally not possible to identify 
which mode of support a funder is being acknowledged for, or even which author 
or organisation a given funder is supporting. Resolving this without speaking to 
one or more of the research paper‟s authors is therefore not possible. A further 
limitation of the approach is that publications may (strategically or mistakenly) 
also acknowledge funders that have not supported a given paper. 
Where the outputs of a research study depend on multiple sources of funding, the 
funders are described here as being interdependent, in that their funding support 
has required additional input from at least one other funder to yield the published 
output. It is important to acknowledge that this does not necessarily mean that 
no research would have been possible without all of the funders, but rather that 
the observed output would not have been possible in its exact form. One 
researcher interviewed said “I would strongly say that my research is not 
dependent on other people‟s funding at all” but said also that they did collaborate 
widely on papers for “scientific reasons”. Another suggested that ad hoc 
collaborations were an efficient way of proceeding because it saved “re-inventing 
the wheel”. Thus interdependency can be weak or strong.   
An example of strong interdependency of funders that would fall within each of 
the three conditions above is described in Case study 1.  
Case Study 1: Interdependency of funders in large scale clinical oncology 
trials 
Tim Maughan is Professor of clinical oncology and Department Director of the 
MRC/ CR-UK Gray Institute for radiation oncology and biology, within the 
Department of Oncology at the University of Oxford. He is also honorary 
consultant at the Churchill Hospital, Oxford. Over the last decade, Professor 
Maughan has played a leading role in the design and execution of several large 
clinical trials of cancer treatments that have depended on funding from multiple 
sources. In particular his work has focused on advancing the stratification of 
therapeutic treatment by studying the effectiveness of different drug 
combinations against colorectal cancers, with the hope that in the future 
biomarker tests will be able to guide clinical treatment choices by molecular 
categorisation of tumour type. 
 
Clinical research demands a much larger cost to answering a given research 
question than laboratory research. However, Maughan has been able to obtain 
OHE and SPRU Report for Cancer Research UK 
March 2014 
 
 34  
support for large and sophisticated multi-arm studies designed to answer 
different questions simultaneously. Phase 2 and Phase 3 trials designed by 
Maughan have be supported though combinations of CRUK, MRC and NIHR 
funding, as well as with contributions by industry and other charities.   
 
A recent example is the COIN trial (results reported in Maughan et al 2011, and 
Adams et al. 2011) which compared three treatment regimes in patients with 
advanced colorectal cancer. Continuous or intermittent use of Oxaliplatin and 
fluoropyrimidine (in combination) were compared to assess whether breaks in 
chemotherapy reduced the toxic side effects suffered by patients. Another arm of 
the trial compared the use of cetuximab in combination with oxaliplatin and 
capecitabine to see if this was superior to the other regimes.  
 
The COIN trial is an example of a large Phase III trial design that changed in form 
according to the availability of new research findings and collaborations even as it 
commenced. The initial idea for the COIN trial emerged from an NCRI study 
group – a group of experts that are funded to meet regularly to discuss research 
proposals. Maughan was encouraged by colleagues to design a study to explore 
the relative benefits of different drug combinations against advanced colorectal 
cancer, including to assess variants of a treatment protocol (Oxaliplatin with 
fluoropyrimidine) widely used outside the UK, but not yet approved by NICE.  
 
The great expense of large trials such as COIN (with >1600 patients) means 
these are often prohibitively expensive without industrial support in other parts of 
Europe. However with the availability of government and charitable core funding 
it is possible to undertake independent academic investigator led trials in the UK.  
This has the advantage that the data is publicly owned and publication is 
unhindered by commercial interests. The core cost of the COIN trial was 
supported by a CRUK Clinical Trials Advisory and Awards Committee grant, with 
the MRC clinical trials unit providing infrastructural support and acting as the 
formal trial sponsor. Additionally the trial also relied on industry partners to 
supply drugs and additional funding. 
 
Before the trial could commence the costs of Oxaliplatin had to be met. This drug 
was not yet NICE approved for NHS use, and so funding for this was underwritten 
by the NIHR. However NICE subsequently issued an approval before the trial 
commenced, and so this funding was not drawn on – the drug being purchased 
through routine NHS clinical provision. Several firms were invited to contribute to 
the study but some declined to join. However the team were successful in 
attracting Merck, a major German Pharmaceutical firm, to make a £500 per-
patient contribution to trial costs and to supply around £10M worth of the MAb 
therapy, Cetuximab. Other contributions in the form of discounted drugs were 
made by Baxter, Wyeth, Sanofi. During the trial data was collected by staff 
funded through the National Cancer Research Networks  
 
As the trial progressed, newly published data emerged suggesting that mutations 
in the KRAS gene might affect treatment outcomes in patients receiving 
epidermal growth factor receptor targeted antibodies such as Cetuximab.  
Arrangements had already been made to have a team at UCL hospitals 
undertaking biomarker testing for EGFR-status of tumours, and now plans were 
rapidly made to incorporate into the study the genotyping of patient tumours for 
KRAS status, which involved obtaining additional funding from Merck and CRUK, 
in the form of a Biomarkers and Imaging Discovery and Development Committee 
(BIDD) grant. This work was undertaken by a laboratory at Cardiff University 
where a doctoral research student, supported by local charity Cancer Research 
Wales, genotyped over 2000 tumour samples. The work was subsequently 
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validated by another laboratory in Leuven, in turn supported by the Institute for 
the promotion of Innovation through Science and Technology in Flanders. 
 
The COIN trial made important contributions by showing that the addition of 
Cetuximab to oxaliplatin and fluoropyrimidine chemotherapy was not of benefit to 
patients regardless of tumour KRAS status, and that intermittent chemotherapy 
was not inferior to continuous chemotherapy, allowing oncologists to adjust 
treatments to reduce toxic side effects in selected patients with advanced 
colorectal cancer.  
 
 
Figure 3.8 shows the interdependence of UK funders, where two or more UK 
funders are acknowledged in the same publication. Figure 3.8 reveals at least 250 
UK-based public sector and charitable external funders that support more than 
one publication on neoplasms per year. The most commonly interdependent 
funders are also the largest – namely the MRC, Cancer Research UK and the UK‟s 
Departments of Health (including the NIHR). Figure 3.8 excludes private sector 
funders, non-UK funders and UK-based funders acknowledged in less than two 
publications in 2011. The majority of the funders shown are external to the host 
organisation undertaking the research, however a small proportion of these are 
host organisations that also appear to support neoplasms research through 
internal funds beyond the standard contribution to salary and infrastructure costs 
of staff needed to bring research council or charity grants up to full economic 
costs (although some authors do acknowledge such contributions, authors 
generally do not acknowledge their employer as a funder, but it is not possible to 
exclude these where they do occur). 
By reading the symmetric matrix (in Figure 3.8 above) by row the top-3 „co-
funders‟ for each funder can be identified (highlighted green), e.g. Wellcome 
Trust co-funds papers most often with MRC (86), Cancer Research UK (83) and 
the Departments of Health (75).  
Beyond interdependencies at the national level, there is interdependence of 
national research systems and their funders, as explored in the previous section. 
This interdependence is further confirmed by assessing the numbers of UK 
publications that acknowledge non-UK funders: see Figure 3.9, which shows all 
funders acknowledged in more than 2% of publications in the sample. This 
reveals that of the top 17 funders of neoplasms papers with UK authors, nine are 
UK based and eight are non-UK. 
Notably, the top five contains two non-UK funders: the NIH and the European 
Commission. The NIH is acknowledged almost as much as the MRC, while the 
contributions to UK publication output of the Swedish Cancer Society or Italian 
Association for Cancer Research is comparable to that of Leukaemia and 
Lymphoma Research, Breakthrough Breast Cancer or the Breast Cancer 
Campaign. However it must be recognised that these funders are not supporting 
UK researchers directly, but rather their co-authors in other countries. An 
exception is the European Commission which does directly support UK 
researchers through its funding programmes. With acknowledgements to the 
European Commission in 384 papers, this suggests that the European 
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Commission supports UK researchers in neoplasms more frequently than does the 
Wellcome Trust. However, this finding should be interpreted with caution because 
an unknown number of these acknowledgements will support non-UK 
collaborators of UK authors more often than is likely to be the case for the more 
UK-focused Wellcome Trust. Figure 3.9 also confirms the key importance to UK 
scientists of funding for non-UK co-authors in the USA, Italy Sweden, Australia, 
Germany and France. 
Figure 3.8: Co-funding of UK funders that were acknowledged in at least 
in two publications (excluding industry) and co-occurrence matrix for the 
funders that acknowledged in at least 2% of the publication sample 
 
Funder 1 2 3 4 5 6 7 8 9 
1. Cancer Research UK  - 315 216 83 42 51 54 44 21 
2. Departments of Health (including NHS and NIHR) 315 - 183 75 24 52 19 46 10 
3. Medical Research Council (MRC) 216 183 - 86 41 15 7 43 25 
4. Wellcome Trust 83 75  86 - 9 10 3 7 15 
5. Leukaemia and Lymphoma Research 42 24 41 9 - 3 0 2 9 
6. Breakthrough Breast Cancer 51 52 15 10 3 - 7 4 1 
7. Breast Cancer Campaign 54 19 7 3 0 7 - 2 1 
8. Engineering and Physical Science Research Council (EPSRC) 44 46 43 7 2 4 2 - 15 
9. Biotechonolgy and Biological Sciences Research Council (BBSRC) 21 10 25 15 9 1 1 15  
Total number of publications supported 949 890 477 202 137 110 95 93 92 
 
These findings are highly contextual to neoplasms research and generalisations 
cannot be made outside the field of neoplasms because the sample of papers 
captured for this study excludes many papers that are funded by host 
organisations and external funders. Those funders that are more specialised on 
neoplasms will have a greater proportion of their activities included within the 
analysis. All tabulations of data should therefore be interpreted with this in mind. 
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This is a selective lens that focuses on neoplasms, and organisations‟ activities 
beyond neoplasms are excluded.  
Figure 3.9: UK (red), EU (blue), and non-EU (green) funding 
organisations acknowledged in at least 2% of the publication sample (N 
= 3,914). The chart excludes private actors. 
 
 
Table 3.5 and Figure 3.10 demonstrate that articles acknowledging external 
funding are more likely to involve more international organisations (as measured 
by the number of distinct countries in the list of host organisations). This 
suggests that external funders provide support for authors to collaborate 
internationally and that one consequence of such international collaboration is a 
leveraging of national research funding as UK authors‟ publications benefit from 
the financial support of their co-authors‟ funders.  
Table 3.5: Availability of funding data and number of countries 
Type of publication 
Number of countries 
Mean Std.Dev. Min Max 
Publication with funding data in acknowledgement 
sections 
 
2.5 2.5 1 25 
Publications with no acknowledgements sections or 
no funding data in acknowledgement sections 
 
1.6 1.4 1 20 
Notes. The t-test on mean (t=20.31, p<0.001) confirmed that publications providing funding data in 
acknowledgement sections involves on average more countries than those that do not. This result is 
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Figure 3.10: Numbers of publications and countries involved  
 
Figure 3.11: Number of funders per publication and types of publications 
 
Figure 3.11 shows that the it is most common for papers acknowledging funders 
to be supported by one funder, however 64% of papers have more than one 
funder, with the mean number of funders acknowledged per paper being 3.3. 
Industry plays a significant role in UK neoplasms research, with 698/3,914 
publications acknowledging funders including a private organisation (17.8%). By 
comparison, industry co-authors less frequently, with 647/7,510 publications 
having a co-author at a private organisation (8.6%). However combining these 
categories reveals that industry supports 1,084/7,510 publications (14.4%). A 
minority (261) of industry-supported papers provides a co-author and 
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frequently co-author publications with UK authors. The largest publisher is shown 
in green (Pfizer), the second largest in blue (AstraZeneca) and the third largest in 
orange (Novartis). 
Figure 3.12: Private organisation acknowledged in at least 1% of the 
publication sample (N = 3,914) 
 
As reported in Figure 3.13, on average ~17% of the publications supported by 
major UK funders involve industry – from a minimum of ~8% for Breast Cancer 
Campaign to a maximum of ~23% for MRC.  
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3.5 Scientometric analysis: Complementarities in neoplasms 
research 
Complementarities in research funding are regarded here as where the activities 
of funders and/or research host organisations support research in distinct areas 
rather than wholly overlapping (or being similar) in the activities that they 
support. For example, research grant funding can also be used to support 
projects that are complementary to each other by aiding the creation of multi-
disciplinary groups, so broadening a research effort. A series of grants can also 
be used to lengthen the duration of a research effort, such that these are 
complementary in their use to develop a line of research towards application.    
3.5.1 Complementarities across regions 
One of the most basic complementarities is revealed in the exploration of how 
hosts and funders are active across the geography of the UK. In order to divide 
geographies up into regions, the „Nomenclature of territorial units for statistics‟ is 
adopted, using the Level 2 codes (NUTS-2 divides the UK into 36 regions, vs. only 
12 for NUTS-1).3 Table 3.7, Figure 3.13 and Figure 3.14 divide the UK into NUTS-
2 regions. Table 3.7 demonstrates that all regions of the UK are active in 
neoplasms research to some extent. 
Table 3.7: UK regions (NUTS-2) and number of publications 
 NUTS-2 Code Region Number of publications 
1) UKI1 and UKI2 Inner London and Outer London 3124 
2) UKH1 East Anglia 720 
3) UKJ1 Berkshire, Buckinghamshire and Oxfordshire 713 
4) UKD3 Greater Manchester 540 
5) UKM2 Eastern Scotland 495 
6) UKG3 West Midlands 485 
7) UKE4 West Yorkshire 452 
8) UKM3 South Western Scotland 395 
9) UKD7 Merseyside 322 
10) UKK1 Gloucestershire, Wiltshire and Bristol/Bath area 313 
11) UKF1 Derbyshire and Nottinghamshire 307 
12) UKC2 Northumberland and Tyne and Wear 291 
13) UKJ3 Hampshire and Isle of Wight 286 
14) UKL2 East Wales 278 
15) UKE3 South Yorkshire 269 
16) UKF2 Leicestershire, Rutland and Northamptonshire 203 
17) UKN0 Northern Ireland 195 
18) UKM5 North Eastern Scotland 130 
19) UKJ2 Surrey, East and West Sussex 120 
20) UKK4 Devon 107 
21) UKD4 Lancashire 97 
22) UKD6 Cheshire 96 
23) UKE2 North Yorkshire 78 
24) UKL1 West Wales and The Valleys 69 
25) UKJ4 Kent 58 
26) UKE1 East Yorkshire and Northern Lincolnshire 57 
27) UKK2 Dorset and Somerset 54 
28) UKH2 Bedfordshire and Hertfordshire 47 
29) UKH3 Essex 41 
30) UKC1 Tees Valley and Durham 37 
31) UKG2 Shropshire and Staffordshire 30 
32) UKG1 Herefordshire, Worcestershire and Warwickshire 27 
33) UKF3 Lincolnshire 12 
34) UKK3 Cornwall and Isles of Scilly 12 
35) UKD1 Cumbria 7 
36) UKM6 Highlands and Islands 7 
                                           
3 http://epp.eurostat.ec.europa.eu/portal/page/portal/nuts_nomenclature/introduction 
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Figure 3.14 shows how co-author ties generate a collaborative network that 
reflects some of the geospatial relationship of towns the UK, with remote, 
sparsely populated regions at the margins of the map. Figure 3.13 also shows 
that the UK is highly dependent on research in London, Cambridge and Oxford 
areas as 4,032/7,510 publications (~54% of the sample) were produced with at 
least one co-author in “Inner and Outer London”, “East Anglia” or “Berkshire, 
Buckinghamshire and Oxfordshire”. However, the remaining ~46% of the output 
has no co-author from a research host organisation from these regions. 
Vosviewer software identifies clusters within this co-authorship network, 
highlighting how authors in “Inner and Outer London”, “East Anglia” or 
“Berkshire, Buckinghamshire and Oxfordshire” are more closely linked with “West 
Yorkshire” “Herefordshire, Worcestershire and Warwickshire” and “Surrey, East 
and West Sussex” than other parts of the country. See Figure 3.14. The Scottish 
regions also form a notably distinct cluster, as does the North West of England. 
Table 3.8 shows funding by the funders acknowledged in at least 2% of the 
publications combined with region of the UK identified from host organisations‟ 
addresses. A strong limitation of the data is that publications do not consistently 
reveal which host organisations obtain support from specific funders in multi-host 
multi-funder papers. However, it is possible to demonstrate regions where no 
publications supported by a given funder have a host organisation in a particular 
region. In this way it is possible to show that eight NUTS-2 regions received 
funding from fewer than half of the top nine funders. These include “Cornwall & 
the Isles of Scilly” “Cumbria”, “Devon”, “Essex”, “Kent”, “Hertfordshire, 
Worstershire and Warwickshire”, “Lincolnshire”, “Tees Valley & Durham”, and 
“West Wales and the Valleys”. 
Cancer Research UK, the Departments of Health and the MRC provide the most 
comprehensive geographic coverage by regional funding, which is unremarkable 
given the size of their funding portfolios. However, these funders and the 
Wellcome Trust are notable in focusing the most research funding in London, East 
Anglia and Berkshire, Buckinghamshire and Oxfordshire – the so-called „Golden 
Triangle‟ of London, Cambridge and Oxford. While the smaller funders shown also 
generally have the core focus of their research on London, they more often have 
a secondary geographical focus outside the „Golden Triangle‟. For example 
Leukaemia and Lymphoma Research appears to focus in “Northumberland, and 
Tyne and Wear”, and “West Yorkshire”, while Breakthrough Breast Cancer 
supports research in “Greater Manchester” and “Eastern Scotland”. 
This suggests that there is complementarity between the large national funders 
that focus on the South East and smaller, perhaps more regionally oriented, 
charities that focus elsewhere as well as in London. Examples outside the top nine 
include Yorkshire Cancer Research, Scottish Funding Council, Cancer Research 
Wales, Northwest Cancer Research Fund and the Newcastle Healthcare Charity. 
There are also many smaller charities that also focus their funding efforts in the 
Golden Triangle, so this is not to say that small funders offset the focus 
demonstrated by the large funders.   
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Figure 3.14: Co-authorship between UK NUTS-2 regions. Network and 
relative clusters are produced using VOSviewer Version 1.5.4 
 
(a) Network view 
 
 
(b) Cluster view 
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Table 3.8: UK funding organisations acknowledged in at least 2% of the 








































































































































































































































Tees Valley and Durham 6 6 3 1 0 0 0 0 0 
Northumberland and Tyne and Wear 54 46 32 8 19 3 2 2 6 
Cumbria 0 0 0 0 0 0 0 0 0 
Greater Manchester 102 89 35 11 9 24 8 7 13 
Lancashire 5 7 3 1 0 0 0 1 0 
Cheshire 8 5 4 1 0 0 0 2 2 
Merseyside 42 39 20 6 2 1 1 0 8 
East Yorkshire and Northern Lincolnshire 2 6 4 1 1 0 0 1 1 
North Yorkshire 5 7 4 1 7 0 0 1 1 
South Yorkshire 40 42 14 3 4 6 12 6 5 
West Yorkshire 88 60 40 10 18 1 6 2 7 
Derbyshire and Nottinghamshire 38 32 19 1 1 3 9 4 5 
Leicestershire, Rutland and Northamptonshire 24 28 15 5 7 1 5 0 1 
Lincolnshire 0 0 1 0 0 0 0 0 0 
Herefordshire, Worcestershire and Warwickshire 0 3 1 0 0 0 0 0 0 
Shropshire and Staffordshire 2 2 0 0 0 0 1 1 1 
West Midlands 85 54 45 11 15 1 7 7 5 
East Anglia 224 177 115 70 19 8 22 5 8 
Bedfordshire and Hertfordshire 1 2 2 0 1 0 1 1 0 
Essex 2 1 0 0 0 0 0 0 0 
Inner London and Outer London 518 613 274 113 62 78 41 47 26 
Berkshire, Buckinghamshire and Oxfordshire 185 168 128 57 17 10 7 18 13 
Surrey, East and West Sussex 14 16 7 3 2 1 1 1 1 
Hampshire and Isle of Wight 50 35 17 5 16 2 7 1 4 
Kent 3 4 0 0 0 0 1 0 0 
Gloucestershire, Wiltshire and Bristol/Bath area 48 53 36 13 10 1 4 2 3 
Dorset and Somerset 9 5 7 0 7 1 0 0 0 
Cornwall and Isles of Scilly 1 2 1 0 0 0 0 0 0 
Devon 20 27 10 3 0 1 0 0 0 
West Wales and The Valleys 11 5 3 0 0 0 0 1 0 
East Wales 39 36 23 9 14 2 2 4 5 
Eastern Scotland 73 43 55 23 5 18 6 7 8 
South Western Scotland 75 29 37 20 6 3 1 2 4 
North Eastern Scotland 14 25 10 3 0 1 4 1 3 
 
Around half of the organisations working on neoplasms in the UK produced work 
through international collaboration, while the remaining 576 worked alone or with 
national co-authors. Most such organisations (426) produced only one publication 
on neoplasms in 2011. This is a highly diverse group of organisations, including 
hospitals (157) government offices or organisations (34), industry (47) and 
charities (33). A further 152 – the majority of which were hospitals (116) – 
produced between 1 and 15 publications in 2011. This suggests there may also 
be a complementarity between institutions that have an international focus and 
those addressing national-level research agendas. However this requires further 
investigation to confirm.  
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It is possible that the national-level, low volume publishing organisations are 
producing distinct types of output to the high volume, highly international 
publishers. This remains to be investigated. 
3.5.2 Funder complementarities at research host organisation level 
Following from the discussion above, it is possible to explore the coverage of the 
UK research host organisations by the major funders to understand the number 
of distinct UK organisations directly or indirectly supported by them. As noted in 
Figure 3.1, it is not possible to distinguish between direct benefit (where a host 
organisation has funding) and indirect benefit (where host organisations and 
funders support a single publication). The funders shown in Table 3.9 supported 
(directly or indirectly) in total 430 UK organisations (out of 699 organisations 
involved in those publications with acknowledgment sections). 
Table 3.9: Number of research host organisations involved in papers 
supported by major UK funders 
 
 Funder Number of 
organisations 
1) UK Departments of Health (inc. NHS, NIHR) 330 
2) Cancer Research UK 259 
3) Medical Research Council 175 
4) Wellcome Trust 91 
5) Breast cancer Campaign 68 
6) Engineering and Physical Sciences Research Council 60 
7) Leukaemia and Lymphoma Research 59 
8) Biotechnology and Biological Sciences Research Council 49 
9) Breakthrough Breast Cancer 48 
 
3.5.3 Complementarities across MESH codes within neoplasms 
Complementarity of funders and host organisations can be investigated by 
analysing the specific focus of the research that these organisations are pursuing. 
This allows the relative focus of research on neoplasms at national and 
organisational level to be studied, and identification of relatively neglected areas.  
We use the MeSH descriptors under the „parent‟ descriptor “Neoplasms” to profile 
the research of these organisations. Table 3.10 shows that the publications in our 
sample were classified by descriptors belonging to the sub-branches “Neoplasms 
by Site” and “Neoplasms by Histologic Type” which hold ~68% and ~43% of the 
sample respectively (see Table A2 in the appendix for more details on the MeSH 
classification system). Table 3.11 reports the descriptors of these „sub-branches‟ 
at the next level of detail (the third MESH level) with the corresponding number 
of publications. The three areas with most publications are “Neoplasms, Glandular 
and Epithelial”, “Digestive System Neoplasms”, and “Urogenital Neoplasms”. 
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Table 3.10: “Neoplasms” MeSH Descriptors at level 2 (N=7,510). 
Descriptor Tree number Number of 
publications 
Neoplasms by Site C04.588 5,137 
Neoplasms by Histologic Type C04.557 3,252 
Neoplastic Processes C04.697 970 
Cysts C04.182 175 
Neoplasms, Experimental C04.619 158 
Neoplastic Syndromes, Hereditary C04.700 112 
Precancerous Conditions C04.834 109 
Tumor Virus Infections C04.925 106 
Neoplasms, Multiple Primary C04.651 56 
Neoplasms, Radiation-Induced C04.682 50 
Paraneoplastic Syndromes C04.730 44 
Neoplasms, Second Primary C04.692 40 
Pregnancy Complications, Neoplastic C04.850 37 
Neoplasms, Hormone-Dependent C04.626 24 
Hamartoma C04.445 23 
Neoplasms, Post-Traumatic C04.666 0 
Note: More than one descriptor can be assigned to a publication. The publication count includes also 
the lower levels of the MeSH tree. 1,126 publications (14.99%) are classified as “Neoplasms” at the 
first level of the MeSH tree, i.e. no additional MeSH descriptors at second or lower level are reported. 
 
Table 3.11: “Neoplasms by Site” and “Neoplasms by Histologic Type” 
MeSH Descriptors at level 3. 
Descriptor Tree number No. of pubs 
Neoplasms, Glandular and Epithelial C04.557.470 1,633 
Digestive System Neoplasms C04.588.274 1,253 
Urogenital Neoplasms C04.588.945 1,017 
Breast Neoplasms C04.588.180 1,008 
Head and Neck Neoplasms C04.588.443 663 
Neoplasms, Germ Cell and Embryonal C04.557.465 652 
Neoplasms, Nerve Tissue C04.557.580 614 
Endocrine Gland Neoplasms C04.588.322 565 
Thoracic Neoplasms C04.588.894 533 
Leukemia C04.557.337 435 
Nervous System Neoplasms C04.588.614 373 
Neoplasms, Connective and Soft Tissue C04.557.450 328 
Lymphoma C04.557.386 302 
Skin Neoplasms C04.588.805 287 
Bone Neoplasms C04.588.149 236 
Nevi and Melanomas C04.557.665 229 
Neoplasms, Plasma Cell C04.557.595 132 
Neoplasms, Vascular Tissue C04.557.645 115 
Neoplasms, Complex and Mixed C04.557.435 62 
Soft Tissue Neoplasms C04.588.839 62 
Eye Neoplasms C04.588.364 61 
Hematologic Neoplasms C04.588.448 60 
Abdominal Neoplasms C04.588.33 46 
Mammary Neoplasms, Animal C04.588.531 23 
Pelvic Neoplasms C04.588.699 13 
Neoplasms, Gonadal Tissue C04.557.475 11 
Lymphatic Vessel Tumors C04.557.375 10 
Histiocytic Disorders, Malignant C04.557.227 5 
Splenic Neoplasms C04.588.842 5 
Odontogenic Tumors C04.557.695 1 
Anal Gland Neoplasms C04.588.83 1 
Notes. More than one descriptor can be assigned to a publication. Publications to which multiple 
descriptors belonging to the same branch (at the third level of the MeSH tree) are assigned are not 
double counted. The third level of the MeSH tree allows classifying 6,174 publications (82.2%). 
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Major UK research host organisations (17) and funders (9) are profiled according 
to the most frequently occurring 25 MeSH descriptors in Figure 3.14 and Figure 
3.15, respectively. These figures report two types of information for each major 
UK host organisation and funder. The radar chart on the left of each page depicts 
the proportion of research that a host organisations produced or a funder 
supported in a given neoplasm domain relatively to overall number of publications 
that they produced/supported in neoplasms. The radar chart on the right of the 
page normalises the organisations‟ profiles by comparing the proportion of 
publications a host organisation produced or a funder supported in a given 
neoplasm domain versus the expected value of publications in that domain. The 
expected value (number) of publications in the neoplasms domain is calculated as 
the average number of publications per organisation in that domain. This allows 
an organisation‟s research contribution by neoplasm domains in relation to the 
overall activity in those domains and to the organisation‟s output. For example, if 
a domain is indicated to have a value higher than 1, then the focal organisation is 
contributing to that domain more than expected.4 
Figure 3.15 explores how the research of the major host organisation is 
distributed over the major neoplasm domains (as reported in Table 3.11). The 
Figure 3.15 indicates that major UK host organisations (except for Cardiff 
University and University of Southampton) contributed at least 20% of their 
research output to the “Neoplasms, Glandular and Epithelial” domain. At least 
20% of the research output of University College London, Imperial College, 
Oxford University, University of Leeds, and University of Glasgow is focused on 
“Digestive System Neoplasms”. Finally, the Institute of Cancer Research, 
University of Cambridge, Oxford University, Queen Mary University of London, 
and Cardiff University focused more than 20% of their research output on 
“Urogenital Neoplasms”. Overall the top-9 major host organisations‟ research 
profiles are relatively similar. However the radar charts suggest that University of 
Edinburgh and University of Sheffield are particularly focused on “Breast 
Neoplasms” domains to which they contribute ~30% of their neoplasms research 
outputs. Other distinctive features include a relative focus at University of 
Liverpool on “Head and Neck Neoplasms” and at Cardiff University and University 
of Southampton on “Leukemia”. 
Additional information on the host organisations‟ research profile is provided by 
the radar charts on the right of each page in Figure 3.15, which show output 
relative to other organisations nationally. The charts reveal that while all UK 
major host organisations (except for Cardiff University and University of 
Southampton) contributed to the “Neoplasms, Glandular and Epithelial” domain 
with at least 20% of their research output in neoplasms, none of these 
organisations is contributing more than expected to this neoplasm domain, which 
is a major focus at the national level.  
Similarly University College London, Imperial College, Oxford University, 
University of Leeds, and University of Glasgow undertake a high proportion of 
                                           
4 An alternative normalisation approach could consider the incidence ratio of different neoplasms on 
UK population. However, the available statistics do not fully match the MeSH classification making this 
type of normalisation possible only for certain types of neoplasms. This would provide partial 
statistics. We therefore deemed it more suitable to undertake a normalisation based on publication 
count. 
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their neoplasms research on “Digestive System Neoplasms”. However, only 
Oxford University, University of Leeds, and University of Glasgow are contributing 
more than expected to this domain. Finally, the Institute of Cancer Research, 
University of Cambridge, Oxford University, Queen Mary University of London, 
and Cardiff University focus more than 20% of their research output in 
“Urogenital Neoplasms” and are also contributing more than expected to this type 
of neoplasm research.  
The charts also reveal major contributions to relatively smaller neoplasms 
domains. For example, the Institute of Cancer Research, University of Leeds, 
University of Newcastle, University of Birmingham are contributing at least twice 
as much as is expected to “Neoplasms, Plasma Cell”. In addition, University of 
Newcastle and University of Cardiff produced more publications than expected in 
“Leukemia”. 
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Figure 3.15a: Major UK research host organisations in “Neoplasms” area 
and distribution of publications across the different types of cancer. Left 
charts report the percentage of research host organisations’ total 
publications in different neoplasm domains. Right charts report whether 
research host organisations are more (>1.0) or less (<1.0) active in each 
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Figure 3.15b: Major UK research host organisations in “Neoplasms” area 
and distribution of publications across the different types of cancer. Left 
charts report the percentage of research host organisations’ total 
publications in different neoplasm domains. Right charts report whether 
research host organisations are more (>1.0) or less (<1.0) active in each 
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Figure 3.15c: Major UK research host organisations in “Neoplasms” area 
and distribution of publications across the different types of cancer. Left 
charts report the percentage of research host organisations’ total 
publications in different neoplasm domains. Right charts report whether 
research host organisations are more (>1.0) or less (<1.0) active in each 
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Figure 3.15d: Major UK research host organisations in “Neoplasms” area 
and distribution of publications across the different types of cancer. Left 
charts report the percentage of research host organisations’ total 
publications in different neoplasm domains. Right charts report whether 
research host organisations are more (>1.0) or less (<1.0) active in each 
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Figure 3.15e: Major UK research host organisations in “Neoplasms” area 
and distribution of publications across the different types of cancer. Left 
charts report the percentage of research host organisations’ total 
publications in different neoplasm domains. Right charts report whether 
research host organisations are more (>1.0) or less (<1.0) active in each 











Neoplasms, Glandular and Epithelial 
Digestive System Neoplasms 
Urogenital Neoplasms 
Breast Neoplasms 
Head and Neck Neoplasms 
Neoplasms, Germ Cell and Embryonal 
Neoplasms, Nerve Tissue 
Endocrine Gland Neoplasms 
Thoracic Neoplasms 
Leukemia 
Nervous System Neoplasms 
Neoplasms, Connective and Soft Tissue 
Lymphoma Skin Neoplasms 
Bone Neoplasms 
Nevi and Melanomas 
Neoplasms, Plasma Cell 
Neoplasms, Vascular Tissue 
Neoplasms, Complex and Mixed 




Mammary Neoplasms, Animal 
Pelvic Neoplasms 










Neoplasms, Glandular and Epithelial 
Digestive System Neoplasms 
Urogenital Neoplasms 
Breast Neoplasms 
Head and Neck Neoplasms 
Neoplasms, Germ Cell and Embryonal 
Neoplasms, Nerve Tissue 
Endocrine Gland Neoplasms 
Thoracic Neoplasms 
Leukemia 
Nervous System Neoplasms 
Neoplasms, Connective and Soft Tissue 
Lymphoma Skin Neoplasms 
Bone Neoplasms 
Nevi and Melanomas 
Neoplasms, Plasma Cell 
Neoplasms, Vascular Tissue 
Neoplasms, Complex and Mixed 




Mammary Neoplasms, Animal 
Pelvic Neoplasms 










Neoplasms, Glandular and Epithelial 
Digestive System Neoplasms 
Urogenital Neoplasms 
Breast Neoplasms 
Head and Neck Neoplasms 
Neoplasms, Germ Cell and Embryonal 
Neoplasms, Nerve Tissue 
Endocrine Gland Neoplasms 
Thoracic Neoplasms 
Leukemia 
Nervous System Neoplasms 
Neoplasms, Connective and Soft Tissue 
Lymphoma Skin Neoplasms 
Bone Neoplasms 
Nevi and Melanomas 
Neoplasms, Plasma Cell 
Neoplasms, Vascular Tissue 
Neoplasms, Complex and Mixed 




Mammary Neoplasms, Animal 
Pelvic Neoplasms 





Neoplasms, Glandular and Epithelial 
Digestive System Neoplasms 
Urogenital Neoplasms 
Breast Neoplasms 
Head and Neck Neoplasms 
Neoplasms, Germ Cell and Embryonal 
Neoplasms, Nerve Tissue 
Endocrine Gland Neoplasms 
Thoracic Neoplasms 
Leukemia 
Nervous System Neoplasms 
Neoplasms, Connective and Soft Tissue 
Lymphoma Skin Neoplasms 
Bone Neoplasms 
Nevi and Melanomas 
Neoplasms, Plasma Cell 
Neoplasms, Vascular Tissue 
Neoplasms, Complex and Mixed 




Mammary Neoplasms, Animal 
Pelvic Neoplasms 





Neoplasms, Glandular and Epithelial 
Digestive System Neoplasms 
Urogenital Neoplasms 
Breast Neoplasms 
Head and Neck Neoplasms 
Neoplasms, Germ Cell and Embryonal 
Neoplasms, Nerve Tissue 
Endocrine Gland Neoplasms 
Thoracic Neoplasms 
Leukemia 
Nervous System Neoplasms 
Neoplasms, Connective and Soft Tissue 
Lymphoma Skin Neoplasms 
Bone Neoplasms 
Nevi and Melanomas 
Neoplasms, Plasma Cell 
Neoplasms, Vascular Tissue 
Neoplasms, Complex and Mixed 




Mammary Neoplasms, Animal 
Pelvic Neoplasms 





Neoplasms, Glandular and Epithelial 
Digestive System Neoplasms 
Urogenital Neoplasms 
Breast Neoplasms 
Head and Neck Neoplasms 
Neoplasms, Germ Cell and Embryonal 
Neoplasms, Nerve Tissue 
Endocrine Gland Neoplasms 
Thoracic Neoplasms 
Leukemia 
Nervous System Neoplasms 
Neoplasms, Connective and Soft Tissue 
Lymphoma Skin Neoplasms 
Bone Neoplasms 
Nevi and Melanomas 
Neoplasms, Plasma Cell 
Neoplasms, Vascular Tissue 
Neoplasms, Complex and Mixed 




Mammary Neoplasms, Animal 
Pelvic Neoplasms 
15. Cardiff University, Cardiff 
OHE and SPRU Report for Cancer Research UK 
March 2014 
 
 53  
Figure 3.15f: Major UK research host organisations in “Neoplasms” area 
and distribution of publications across the different types of cancer. Left 
charts report the percentage of research host organisations’ total 
publications in different neoplasm domains. Right charts report whether 
research host organisations are more (>1.0) or less (<1.0) active in each 
domain than expected. 
 
 
Figure 3.16 shows that the top three external research funders (CR-UK, DH and 
MRC) also mainly focus on “Neoplasms, Glandular and Epithelial”, “Digestive 
System Neoplasms”, and “Urogenital Neoplasms”. The remaining funders have a 
more specialised research profile across the neoplasms domains. For instance, 
~80% of the publications supported by Breakthrough Breast Cancer or Breast 
Cancer Campaign are classified as “Breast Neoplasms”. Leukaemia and 
Lymphoma Research support paper mainly related to “Leukemia” and 
“Lymphoma” domains. The Wellcome Trust and BBSRC are relatively more 
focused on “Neoplasms, Germ Cell and Embryonal” and “Neoplasms, Nerve 
Tissue” domains. While the top-3 funders‟ research profiles are relatively similar 
in the neoplasms domains that they support, it is worth noting that relatively 
„minor‟ neoplasm sites such as eye, bone, skin and soft tissue are neglected by 
these funders. However, the remaining major funders seem to complement this. 
For example, BBSRC and EPSRC are contributing more than expected to eye, 
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Figure 3.16a: Major UK funders acknowledged in “Neoplasms” area and 
distribution of publications across the different types of cancer. Left 
charts report the percentage of funders’ total publications in different 
neoplasm domains. Right charts report whether funders are more (>1.0) 
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Figure 3.16b: Major UK funders acknowledged in “Neoplasms” area and 
distribution of publications across the different types of cancer. Left 
charts report the percentage of funders’ total publications in different 
neoplasm domains. Right charts report whether funders are more (>1.0) 
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Figure 3.16c: Major UK funders acknowledged in “Neoplasms” area and 
distribution of publications across the different types of cancer. Left 
charts report the percentage of funders’ total publications in different 
neoplasm domains. Right charts report whether funders are more (>1.0) 
or less (<1.0) active in each domain than expected. 
 
The analysis also compares the major UK funders collectively (defined as those 
supporting at least 2% of the research output) with the remaining research 
funders that are more minor by funding activity in neoplasms research. To 
facilitate comparisons at the aggregate level, we first to chart the 
interdependence between different types of funders and set out the overall 
contributions by each set of funders individually and with other funders by group. 
To do so, we defines three categories of funder as in the followings: 
 Major UK funders: UK funders acknowledged in at least 2% of the 
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 Minor UK funders: UK funders acknowledged in less than 2% of the 
publications (however these are not necessarily small funders by size). 
 Other Funders and Industry: all other funders not falling in the previous 
categories including industrial actors 
A publication may be supported by one of these categories of funders or by 
combinations of these. We represent the possible combinations in Figure 3.17 and 
report the number of publications supported by each combination of funders. 
Figure 3.17: Conceptualising the co-funding 
 









The analysis reveals that 697 publications (17.8%) are exclusively supported by 
one or more UK major funders, 466 publications (10.9%) are exclusively 
supported by one or more UK minor funders, and 1,344 publications (34.3%) are 
exclusively supported by other funders and industry. Adopting the same radar 
chart approach used to profile the research produced by major UK host 
organisations or supported by the major UK funders, we profile the publications 
according to the combination of categories of funders that supported them. This 
analysis is reported in Figure 3.17. 
Publications supported only by major UK funders (a) are mainly focused on 
“Neoplasms, Glandular and Epithelial”, “Digestive System Neoplasms”, 
“Urogenital Neoplasms”, and “Breast Neoplasms” while “Head and Neck 
Neoplasms”, “Neoplasms, Germ Cell and Embryonal”, “Neoplasms, Nerve Tissue”, 
“Endocrine Gland Neoplasms”, and “Thoracic Neoplasms” are relatively neglected 
when compared to research outputs supported only by minor UK funders (b). This 
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finding is confirmed also when the observed number of publications is compared 
with the expected one (see right radar charts in Figure 3.18b). Interestingly, the 
subset of publications supported by UK minor funders and other funders including 
industry (e) is unevenly distributed across neoplasms domains when it is 
compared to the subset of publications supported by other funders‟ combinations 
(left charts). The combination of minor UK funder and other funders including 
industry is also disproportionally contributing to specific neoplasms domains 
(right charts) such as “Breast Neoplasms”, “Neoplasms, Germ Cell and 
Embryonal”, “Thoracic Neoplasms”, “Bone Neoplasms”, and “Nevi and 
Melanomas”.  
Figure 3.18a: Funders acknowledged in “Neoplasms” area and 
distribution of publications across the different types of cancer. Left 
charts report the percentage of funders’ total publications in different 
neoplasm domains. Right charts report whether funders are more (>1.0) 
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Figure 3.18b: Funders acknowledged in “Neoplasms” area and 
distribution of publications across the different types of cancer. Left 
charts report the percentage of funders’ total publications in different 
neoplasm domains. Right charts report whether funders are more (>1.0) 
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Figure 3.19 summarizes how different categories of funders contribute to the 
neoplasms domains independently or in combination – based only publications 
reporting funding sources in the acknowledgement section. Results shows that 
the proportion of publications supported exclusively by major UK funders (blue) 
or minor UK funders (red) is very similar across a number of domains such as 
“Head and Neck Neoplasms”, “Neoplasms, Nerve Tissue”, “Thoracic Neoplasms”, 
and “Skin Neoplasms”. Major UK funders are more active than minor UK funders 
in domains such as “Digestive System Neoplasms”, “Urogenital Neoplasms”, 
“Breast Neoplasms”, “Neoplasms, Vascular Tissue”, “Soft Tissue, Neoplasms”, and 
“Pelvic Neoplasms”. As there are only nine major funders this suggests funding is 
relatively more concentrated in these domains. Publications supported exclusively 
by “Other Funders and Industry” (green) are relatively equally distributed across 
the different neoplasms domains (except for “Abdominal Neoplasms”, “Mammary 
Neoplasms, Animal” and “Pelvic Neoplasms”) showing that industrial funders and 
non-UK funders support on average ~33% of publications across the neoplasms 
domains. 
Figure 3.19: Funders acknowledged in “Neoplasms” area and distribution 
of publications across the different types of neoplasms (N=3,914) 
 
 
Figure 3.20 further explore this by combining the different categories in three 
overlapping groups, i.e. publications supported at least by one major UK funder 
(a+d+f+g), publications supported by at least one minor UK funder (b+d+e+g), 
and publications supported at least by one „other‟ funder or industry (c+e+f+g). 
While the three groups have a relative similar research profile when compared in 
term of proportion of publications supported in a given neoplasms domains (top 
charts in Figure 3.20), the charts comparing the observed number of publication 
with the expected one in each domains provide evidence of the diversity of 
research profiles of the three groups. Publications supported by at least one UK 
minor funder seems to be more evenly spread across the neoplasms domains, i.e. 
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the number of publications is close to the expected one in many domains, when 
compared to the distribution of publications supported by at least one major UK 
funder. The analysis also shows that publications supported at least by one 
funder not falling to the other two groups or industry are concentrated more than 
expected in a number of neoplasms domains such as “Neoplasms, Plasma Cell”, 
“Nevi and Melanomas”, “Hematological Neoplasms”, and “Abdominal Neoplasms”. 
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Figure 3.20: Comparing major and minor UK funders acknowledged in “Neoplasms”. Upper charts report the percentage of 
funders’ total publications in different neoplasm domains. Lower charts report whether funders are more (>1.0) or less 
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3.5.4 Complementarities across funding schemes  
For the purpose of this study we identify complementary funders‟ schemes as 
being those that collectively support a wider range of research activity than 
individual funders, and by doing so facilitate researchers to obtain funding 
throughout their career for different types of research, rather than a narrower 
range of activity. In order to explore how funding schemes might be 
complementary, the top public funders in neoplasms were identified by 
publication counts, and data regarding the funding schemes they support 
gathered from their websites and their most recent annual reports.  
The top funders were: Cancer Research UK, the UK Departments of Health (DH, 
subdivided into NHS and NIHR), the Medical Research Council (MRC), the National 
Institutes for Health (NIH, USA), The Wellcome Trust, Breast Cancer Campaign 
(BCC), Biotechnology and Biological Sciences Research Council (BBSRC), 
Yorkshire Cancer Research (YCR), Economic and Physical Sciences Research 
Council (EPSRC), Leukaemia and Lymphoma Research (LLR), European Union 
(EU, under Framework Programme 7 (FP 7) and European Commission 
Department of Health and Consumers (DG SANCO).  
The data collected from these funders covered the purpose, duration and amount 
of the funding, in addition to an idea of the people who would be eligible to apply. 
A subjective interpretation has been made to develop a classification system in an 
attempt to overcome the issues associated with the diversity of terminology used 
by different funding bodies (see Table 3.12). The terminology used by funders to 
describe their schemes may vary from the description here.  
Table 3.12: Classification system to enable the categorisation of the 
different types of funding available from the top funders of UK research 
in neoplasms 
Type of funding 
 
Purpose Scale of award Duration 
Fellowships To set up research groups, provide further 
training or to further academic career 










Studentships To fund academic development of fund 
further formal training (up to and including 
PhD training). Mainly stand-alone 
studentships (i.e. excluding studentships 




salary and tuition 
fees for the 
duration 
3-4 years 
Projects To fund a defined piece of work with 
clearly state and achievable objectives 
Some have no fixed 
limits but tend to 
range from £25,000 
up to £1m per year  
 
1-5 years 
Programmes To provide long term support for larger 
research groups that aim to answer an 
interrelated set of questions and utilise a  
multidisciplinary team 
Often with no pre-
defined funding 
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Other types of funding categorised but not shown include funding specifically for 
infrastructure (sometimes including equipment and resources) or travel. The 
summary table of funding schemes offered by top funders is presented below 
(Table 3.13).  
Table 3.13: A summary overview of the different types of funding 
available from the top public funders of UK cancer research 
Funder 





















































Cancer Research UK  ✔  ✔ ✔ ✔ ✔ 
DH (NHS)  ✔     
NIHR ✔ ✔ ✔ ✔ ✔  
Medical Research Council (MRC) ✔ ✔  ✔ ✔  
National Institutes of Health (NIH) ✔   ✔ ✔ ✔ 
Wellcome Trust ✔ ✔ ✔ ✔ ✔ ✔ 
Breast Cancer Campaign ✔ ✔   ✔  
Biotechnology and Biological Sciences Research Council (BBSRC) ✔ ✔  ✔ ✔ ✔ 
Yorkshire Cancer Research (YCR) ✔ ✔  ✔ ✔ ✔ 
Engineering and Physical Science Research Council (EPSRC) ✔ ✔  ✔ ✔ ✔ 
Leukaemia and Lymphoma Research ✔ ✔  ✔ ✔ ✔ 
European Commission (FP7) ✔  ✔ ✔ ✔  
European Commission DG SANCO   ✔  ✔ ✔ 
 
PhD Studentships 
PhD Studentships in cancer research represent a subset of the studentships 
categorised above. There are two reasons for this: 1) studentships in general was 
taken to include schemes such as internships for undergraduates, summer 
research placements, funding for masters programmes, „in-practice‟ fellowships 
and funding for specific training for doctoral students, and 2) only those 
studentships that provided a full stipend and coverage of tuition fees are 
discussed further here. These studentships were available from seven of the top 
funders including BBSRC, BCC, EPSRC, LLR, MRC, NIHR and The Wellcome Trust. 
This shows that the UK funding system provides significant choice for prospective 
PhD students seeking funding. 
Interestingly, the top two funders in the UK, Cancer Research UK and the DH 
(NHS division), do not appear on this list, principally because the NHS only 
provides bursaries for tuition fees, and not stipends to students and Cancer 
Research UK fund studentships within PI led projects rather than awarding direct-
to-student funding..Of the studentships available, it notable that the three UK 
research councils offering studentships, the BBSRC, EPSRC and MRC, all offer a 
stream of funding available for research to be carried out in collaboration with 
industry partners. Termed CASE (Collaborative Awards in Science and 
Engineering) studentships, these provide students with research training 
experience and an opportunity to take their research into the private sphere.  
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Early Career Researchers 
For a more detailed analysis of the funding available for early career researchers, 
we take a subset of the fellowships category, as defined in Table 3.11. For these 
purposes we take the threshold for „early‟ career funding opportunities to be any 
available to researchers who completed their PhD less than five years prior to 
application5. Included under this categorisation are fellowships open to post-
doctoral researchers, where the funding is specifically aimed at early career 
researchers, or where there is no specification of career stage. Only fellowships 
supporting awardees salary are included.6 Nine of the major funding bodies 
provide early career fellowships including the BBSRC, Cancer Research UK, 
EPSRC, EU (under FP7), LLR, MRC, NIHR, The Wellcome Trust and YCR. The UK 
funding system therefore benefits from a wide range of funding options for early 
career researchers. 
One common characteristic of these fellowships is that there are many that are 
collaborative in nature and involve cooperation between more than one type of 
institution or funder, be it in terms of sector, discipline or geographic location. For 
instance, all three fellowships offered by BBSRC are funded in partnership with 
another funding body (the Food Standards Agency, Royal Society of Edinburgh 
and Royal Society/EPSRC/NERC and Rolls Royce) with one requiring the 
establishment or strengthening of corporate ties between industry and academia. 
Other funders tend to encourage clinical/academia links with fellowships offering 
clinicians academic research training or lectureships (LLR, MRC and NIHR). In 
terms of encouraging research outside the biological and chemical sciences the 
MRC, Cancer Research UK and Wellcome show some focus towards social science 
disciplines such as health economics, population studies, biomedical informatics 
and public health, whereas the NIHR and Wellcome have fellowships in 
transitional/translational research areas, emphasising the shift from basic to 
clinical science. The EPSRC support a scheme focusing high risk research. In 
terms of fellowships that encourage geographic movement, the EU (FP7) presents 
several outgoing (and ingoing – although these were not specifically included in 
this analysis due to the lack of salary funding) fellowships in collaboration with 
Marie Curie, and the support of training networks, that allow networks to bring 
early career researchers in directly. In addition, Wellcome has a collaborative 
fellowship with the Massachusetts Institute of Technology (MIT) that allows 
researchers time in both a UK (host) institution and at MIT.  
Projects 
Project grants represent the most common pathway to funding from the sample 
of funders we assessed: 12 of the 13 funding bodies analysed showed 
opportunities for project funding. The only funder that shows no availability of 
project funding was the NHS, which is likely explained by the responsibility for 
this type of funding for the DH being taken on by the NIHR. As with fellowships 
there are distinctions between the ways organisations approach the distribution of 
                                           
5 Fellowships aimed at clinicians with professional qualifications were not deemed to be „early career‟. 
6 This inclusion criterion, therefore excludes schemes such as the CRUK Career Establishment Award, 
which aims to help researchers develop an independent career in cancer research by establishing a 
research group, as it does not fund the award holders salary.  
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funding for projects. Since the period studied, Cancer Research UK has withdrawn 
the availability of project grants. 
Table 3.14: Summary of the different types of project funding available 
from the top public funders of UK cancer research  
Funder 













































































































































































Cancer Research UK    ✔ ✔    
NIHR   ✔ ✔    
Medical Research Council (MRC)   ✔   ✔  
National Institutes of Health (NIH)   ✔   ✔  
Wellcome Trust  ✔ ✔ ✔  ✔  
Breast Cancer Campaign    ✔    
Biotechnolgy and Biological Sciences Research Council (BBSRC) ✔ ✔ ✔  ✔   
Yorkshire Cancer Research (YCR)   ✔     
Engineering and Physical Science Research Council (EPSRC)  ✔   ✔  ✔ 
Leukaemia and Lymphoma Research    ✔    
European Commission (FP7) ✔ ✔   ✔ ✔ ✔ 
European Commission DG SANCO ✔       
 
The diverse range of project grants available from the top public cancer funders is 
summarised in Table 3.14. Whilst some of these categories are straightforward, 
others show a large amount of variation. For instance, funding for translational, 
feasibility or innovation purposes can range from translation of research from lab 
to clinic (BBSRC, MRC, Wellcome, YCR), drug discovery (Cancer Research UK, 
YCR) and innovation of medical technologies more broadly (NIHR) to pilot or 
feasibility studies (NIH). However, this category does not include grants 
specifically aimed at proving funding for clinical trials (discussed in a separate 
section below). In addition, the project funding categorised under specific 
research covers general funding for particular subtypes of cancer (as in the cases 
of BCC or LLR) and the various disciplinary approaches to cancer research (e.g. 
Cancer Research UK funds specific projects relating to tobacco advisory groups, 
population research and biomarkers; NIHR funds more patient-related research 
such as health services and delivery, public health, health technology 
assessment, efficacy and mechanism evaluation and patient benefit; and 
Wellcome funds initiatives towards sustaining health). Projects that are linked to 
prior or additional research has been indicated where a funding body sets out 
project grants for research projects that may lead to programme grants (MRC), 
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grants linked to a renewal of a previous project (NIH), strategic grants that add 
value to existing research groups7 (Wellcome) or for the support for recently 
created teams (EU FP7). In addition to these variations within groups there are 
also distinct strategies for project funding that do not fit into any of the above 
categories. For instance, the NIH offer more general and exploratory options for 
the direction of their project funding, as well as projects that encourage 
cooperation between itself (the NIH) and the research groups. In addition the 
MRC have a stream of project funding that focuses on the development of 
methods for research.  
Programmes 
Ten of the 13 funders support large, multidisciplinary programme grants. These 
are BBSRC, Cancer Research UK, EPSRC, EU (FP7), LLR, MRC, NIH, NIHR, 
Wellcome and YCR. Most of these programme grants lack specified directions, 
where most simply require a proposal that identifies an integrated but 
multidisciplinary research stream. Some do, however, specify particular research 
area interests, such as the Cancer Research UK Population Research Committee 
Programme Grants, the MRC Experimental Medicine Challenge Grant (focusing on 
disease pathophysiology), the NIH Specialised Centre, supporting specific disease 
areas, and the Wellcome/EPSRC Innovative Engineering for Health scheme which 
focuses on biomedical engineering. The LLR Specialist Programme grant and the 
NIHR Programme Development Grant also show a distinction from other 
initiatives, where the LLR scheme provides further support existing grant holders, 
and the NIHR supports the preparation of programme grants.  
Clinical trials 
Schemes that explicitly support clinical trials are available from four of the 13 
funding bodies in this analysis: Cancer Research UK, LLR, MRC and NIH. Cancer 
Research UK have three such grant options, ranging from small project grants for 
feasibility studies (allowing for £25,000 per annum to be obtained for a maximum 
of four years) to larger scale Phase III Clinical Trial Grants, which appreciate how 
costly and time consuming this later stage of development can be by offering 
£100,000 per annum for 10 years. The charity‟s New Agents Committee Trials 
Funds also claims to provide a process for selecting new treatments and 
diagnostics and allowing them to enter early clinical trials (offering £40,000 per 
annum for two years). LLR also offer Clinical Trial awards for Phase I/II trials of 
new therapy options, however the financial and duration limitations are not 
publicly disclosed. The MRC (in collaboration with the Technology Strategy Board 
(TSB)) offer £250,000 as a minimum for clinical projects under their Biomedical 
Catalyst: Developmental Pathway Funding Scheme. Finally the NIH offer a 
smaller amount, up to $100,000 for 1-3 years to support the planning of clinical 
trials as part of their Clinical Trial Planning Grant Program.  
  
                                           
7 Note that this stream shows possible overlap with the type of funding provided by CRUK in their 
Senior Cancer Research Fellowship which supports the establishment or further development of an 
independent research group.  
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Industry 
There are several ways in which funders seem to be encouraging collaboration 
between academic and industrial research. One is through the industrial 
fellowships where researchers from industry are encouraged to bring their skills 
into an academic context (run by BBSRC). Other schemes involve encouraging 
partnerships between industry and academia (EPSRC/TSB and MRC), while some 
of these entail the expectation that the industrial partner will contribute some 
funding towards the collaboration (BBSRC). The EU (FP7) shows support for 
industry through their collaborative projects and Industry-Academia Partnerships 
and Pathways (under the Marie Curie Actions), that encourage industry/academia 
consortia, and support for industry directly through a Risk-Sharing Finance 
Facility and Small and Medium Size Enterprises (SMEs) initiatives.  
Non-UK-based funding bodies 
The analysis major funders of UK neoplasm research identified five funding bodies 
based outside the UK8. The NIH (National Institutes of Health in the USA), was 
included in the main analysis due to the apparent wide-ranging coverage of their 
project and programme funding and its availability to institutions from other 
countries outside the USA, ranging from public or private, non-profit or for-profit. 
It is therefore justifiable to conclude that researchers based in the UK may be 
gaining access to funding streams from the NIH. The remaining foreign funding 
bodies, which include the Swedish Cancer Society (SCS), the Italian Association 
for Cancer Research (AIRC), German Cancer Aid (GCA) and Australia‟s National 
Health and Medical Research Council (NHMRC), generally limit the amount of 
funding available to UK researchers/institutions and focus on domestic 
institutions. For the NHMRC, the general rules of eligibility are that the chief 
(principal) researchers should be Australian citizens or have permanent 
residency, however other listed researchers on grants can be of any nationality.  
In light of this there are two potential explanations for the inclusion of these 
foreign funding bodies in the top funders of UK cancer research. One is that the 
data shows a large amount of international collaboration, where UK researchers 
are working alongside non-UK researchers, and the funding patterns of all 
collaborating authors are being picked up by our methods. The other explanation 
is that researchers based in the UK may have dual institutional affiliations or have 
undertaken visits abroad and therefore have had some funding from non-UK/EU 
funding sources.  
Summary on complementarities of funding schemes 
This analysis shows that the funding opportunities available to researchers from 
the funding bodies most active in supporting cancer research in the UK are both 
overlapping and complementary. 
The most overlap is seen with fellowships (including those for early career 
researchers) and project grants. Studentships are also readily available from a 
number of these funders, with particular significance lying in the existence of an 
                                           
8 This is with exception of the European Union FP7 and DG SANCO (EC) which are included in the 
analysis. 
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emphasis, from the UK research councils, on collaborative studentships with 
industrial partners.  
Funders of UK research are particularly complementary to each other in the area 
of project grants where there are a broad range of different types of scheme 
available to suit the diverse needs of researchers.  
Where there is least opportunity for support is in the later stages of the 
development spectrum in the area of clinical trials and industrial funding, 
opportunities are less broad particularly where studies require large amounts of 
funding over longer term. Exceptions include the Cancer Research UK Phase III 
Clinical Trial Grants and the MRC/TSB Biomedical Catalyst Developmental 
Pathways Funding Scheme being the only later stage development funding 
available from these sources. This implies that, despite the relatively well-funded 
area of translational studies, there are limitations to the extent to which public 
funding can provide the necessary funding for bodies of research to be taken 
towards commercialisation, creating a bottleneck with a smaller number of 
funders. Furthermore, despite the support for industry-academia links, there 
seems relatively little direct support for industry research from public funding 
bodies. 
3.5.5 Researchers use of complementary funding schemes over time 
As described in the previous section, diverse funding schemes are available to UK 
researchers studying neoplasms. This section uses interviews to explore case 
studies of how researchers can use a series of funding schemes to develop a line 
of research over a period of years or even over a decade. As the examples 
discussed illustrate, this is often necessary to achieve significant breakthroughs.  
Such breakthroughs may depend on bringing together and sustaining multi-
disciplinary teams or organisations with diverse missions, meaning that 
complementary types of funding scheme need to be accessed. Case studies 
drawing on the experiences of three scientists leading programmes of research 
are presented here, followed by discussion of common themes. 
Case study 2: Research on DNA-repair mechanisms leads to promising 
drug candidates    
Professor Steve Jackson heads a laboratory at The Gurdon Institute, University of 
Cambridge, exploring the molecular pathways controlling DNA repair. DNA repair 
mechanisms are of particular interest because drugs that inhibit the body‟s cells‟ 
ability to repair damaged genes are considered a promising avenue to inhibit 
cancer growth. Jackson‟s laboratory has spun out two biotech firms, KuDOS 
Pharmaceuticals and MISSION Therapeutics, to aid translation of this 
fundamental biological science into commercial drug programmes. KuDOS 
attracted more than £40 million in private sector investment mainly from Venture 
Capital, before it was acquired for over £120 million by AstraZeneca in 2005. The 
resulting drugs are now in clinical trials.   
What kinds of funding allowed Jackson’s work to develop to the stage where it 
attracted large scale commercial investment?  
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Jackson, originally from Nottingham, conducted his early work on DNA repair 
during a post-doc in the USA in the late 1980s where he was funded by a Lucille 
P. Markey Fellowship and the Howard Hughes Medical Institute as well as the 
Leukaemia Society of America. He was offered further funding to stay in the USA 
and might not have returned: “I would not come back to the UK just to be 
scratching around for smaller grants” Jackson said. One substantial opportunity 
Jackson pursued was an application for a Cancer Research Campaign programme 
grant, which he won. This gave Jackson five years of funding. Jackson recalls 
“[For] me having a starting point where you can hire 2-3 individuals and form a 
coherent group is important and that was fundamental for me to come back to 
the UK.” Returning to the UK in 1991, Jackson‟s laboratory was founded and 
hosted in an institute jointly funded by the Wellcome Trust and the Cancer 
Research Campaign. In what was then a new funding model, these charities 
provided research infrastructure, but the hosted scientists had to find their own 
additional grant funding to support researchers‟ salaries and the direct costs of 
their projects. The five-year CRC programme grant allowed Jackson considerable 
flexibility, which retrospectively can be seen as having allowed him to exploit the 
emerging promise of DNA repair enzymes: “A lot of good science comes along as 
unexpected. So way back to 1990-1992, I had no idea that my lab was going to 
be focusing on DNA repair… since then…almost all my publications, nearly a 
couple of hundred, have been on DNA repair and I set up two companies. That 
was not planned. So I think best science and the best opportunities are often 
through doing cutting edge studies in a good environment with good people and 
following your nose as much anything else.” 
The CRC programme grant became a platform from which to expand the team 
from 3-4 to around eight scientists. Jackson suggests that “In order to get a 
grant you need to have preliminary data to have a compelling case for your 
proposal and [there is] momentum… if you have an existing grant ongoing … data 
can be used as starting point for applying to further grants." These extra grants 
were necessary to expand the group to fully develop the emerging research lines. 
Through the early and mid-1990s, Jackson‟s laboratory had additional funding 
support from the Medical Research Council, the Leverhulme Trust, the A-T 
Medical Trust, the Kay Kendall Leukaemia Research Fund, European Union 
funding schemes, and CRC project grants.  Each extra grant would cover at least 
one additional post-doc‟s salary. Jackson laments these bolt-on awards are more 
difficult obtain now that Cancer Research UK focuses on distributing Programme 
grants and no longer offers stand-alone project grants. This makes it difficult to 
expand existing groups and also it concentrates resources so that some 
investigators in less well established groups will not get an opportunity to 
investigate their novel ideas: “we spend £2000 a day just for reagents and that 
does not include the salaries. Proper cell and molecular biology science in [the] 
lab is expensive.  UK universities would not be able to do science without external 
funding… and that is just a matter [of] how science is done now.” 
As DNA repair became a major area of interest for researchers in the field, 
Jackson‟s laboratory has collaborated widely. Co-authorship patterns on Jackson‟s 
papers show a particularly strong link with an MRC centre at the University of 
Sussex. Jackson notes that the MRC investment here was also leveraged in 
supporting research that led to the founding of KuDOS. However, perhaps 
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surprisingly the grants that have facilitated these interactions have generally not 
been formal collaborative grants. Jackson suggests “[this area of] science isn‟t 
like assembling an airbus… where you can plan several years in advance… It is 
perhaps more preferable from the scientists‟ point of view that scientists are 
funded in a manner so that they can afford to collaborate in a spontaneous way”. 
In this manner, dozens of funders can be identified as supporting Jackson‟s 
publications mainly by funding his co-authors. 
It took almost a decade of activity from Jackson‟s first paper on DNA repair 
mechanisms in 1988 to the founding of KuDOS in 1997 and then several more 
years to the development of pharmaceutical candidates known as PARP inhibitors. 
During this time not only was much fundamental science explored through an 
international network, but also the build-up of skills and knowledge in a single 
location, allowed KuDOS to be founded. Multiple charities and government grants 
were important to support this work, and CRC continued to support Jackson‟s 
work as an early investor in facilities for KuDOS. Jackson has also played an 
active role in stewarding the commercial R&D, although as Chief Scientific Officer 
of KuDOS and now MISSION, he is concerned not to allow industrial influence to 
shape the scientific agenda. 
 
 
Case study 3: Controversial hypotheses yield results with long term 
support 
Fran Balkwill is a Professor of Cancer Biology at Barts Cancer Institute, Queen 
Mary University of London, where she leads the Centre for Cancer and 
Inflammation and the Cytokine and Cancer group. Balkwill‟s research began at 
the Imperial Cancer Research Fund laboratories at Lincoln‟s Inn Fields, London 
(now Cancer Research UK‟s London Research Institute). Balkwill has long been 
interested in translational research, exploring the therapeutic potential of 
cytokines such as tumour necrosis factor (TNF) and interferons.   
Until the early 1990s TNF was largely characterised as an anti-cancer agent 
(Balkwill 2009). However during this period it began to be appreciated, by 
Balkwill‟s group and others that under certain circumstances TNF may actually 
encourage tumour growth. Balkwill recalls a “eureka moment” when she took 
inspiration from a talk about the application of anti-TNF to treat Rheumatoid 
Arthritis, in which clinical activity was first shown in 1994: “I heard Mark 
Feldmann talk about how anti-TNF inhibited inflammatory cytokine production, 
inhibited the leukocyte infiltrate into the joint, inhibited angiogensis and inhibited 
matrix metalloproteinases, and I thought, well that‟s what you want to do in the 
tumour microenvironment”. At the time this was a particularly controversial view 
as prior evidence dating back to the 19th century suggested that TNF would inhibit 
cancer and subsequent clinical findings leading to the approval of a TNF agent for 
the treatment of soft tissue sarcoma in 1999 (Balkwill 2009). Balkwill‟s 
unconventional work in the TNF field was nonetheless supported by ICRF (support 
which continued when it became Cancer Research UK) and she persevered with a 
trajectory of work on anti-TNF molecules. Balkwill‟s work has supported the 
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clinical testing of anti-TNFs as anti-cancer agents, such as infliximab (Remicade, 
developed by Centocor), found other cytokine drug targets such as IL-6 and the 
chemokine receptor CCR4 and developed more fundamental understanding of 
cancers by showing the potential of some cytokines to have a dual role in tumour 
development, thus revealing the complexity of the tumour microenvironment.  
What kind of funding allowed Balkwill’s work to develop to produce clinically 
applicable knowledge? 
During the 20 years Balkwill spent at the ICRF at Lincoln Inn Fields in London 
there was little need to gain access to external funding. However, when Balkwill 
moved to the Barts Cancer Institute at Queen Mary University of London (then 
the ICRF Translational Oncology Laboratory) it was necessary to find diverse 
sources of funding to ensure her group of scientists and their work could be 
sustained. One of the first things Balkwill did at her new lab was to persuade a 
commercial partner, Centocor, to fund the preclinical and clinical studies of 
infliximab, in cancer patients, a stream of funded work that continued for nearly a 
decade. Balkwill continues to receive funding from diversity of public and private 
sources reflecting the different streams of research relating to anti-TNF and IL-6 
molecules and their clinical applications, to understanding the underlying 
molecular mechanisms surrounding the activity of TNF and IL-6 as well 
understanding the cytokine network in the tumour microenvironment as a whole. 
She also sees it as vital to have diverse funding support and currently holds both 
a Cancer Research UK Programme grant and an ERC Advanced Researcher grant. 
While such large grants are important for sustaining the group, sub-projects can 
still require additional support as interesting opportunities arise. Balkwill recalls “I 
had a Cancer Research UK PhD student who came up with an unexpected 
observation about a chemokine receptor (CCR4) in renal cancer. I got a Discovery 
Committee grant from Cancer Research UK for 2 years for target validation.  
During that time, we were able to access a small molecule inhibitor for CCR4 in a 
collaboration with AstraZeneca”. It is hoped that this drug, previously a shelved 
Asthma drug-candidate can be repurposed if further grant support is forthcoming. 
Subsequently this avenue of research targeting CCR4 also has proved of interest 
to Affitech, a Danish biotech firm identified by CRT, who helped to form a 
licensing and R&D agreement which secured Queen Mary‟s University further 
research funding to support Affitech – Balkwill said “we‟ve had now 2 years of 
very substantial industry funding from them for pre-clinical studies of anti-CCR4 
antibodies”. 
 
Case study 4: Gene hunting provides new cancer diagnostics 
Ian Tomlinson is a Professor of Molecular and Population Genetics, Group Head/PI 
and Consultant Clinical Geneticist based at the Wellcome Trust Centre for Human 
Genetics, Oxford. Tomlinson‟s research is particularly concerned with genetic 
predispositions to cancers such as colorectal and renal cancers. His research has 
revealed a series of genetic mutations in several genes related to rare hereditary 
cancers. During the period 1995 to 1998, as a post-doctoral researcher, 
Tomlinson carried out several studies to determine the genetic basis for Peutz-
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Jeghers syndrome (PJS), a rare inherited disorder causing hyperpigmented 
patches of mucosa and gastrointestinal polyps that present elevated malignancy 
risk. Beginning with genetic linkage studies, Tomlinson worked to gain an insight 
into the pathway linking PJS with a predisposition to cancers, and to find the 
genetic locus of PJS (see Hemminki, Tomlinson et al. 1997). The discovery of this 
specific locus rapidly allowed for the development of improved cancer screening 
for PJS patients (Tomlinson and Houlston 1997). 
Tomlinson‟s work on PJS was facilitated by two grants, from the European 
Commission and the other from the Cancer Research Campaign (CRC). These 
grants covered different aspects of the PJS but presented complementary 
research themes. Tomlinson recalls: “the actual aims of [the grants] were 
interrelated, as it happened, doing slightly different things within that disease but 
very much linked”. In addition to the work on PJS, the group also received a 
small exploratory pump priming award working on breast tumours9 from the 
Medical Research Council (MRC).  
Cross cutting themes  
The above case studies illustrate how multiple grants and funders are often 
necessary to generate a breakthrough such as developing a new diagnostic or 
advancing a new class of drug molecule to the clinic.  
In the past, Cancer Research UK has been able to sustain researchers in its own 
laboratories allowing them over decades to develop controversial hypotheses into 
applied therapeutic programmes, however this is beginning to change as across 
the UK scientists are required to raise external grants.   
Three interviewees discuss the particular importance of Cancer Research UK 
programme grants as a basis from which to grow larger teams by gaining 
additional grants. Although more than one suggested their institution would 
encourage them to look for other funding rather than Cancer Research UK (due to 
lack of overheads paid), Cancer Research UK grants were suggested by two of 
the three to be a “mark of quality” for peer reviewers and that helped to attract 
further grants. Also it was noted that a “core” grant provided the opportunity to 
generate the data necessary to develop interesting proposals to win further 
grants. In this way a core grant can help an investigator to rapidly build on 
promising research to develop a stronger research line. 
Having multiple grants at the same time is also important for hedging and 
providing for continuity of the group, as there is a constant battle to keep post-
doctoral researchers funded. Tomlinson suggests a key aim is to avoid sharp 
peaks or troughs in group size and instead aim for ”a gentle undulation”. He 
noted “There‟s always a potential crisis looming two years down the road for 
certain members of the group. In Oxford we are quite lucky in that people with 
their own fellowships, for example, are not that uncommon....they help to even 
out the natural cycle of [larger] grants.”   
                                           
9 Pump priming awards are generally given out to research aimed at developing new ideas with 
promising potential. 
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Jackson also emphasised the importance of individual laboratories having multiple 
sources of funding: “I think it is a sort of healthy way in running a lab where you 
have at least two funding bodies contributing” although he (and other 
interviewees) emphasised that they should not be funded twice to do the same 
work. Balkwill also suggested it was important not to be over-reliant on one 
funding source, recalling “When I moved from CR-UK we probably had 11-12 
people on Cancer Research UK grants, by the time it got to my previous one it 
was three... they just don’t give that kind of money any more, it’s also got so 
expensive”. Balkwill was awarded a further Cancer Research UK Programme 
Grant in 2013 with four posts granted. Balkwill currently aims to have no more 
than 25-30% of her group reliant on one funding source. 
How do interviewees see today’s UK funding environment? 
All four interviewed scientists suggested that the UK funding system was better, 
from their perspective, than the USA. Jackson suggests scientists studying cancer 
in the UK have a good choice of funders, including charities, government research 
councils and European funding opportunities. The situation at the present time is 
better than the USA where key grant funders such as the NIH are having their 
budgets cut. 
Balkwill’s perspective on the funding environment for cancer research in the UK is 
generally positive, exceeding the system much of the rest of Europe and the USA. 
In the latter case, part of the strength of the UK funding environment is the 
introduction of the European Research Council. 
Jackson also agreed that the UK funding environment remains strong while the 
US was experiencing funding cuts. Tomlinson observes that the access to funding 
in the UK is relatively healthy, with a more “streamlined” process of grant 
applications, than is the case in other countries, particularly the USA. However, 
Tomlinson also suggests that there are frequently significant changes in 
directions in the types of research receiving funding. These changes are, perhaps, 
inevitable, and he likens them to “fashion in science” or “oscillations in how 
exciting various sorts of research are perceived”. Jackson is also concerned that 
politics is driving UK research councils to be more prescriptive, and focusing too 
much on seeking economic benefits: “The reality is that innovation and 
opportunities, and ensuing healthcare companies, in most cases come out from 
doing good science in a good environment not through translational science in a 
very applied institute.”  
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3.6 Scientometric analysis: Diversity in neoplasm research 
3.6.1 Diversity of funders and host organisations across scientific 
disciplines 
One of the questions posed in the proposal was „Which funders support more 
interdisciplinary research?‟ We considered that this question did not sufficiently 
address any of the three overarching questions posed by Cancer Research-UK, 
and so we therefore address a different question more related to the main thrust 
of the analysis – namely, „which funders support more diversity in research‟. 
We investigate the diversity of research that funders and research host 
organisations support using the ISI journal subject categories for the journals 
their publications are in as a proxy for the disciplines they contribute to. We 
analyse three dimensions of diversity (Rafols et al. 2012, Stirling 1998) as shown 
in Figure 3.21.  
 Variety: the number of scientific disciplines a funder or research host 
organisation contributes to by supporting or producing publications. Higher 
numbers indicate higher variety. 
 Balance: the distribution of the publications a funder or research host 
organisation supported or produced across the scientific disciplines. A 
value of 1 would indicate each subject category has the same number of 
publications. 
 Disparity: the cognitive distance between the scientific disciplines a 
funder (host organisation) contributed to by supporting (producing) 
publications. A value of 1 indicates the highest disparity between 
supported publications‟ subject categories, and 0 indicates no disparity. 
 
Figure 3.21: Conceptualisation of diversity measures (based on Rafols 
and Meyer 2010 and Stirling 1998). 
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We also consider an „aggregate‟ indicator of diversity that considers both the 
proportion of publications in each discipline and the cognitive distance between 
those disciplines. This indicator is the Rao-Stirling diversity index (Stirling 2007), 
with a value closer to 1 indicating higher diversity.  
We assessed the diversity of publications for the major funders and research host 
organisations that contributed to at least 2% of the UK neoplasm research output 
in 2011. Table 3.15 and Table 3.16 report the results respectively for funders 
(based on the 3,914 publications with funder acknowledgements) and research 
host organisations (based on 7,510 publications in the total sample). 
In Table 3.15, Variety refers to the number of subject categories that publications 
appear in, counted in absolute terms (no threshold) and counting only those 
subject categories where >1% of an organisations‟ research output is published. 
When counting without threshold restrictions, the Departments of Health 
(including NHS and NIHR) and Cancer Research UK support the greatest variety 
of subject categories, although when a 1% threshold is imposed, the BBSRC and 
EPSRC support more diverse research. The BBSRC and EPSRC also perform well 
in terms of providing a balance in the support they give to publications across 
subject categories.  
In terms of the disparity of publications supported, the Departments of Health 
and Cancer Research UK support the most disparate publications overall, but the 
most disparate are not supported often, so that when a threshold is imposed, 
BBSRC performs more strongly. The BBSRC is also the funder supporting the 
most diverse publications. Of the top nine funders, Leukaemia and Lymphoma 
Research and Breakthrough Breast Cancer support the least diverse publications. 
Table 3.16 shows diversity measures for the 17 top research host organisations. 
University College London and Oxford University publish across the highest 
variety of journal subject categories, however the majority of these do not 
contribute to >1% of the host‟s output. The University of Sheffield and King‟s 
College London contribute >1% of their publications to the widest variety of 
subject categories.  
The Universities of Birmingham, Liverpool and Cardiff are the most balanced in 
terms of their contributions to subject categories, whereas the Institute of Cancer 
Research is the least balanced.  
Disparity in the types of subject categories published in is highest in absolute 
terms for University College London and King‟s College London, but when a 1% 
threshold is imposed, Liverpool and King‟s College London publish in the most 
disparate range of publications. The University of Liverpool is the most diverse of 
the top 17 research host organisations based on the Rao-Stirling diversity index, 
and the Institute for Cancer Research is the least diverse. 
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Table 3.15: UK funding organisations acknowledged in at least 2% of the publication sample (N = 3,914) and diversity 
measures on the supported research (funders sorted by total number of publications) 
  Diversity Measures 
  Variety Balance Disparity Rao-Stirling 








1) Cancer Research UK  75  16 0.682 0.818  0.623 0.557 
2) Departments of Health (including NHS and NIHR) 78  19 0.701 0.827  0.687 0.612 
3) Medical Research Council (MRC) 66  23 0.747 0.801  0.669 0.587 
4) Wellcome Trust 44  19 0.783 0.726  0.622 0.537 
5) Leukaemia and Lymphoma Research 28  15 0.683 0.639  0.543 0.437 
6) Breakthrough Breast Cancer 24  13 0.712 0.629  0.468 0.407 
7) Breast Cancer Campaign 29  18 0.756 0.721  0.663 0.518 
8) Engineering and Physical Science Research Council (EPSRC) 42  25 0.871 0.765  0.633 0.554 
9) Biotechonolgy and Biological Sciences Research Council (BBSRC) 41  28 0.884 0.789  0.746 0.691 
Notes. The threshold refers to the proportion of publications in a given SC. Figures from Rafols and Meyer (2010) and Stirling (1998).  
 
Table 3.16: UK organisations contributing to at least 2% of the publication sample (N = 7,510) diversity measures on the 
produced research output (organisation sorted by total number of publications) 
  Diversity Measures 
  Variety Balance Disparity Rao-Stirling 








1) Institute of Cancer Research, London  
(including the following organisation or name variations: Royal Marsden NHS Foundation 
Trust) 
52  19 0.667 0.765  0.669 0.537 
2) University College London, London 
(including the following organisation or name variations: University College London 
Hospitals NHS Trust, UCL Cancer Institute, National Hospital for Neurology and 
Neurosurgery, Royal Free Hampstead NHS Trust) 
83  23 0.788 0.829  0.685 0.679 
3) Imperial College, London 
(including the following organisation or name variations: Imperial College Healthcare NHS 
Trust, Hammersmith Hospital, Charing Cross Hospital) 
66  21 0.741 0.784  0.666 0.608 
4) University of Cambridge, Cambridge 
(including the following organisation or name variations: Cancer Research UK Cambridge 
Research Institute, Hutchison/MRC Research Centre, Cambridge Biomedical Research 
Centre, Addenbrooke's University Hospital, Cambridge University Hospital NHS Trust) 
64  24 0.750 0.784  0.654 0.598 
5) Oxford University, Oxford 
(including the following organisation or name variations: Gray Institute, John Radcliffe 
Hospital, Oxford Radcliffe Hospitals NHS Trust, United Kingdom) 
74  21 0.736 0.818  0.676 0.618 
6) King's College London, London 
(including the following organisation or name variations: King's College Hospital NHS Trust, 
Guy's and St Thomas NHS Trust, Guy's Hospital, Western General Hospital) 
69  27 0.787 0.822  0.750 0.672 
7) University of Leeds, Leeds 67  22 0.750 0.816  0.709 0.642 
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  Diversity Measures 
  Variety Balance Disparity Rao-Stirling 








(including the following organisation or name variations: Leeds 
Cancer Research UK Centre, St James's University Hospital, Leeds 
Teaching Hospitals NHS Trust, Leeds General Infirmary) 
8) University of Manchester, Manchester 
(including the following organisation or name variations: Cancer 
Research UK Paterson Institute,  Christie Hospital) 
58  24 0.755 0.790  0.709 0.609 
9) Queen Mary University of London, London 
(including the following organisation or name variations: St 
Bartholomew's Hospital) 
47  20 0.726 0.781  0.670 0.545 
10) University of Edinburgh, Edinburgh 
(including the following organisation or name variations: Edinburgh 
Cancer Research Centre, Western General Hospital) 
 
49  24 0.793 0.782  0.740 0.634 
11) University of Glasgow, Glasgow 
(including the following organisation or name variations: NHS 
Greater Glasgow and Clyde, Gartnaval General Hospital, Glasgow 
Royal Infirmary, Western Infirmary) 
57  26 0.784 0.770  0.721 0.615 
12) University of Newcastle, Newcastle Upon Tyne 
(including the following organisation or name variations: Northern 
Institute of Cancer Research, Newcastle upon Tyne Hospitals NHS 
Trust, Royal Victoria Infirmary, Freeman Hospital) 
45  18 0.747 0.753  0.717 0.601 
13) University of Birmingham, Birmingham 
 
53  23 0.822 0.780  0.694 0.631 
14) University of Sheffield, Sheffield 
(including the following organisation or name variations: Weston 
Park Hospital, Sheffield Children's NHS Trust, Sheffield Teaching 
Hospitals NHS Trust) 
59  28 0.816 0.817  0.767 0.683 
15) Cardiff University, Cardiff 
(including the following organisation or name variations: Velindre 
NHS Trust) 
52  24 0.817 0.775  0.741 0.647 
16) University of Southampton, Southampton 
(including the following organisation or name variations: 
Southampton General Hospital) 
40  24 0.805 0.783  0.741 0.641 
17) University of Liverpool, Liverpool 51  23 0.821 0.806  0.790 0.716 
Notes. The threshold refers to the proportion of publications in a given SC. Figures from Rafols and Meyer (2010) and Stirling (1998).
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3.6.2 Diversity of funders and host organisations across medical areas 
We further explore the diversity of funders and research host organisations by 
analysing the variety of, and balance across, the domains of research they 
support or contributed to using MeSH qualifiers. MeSH qualifiers further qualify 
the meaning of MeSH descriptors, and unlike MeSH descriptors, which operate in 
a hierarchical tree structure, MeSH qualifiers can be used to categorise all 
publications with MeSH codes.  
All MeSH qualifiers assigned to at least 10% of the publications in the total 
sample are reported in Figure 3.22. These show that pathology and genetics are 
the most frequently occurring, followed by surgery (green), diagnosis  (blue) and 
drug therapy (orange). 
Figure 3.23 profiles the major UK funders according to the most frequent MeSH 
qualifiers, i.e. those assigned to at least 10% of the publications in the total 
sample. As in the previous analyses on the MeSH descriptors, we report the 
proportion of publications each funder supported in a domain in relation to the 
overall number of publications the funder supported (above) and the comparison 
between the observed and the expected value of publication number (below) – 
the methodology used here is similar to that described in section 3.5.3. It is 
worth noting that the qualifiers represented in the radar charts describe on 
average ~90% of the publications supported by these organisations, but each 
radar chart does not completely cover the scope of outputs. 
Major UK funders strongly focus on supporting studies in genetics and pathology 
which each account for between 20% and 40% of the publications they support. 
The exception is the EPSRC for which a very small proportion of the supported 
publications are assigned to genetics. However, more than 20% of the 
publications supported by EPSRC are in diagnostics while the remaining major UK 
funders supported a lower proportion of publications in this domain. Unlike the 
overall sample, major UK funders neglect surgery.  
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Figure 3.22: Top MeSH qualifiers (at least ~10% of the publications) 
assigned to the descriptors included in the “Neoplasms” branch of the 
MeSH tree (more than one qualifier can be assigned to a publication; 817 
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Figure 3.23a: Major UK funders in “Neoplasms” area and proportion of publications across the top MeSH qualifiers (90.6% 
of the 3,914 publications with acknowledgements to funders are classified using the reported MeSH qualifiers). Upper 
charts report the percentage of funders’ total publications in different domains. Right charts report whether funders are 
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Figure 3.23b: Major UK funders in “Neoplasms” area and proportion of publications across the top MeSH qualifiers (90.6% 
of the 3,914 publications with acknowledgements to funders are classified using the reported MeSH qualifiers). Upper 
charts report the percentage of funders’ total publications in different domains. Right charts report whether funders are 
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Figure 3.23c: Major UK funders in “Neoplasms” area and proportion of publications across the top MeSH qualifiers (90.6% 
of the 3,914 publications with acknowledgements to funders are classified using the reported MeSH qualifiers). Upper 
charts report the percentage of funders’ total publications in different domains. Right charts report whether funders are 
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3.7 Scientometric analysis: Additional perspectives 
In addition to the main questions of the study – related to the interdependency, 
complementarity and diversity of UK funders and research host organisations, 
there was opportunity to explore the following questions: 
a) Which funders support rapidly cited works? 
 
b) Which funders support international collaborations or public/private 
collaborations?  
3.7.1 Funder, host organisations and highly-cited publications 
In order to identify the most highly cited publications it is necessary to first control 
for the different propensity of authors working in different subject categories to 
cite recent publications. To achieve this, each subject category was considered 
individually to identify the top 5% and top 10% papers by citation (Table 3.17). 
Those papers acknowledging research funding were more highly represented in 
these top cited papers, suggesting that there is a significant correlation between 
research funding acknowledgement and citation (Table 3.18).  
Table 3.17: Citations and publications (N=7,510) 
Number of highly-cited publications  
Top-5% cited within a subject category  486 (6.5%) 
Top-10% cited within a subject category 905 (12.0%) 
  
Top-5% cited normalised by citation rate in subject categories 375 
Top-10% cited normalised by citation rate in subject categories 751 
Note. Since a journal may be assigned to more than one SC, an article is considered highly cited if ranks 
in the top-cited articles of at least one of the SCs assigned to its journal. 
 
Table 3.18: Funding acknowledgements and highly cited publications 
(citations count normalised within ISI WoS subject categories) 




the top-5% cited  
Number of 
publications within 
the top-10% cited  
Publication with funding data in 
acknowledgement sections 
 




Publications with no 
acknowledgements sections or 








Notes. The test on proportion supported (chi2=59.2, p<0.001 and chi2=117.2, p<0.001, respectively) 
shows that publications  acknowledging funding sources are significantly more highly cited than those 
publications without such funding. Results do not change when one considers the top-5% and top-10% 
cited articles according to the citation count normalised by SCs or focusing the analysis on „article‟ type 
of publication. 
 
Table 3.19 shows which research host organisations have the highest citations in 
their papers. To avoid results that are sensitive to publications that are outliers 
with very high numbers of citations coming from organisations with very few 
publications, only those major UK host organisations, i.e. those contributing to at 
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least 2% of the publications sample, are considered. The results show that while 
the Institute for Cancer Research and Oxford University have the highest number 
of publications in the top 5% cited (57 and 46 respectively), when the results are 
normalised by the size of the publication output of the top organisations, Cardiff 
University and Queen Mary University have a higher proportion of their output in 
the top 5% cited (8.9% and 8.67% respectively vs. 8.15% for the Institute of 
Cancer Research and 8.39% for Oxford University). 
Table 3.20 contains the results of the equivalent analysis for funders. It shows that 
although Cancer Research UK and the Departments of Health support more papers 
in the top 5% cited (60 and 59 respectively) than other funders, several funders 
support a proportionally higher percentage of highly cited publications including 
Breakthrough Breast Cancer (10%), Wellcome Trust (7.9%), MRC (7.8%) and 
BBSRC (7.6%) – compared with 6.3% for Cancer Research UK and 6.6% for DH. 
Notably, the EPSRC did not fund neoplasms research papers in the highly cited 
category in this period. 
Figure 3.24 explores the relationship between the number of funders 
acknowledged in publications and the relative proportion of highly cited (top-5%) 
publications. As the number of funders increase the proportion of highly cited 
paper increases up to 6-7 funders when the relationships shows decreasing 
returns.10 The results confirm prior research that suggests papers supported by 
more funders are more highly cited (Lewison and Dawson 1998). 
Table 3.19: UK organisations contributing to at least 2% of the publication 
sample (N = 7,510) and number of highly cited (top-5%) publications 




Number of publications 
within the top-5% 
cited out the number of 
publications produced  
1) Institute of Cancer Research, London  
(including the following organisation or name variations: 
Royal Marsden NHS Foundation Trust) 
57 8.15% 
2) Oxford University, Oxford 
(including the following organisation or name variations: Gray 
Institute, John Radcliffe Hospital, Oxford Radcliffe Hospitals NHS 
Trust, United Kingdom) 
46 8.39% 
3) University of Cambridge, Cambridge 
(including the following organisation or name variations: Cancer 
Research UK Cambridge Research Institute, Hutchison/MRC Research 
Centre, Cambridge Biomedical Research Centre, Addenbrooke's 
University Hospital, Cambridge University Hospital NHS Trust) 
41 7.37% 
4) University of Leeds, Leeds 
(including the following organisation or name variations: Leeds 
Cancer Research UK Centre, St James's University Hospital, Leeds 
Teaching Hospitals NHS Trust, Leeds General Infirmary) 
33 8.35% 
5) Imperial College, London 
(including the following organisation or name variations: Imperial 
College Healthcare NHS Trust, Hammersmith Hospital, Charing Cross 
Hospital) 
32 5.64% 
6) University College London, London 
(including the following organisation or name variations: University 
College London Hospitals NHS Trust, UCL Cancer Institute, National 
Hospital for Neurology and Neurosurgery, Royal Free Hampstead 
NHS Trust) 
30 4.76% 
7) University of Manchester, Manchester 
(including the following organisation or name variations: Cancer 
Research UK Paterson Institute,  Christie Hospital) 
30 7.71% 
8) King's College London, London 
(including the following organisation or name variations: King's 
College Hospital NHS Trust, Guy's and St Thomas NHS Trust, Guy's 
Hospital, Western General Hospital) 
28 5.29% 
9) Queen Mary University of London, London 28 8.67% 
                                           
10 A more detailed analysis that controls for additional variables is required to draw explanatory 
conclusions here. This is beyond the scope of the present study.  
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Number of publications 
within the top-5% 
cited out the number of 
publications produced  
(including the following organisation or name variations: St 
Bartholomew's Hospital) 
10) University of Edinburgh, Edinburgh 
(including the following organisation or name variations: Edinburgh 
Cancer Research Centre, Western General Hospital) 
21 7.45% 
11) Cardiff University, Cardiff 
(including the following organisation or name variations: Velindre 
NHS Trust) 
17 8.90% 
12) University of Glasgow, Glasgow 
(including the following organisation or name variations: NHS 
Greater Glasgow and Clyde, Gartnaval General Hospital, Glasgow 
Royal Infirmary, Western Infirmary) 
15 5.40% 
13) University of Sheffield, Sheffield 
(including the following organisation or name variations: Weston Park 
Hospital, Sheffield Children's NHS Trust, Sheffield Teaching Hospitals 
NHS Trust) 
15 7.08% 
14) University of Southampton, Southampton 
(including the following organisation or name variations: 
Southampton General Hospital) 
13 7.65% 
15) University of Liverpool, Liverpool 
 
12 7.23% 
16) University of Newcastle, Newcastle Upon Tyne 
(including the following organisation or name variations: Northern 
Institute of Cancer Research, Newcastle upon Tyne Hospitals NHS 
Trust, Royal Victoria Infirmary, Freeman Hospital) 
12 4.94% 
17) University of Birmingham, Birmingham 
 
9 4.11% 
Notes. Only organizations contributing to at least 2% of publications are considered. The rank changes 
marginally when one considers the top-10% cited articles according to the citation count within SCs or the 
top-5% and top-10% cited articles according to the citation count normalised by SCs. 
Table 3.20: UK funding organisations acknowledged in at least 2% of the 
publication sample (N = 3,914) and number of highly cited (top-5%) 
publications 




Number of publications 
within the top-5% cited 
out the number of 
publications produced 
1) Cancer Research UK 60 6.3% 
2) Department of Health (including NHS and NIHR) 59 6.6% 
3) Medical Research Council (MRC) 37 7.8% 
4) Wellcome Trust 16 7.9% 
5) Breakthrough Breast Cancer 11 10.0% 
6) Biotechonolgy and Biological Sciences Research Council (BBSRC) 7 7.6% 
7) Leukaemia and Lymphoma Research 7 5.1% 
8) Breast Cancer Campaign 6 6.3% 
9) Engineering and Physical Science Research Council (EPSRC) 0 0.0% 
Notes. Only funder acknowledged in at least 2% of publications were considered. The rank changes 
marginally when one considers the top-10% cited articles according to the citation count within SCs or the 
top-5% and top-10% cited articles according to the citation count normalised by SCs. 
 
We also investigated the citations patterns by following the conceptualisations of 
funders and publications adopted in Section 3.5. We report in Table 3.21 the 
number of highly cited papers by categories of funder and relative compositions. 
We considered both top-5% and top-10% highly cited paper as in the previous 
analysis. Those publications simultaneously supported by all types of funders (g) 
have a higher proportion of highly cited publications (~12% and ~22% when 
considering the top-5% and top-10% cited). Conversely, those publications 
supported only by minor funders (b) report a lower proportion of publications 
(~5.2% and ~10.3% when considering the top-5% and top-10% cited) of highly 
cited publications.  
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Figure 3.24 Number of funders and relative proportion of highly cited 
(top-5%) publications. 
 
We analysed the proportion of highly cited papers by combining the different 
categories in three overlapping groups as in previous analyses, i.e. publications 
supported at least by one major UK funder (a+d+f+g), publications supported by 
at least one minor UK funder (b+d+e+g), and publications supported at least by 
one „other‟ funder or industry (c+e+f+g). The results are reported in the lower 
part of Table 3.21. Publications supported by at least one minor UK funder are less 
likely to be highly cited papers (~7% and ~15% when considering the top-5% and 
top-10% cited) compared to those publications involving at least one major UK 
funder (~9% and ~17% when considering the top-5% and top-10% cited) and 
those publications involving at least one industrial actor or any other funders not 
falling in the previous categories (~11% and ~19% when considering the top-5% 
and top-10% cited). 
Table 3.21: Funders compositions and number of highly cited publications 
Publications 
supported by 




the top-5% cited  
Number of 
publications within 
the top-10% cited  
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Publications 
supported by 




the top-5% cited  
Number of 
publications within 
the top-10% cited  
Other funders and 
industry 
 
(11.1%) (10.8%) (21.2%) 
Major and minor UK 
funders - Other 








     































In addition, we assess the citations of publications supported by industry (i.e. 
those publications with at least one author with an industrial affiliation or 
acknowledging at least one industrial funder. The results, reported in Table 3.22, 
show that industry supported publications are significantly over-represented in the 
top 5% and top 10% of highly cited publications compared to the sample of 
publications not involving industrial actors as funders or as host organisations. 
 
Table 3.22: Involvement of industrial actors and highly cited publications 





Number of publications 
within the top-5% cited  
Number of publications 





















Notes. The test on proportion supported (chi2=56.52, p<0.001 and chi2=79.76, p<0.001, 
respectively) that publications involving industry are significantly more cited than those not 
involving industrial actors. Results do not change focusing the analysis on „scientific article‟ type of 
publication. 
 
3.7.2 Funder, host organisations and intensity of international 
collaboration 
The average number of countries that research host organisations collaborate with 
per publication is shown in Table 3.23. The results show that the University of 
Cambridge, Imperial College London and Oxford University support research that 
includes notably more international research links than other organisations. 
Table 3.24 shows the results of the equivalent analysis for research funders, which 
show that the Wellcome Trust supports research that is notably more collaborative 
with international partners than that of other funders.  
Table 3.25 reports the average number of countries and the relative standard 
deviation for the publication sample classified according to the conceptualisation of 
funders adopted in Section 3.5. Publications supported exclusively by major or 
minor UK funders (a,b, and d) involves on average 1.3 countries. Publications 
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supported by other funders or industrial actors involve on average a larger number 
of countries (3.6). As above, we investigated the involvement of international 
actors in publications by combining the different categories in three overlapping 
groups, i.e. publications supported at least by one major UK funder (a+d+f+g), 
publications supported by at least one minor UK funder (b+d+e+g), and 
publications supported at least by one „other‟ funder or industry (c+e+f+g). The 
first two groups of publications involves on average 2 different countries per 
publications. This suggests that major UK funders are not more likely to support 
researchers to form international links compared to minor UK funders. 
Table 3.23: UK organisations contributing to at least 2% of the publication 
sample (N = 7,510) and international collaborations 
 Organisation Number of countries 
  Mean Std.Dev. Min Max 
1) University of Cambridge, Cambridge 
(including the following organisation or name variations: Cancer 
Research UK Cambridge Research Institute, Hutchison/MRC Research 
Centre, Cambridge Biomedical Research Centre, Addenbrooke's 
University Hospital, Cambridge University Hospital NHS Trust) 
3.4 3.9 1 25 
2) Imperial College, London 
(including the following organisation or name variations: Imperial 
College Healthcare NHS Trust, Hammersmith Hospital, Charing Cross 
Hospital) 
3.4 3.7 1 25 
3) Oxford University, Oxford 
(including the following organisation or name variations: Gray 
Institute, John Radcliffe Hospital, Oxford Radcliffe Hospitals NHS 
Trust, United Kingdom) 
3.2 3.6 1 25 
4) Institute of Cancer Research, London  
(including the following organisation or name variations: Royal 
Marsden NHS Foundation Trust) 
2.7 3.3 1 23 
5) University of Newcastle, Newcastle Upon Tyne 
(including the following organisation or name variations: Northern 
Institute of Cancer Research, Newcastle upon Tyne Hospitals NHS 
Trust, Royal Victoria Infirmary, Freeman Hospital) 
2.6 4.1 1 25 
6) University of Sheffield, Sheffield 
(including the following organisation or name variations: Weston Park 
Hospital, Sheffield Children's NHS Trust, Sheffield Teaching Hospitals 
NHS Trust) 
2.6 3.6 1 23 
7) University of Leeds, Leeds 
(including the following organisation or name variations: Leeds 
Cancer Research UK Centre, St James's University Hospital, Leeds 
Teaching Hospitals NHS Trust, Leeds General Infirmary) 
2.5 3.0 1 25 
8) University of Glasgow, Glasgow 
(including the following organisation or name variations: NHS 
Greater Glasgow and Clyde, Gartnaval General Hospital, Glasgow 
Royal Infirmary, Western Infirmary) 
2.4 3.2 1 25 
9) King's College London, London 
(including the following organisation or name variations: King's 
College Hospital NHS Trust, Guy's and St Thomas NHS Trust, Guy's 
Hospital, Western General Hospital) 
2.4 2.9 1 23 
10) University of Liverpool, Liverpool 
 
2.3 3.1 1 25 
11) University of Manchester, Manchester 
(including the following organisation or name variations: Cancer 
Research UK Paterson Institute,  Christie Hospital) 
2.3 2.5 1 20 
12) Queen Mary University of London, London 
(including the following organisation or name variations: St 
Bartholomew's Hospital) 
2.2 2.4 1 18 
13) Cardiff University, Cardiff 
(including the following organisation or name variations: Velindre 
NHS Trust) 
2.2 2.1 1 14 
14) University of Edinburgh, Edinburgh 
(including the following organisation or name variations: 
Edinburgh Cancer Research Centre, Western General 
Hospital) 
2.2 2.2 1 17 
15) University College London, London 
(including the following organisation or name variations: University 
College London Hospitals NHS Trust, UCL Cancer Institute, National 
Hospital for Neurology and Neurosurgery, Royal Free Hampstead 
NHS Trust) 
2.1 2.0 1 17 
16) University of Birmingham, Birmingham 
 
2.0 1.7 1 14 
17) University of Southampton, Southampton 
(including the following organisation or name variations: 
Southampton General Hospital) 
2.0 2.6 1 20 
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Table 3.24: UK funding organisations acknowledged in at least 2% of the 
publication sample (N = 3,914) and international collaborations 
 Organisation Number of countries  
  Mean Std.Dev. Min Max 
1) Wellcome Trust 3.1 3.4 1 17 
2) Medical Research Council (MRC) 2.6 2.9 1 20 
3) Breakthrough Breast Cancer 2.5 3.1 1 20 
4) Cancer Research UK 2.5 3.0 1 23 
5) Breast Cancer Campaign 2.5 3.5 1 20 
6) Department of Health (including NHS and NIHR) 2.2 2.8 1 23 
7) Leukaemia and Lymphoma Research 1.6 0.9 1 5 
8) Biotechonolgy and Biological Sciences Research Council (BBSRC) 1.6 0.8 1 4 
9) Engineering and Physical Science Research Council (EPSRC) 1.5 0.8 1 4 
 
Table 3.25: Funders composition and international collaborations. 
Publications 
supported by 
Subset Number of 
publications 
Mean number of 
countries per 
publication 
Std.Dev. of the 
number of countries 
per publication 























Minor UK funder-Other 





Major UK funders -Other 





Major and minor UK 






     





















3.8 Future research 
This study has opened up some areas that may warrant further investigation. 
Firstly, it is clear that a high proportion of UK neoplasms research is supported by 
a large number of  relatively small funders. The funding priorities of these funders 
and the ways in which they seek to complement the efforts of the larger funders is 
relatively unknown. Secondly, are such small funders a prominent contributor to 
other fields of biomedical research, or are they more strongly clustered in 
neoplasms? Finally, it is clear that a high proportion of UK research is in some way 
associated with international collaborations and funding from overseas. How would 
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cuts to the budget of UK or overseas funders impact the structure of the dense 
network or reduce the quality of scientific outputs? 
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4. COMPLEMENTARITY/SUBSTITUTABILITY 
OF GOVERNMENT AND CHARITY FUNDING 





















This chapter addresses the question: “If there was a cut in government funding for 
life sciences would other funders (private and public) be able to fill the gap and 
continue to support research activities?” 
In our previous report for Cancer Research UK (OHE, 2011), we examined the 
likely consequences of a hypothetical reduction in the level of public funding for 
medical research. For that report we conducted a review of the peer-reviewed and 
grey literature, identifying 12 key papers that focused on the question of whether 
government and charity funding of medical research substitute for, or 
complement, one another.  
Key Points 
 In a web-based survey of 401 members of the UK general public, we asked 
respondents how they would distribute a hypothetical £100 allocation of 
income tax amongst cancer research and other medical research charities 
under a range of different scenarios regarding changes in government 
spending on cancer research and other medical research. 
 When respondents are asked to suppose that the government has cut (or 
has increased) funding for cancer research, the overall tendency is to give a 
larger (smaller) share of the allocation of income tax to cancer research 
charities. This suggests that, given the opportunity, respondents would try 
to counteract the hypothetical change in government funding of cancer 
research by allocating more (less) of their income tax to cancer research, 
were they given the opportunity. However, most respondents‟ preferred 
allocations did not vary much from scenario to scenario.  
 The vast majority of respondents stated that their existing personal out-of-
pocket donations to cancer research and/or other medical research 
charities would not be affected by changes in government funding levels or 
by being given the opportunity to allocate £100 of their income tax to these 
charities.  
 Respondents‟ decisions about whether to donate to a cancer research 
charity are more likely to be driven by personal experience of cancer or by 
increases in their disposable income than by information about the level of 
government funding for cancer research. 
 Recent additions to the literature suggest that government and charity 
funding of medical research may be complementary, with some empirical 
studies reporting that increases in government spending on a particular 
area may crowd in (rather than crowd out) private donations to charities 
operating in the same area. 
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The main finding of our 2011 review was that there are theoretical arguments 
supporting both “crowding out” effects – i.e. decreases in government funding lead 
to donors increasing their own contributions (Warr, 1982; Roberts, 1984; 
Bergstrom et al., 1986; Andreoni, 1990; Andreoni and Payne, 2003) and 
“crowding in” effects – i.e. decreases in government funding lead to donors 
reducing their own contributions (Rose-Ackerman, 1986; Payne, 2001; Heutel, 
2009). However, no empirical evidence specific to the UK medical research 
environment was found.   
The one relevant UK study we identified (Khanna and Sandler, 2000) suggested 
that government funding of research is more likely to crowd in than to crowd out 
charitable funding. But the evidence was weak and did not relate specifically to 
medical research charities. Outside of the UK, most of the studies were undertaken 
in the US and suggested that whether crowding in or crowding out prevails 
depends on the nature of the activity undertaken by the charity. For example, 
Payne (2001) reported evidence that government funding crowds in charity 
contributions for research universities but not for non-research universities.  
Given the limited literature available at the time, we identified as top of the future 
research agenda: finding UK-specific evidence on the crowding in or crowding out 
effect of government funding vis-à-vis charitable funding of medical research. 
4.2 Updated literature review 
4.2.1 Objectives and scope 
Our objective was to update the literature review we undertook for Cancer 
Research UK in 2011, adopting a similar search strategy to before (OHE, 2011) but 
limited to the period 2010 to 2013. However, we also identified a strand of the 
literature that had not previously been explored (experimental economics), so 
decided to include studies published prior to 2010 that had not been captured in 
the earlier review but were deemed to be relevant to the research question.     
As before, the stated objectives of the review were to: 
 identify the economic principles underpinning charity and government 
contributions to medical research (or research in general); 
 investigate whether government and charitable funding of medical research 
(or research in general) complement and/or substitute each other within 
the UK research funding system. 
4.2.2 Method 
We used three approaches to identify additional literature: 
1. Keyword searches of the major economics, medical and general databases, 
using an updated version of the search strategy used in our earlier review.   
2. Searching for papers published since 2010 that cited one of more of the key 
papers identified in our earlier review, using Google Scholar‟s “cited by” 
feature. 
3. Searching for working papers and other unpublished literature using RePEc 
(Research Papers in Economics; http://repec.org/) and the websites of 
individuals and organisations who are active in this area of research. 
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We began with approach 1, examining the titles of the 12 key papers identified in 
our earlier review: 
 Impure altruism and donations to public goods: a theory of warm-glow 
giving (Andreoni, 1990) 
 Leadership giving in charitable fund-raising (Andreoni, 2006) 
 Do government grants to private charities crowd out giving or fund-raising? 
(Andreoni and Payne, 2003) 
 On the private provision of public goods (Bergstrom et al., 1986)  
 Demand for collective goods in private non-profit markets: can fundraising 
expenditures help overcome free-rider behavior? (Weisbrod and 
Dominguez, 1986) 
 Crowding out and crowding in of private donations and government grants 
(Heutel, 2009) 
 Partners in giving: the crowding-in effects of UK government grants 
(Khanna and Sandler, 2000) 
 Measuring the effect of federal research funding on private donations at 
research universities: is federal research funding more than a substitute for 
private donations? (Payne, 2001) 
 A positive model of private charity and public transfers (Roberts, 1984) 
 The informational value of sequential fundraising (Vesterlund, 2003) 
 Pareto optimal redistribution and private charity (Warr, 1982) 
 Do government grants to charity reduce private donations? (Rose-
Ackerman, 1986) 
We counted the number of times each potential keyword (e.g. “research”) 
appeared in these titles, combining synonymous and related terms where 
appropriate (e.g. “charity”, “charities”, “charitable”). We identified the following 
nine keywords to be the most commonly used amongst the original key papers: 
private; donations; grants; government; charity/charities/charitable; research; 
giving; fund-raising/fundraising; crowd/crowding. 
In addition, we included two further terms: “experimental” (in order to capture 
relevant papers in the experimental economics literature) and “medical research”. 
This gave a total of 11 keywords. 
We conducted a series of electronic searches of economics, medical and general 
databases in April 2013 using logical combinations of the 11 keywords. The 
keyword searches identified 346 potentially relevant English language records, 120 
of which had been published since 2010. 
We then proceeded to approach 2, using Google Scholar to identify papers 
published since 2010 that had cited the key papers from the original review: 
 Andreoni (1990) – 777 citations since 2010 
 Andreoni (2006) – 54 citations since 2010 
 Andreoni and Payne (2003) – 105 citations since 2010 
 Bergstrom et al. (1986) – 347 citations since 2010 
 Weisbrod and Dominguez (1986) – 66 citations since 2010 
 Heutel (2009) – 19 citations since 2010 
 Khanna and Sandler (2000) – 41 citations since 2010 
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 Payne (2001) – 12 citations since 2010 
 Roberts (1984) – 68 citations since 2010 
 Rose-Ackerman (1986) – not a journal article therefore no citation statistics 
available via Google Scholar 
 Vesterlund (2003) – 83 citations since 2010 
 Warr (1982) – 86 citations since 2010  
In total, the key papers (excluding Rose-Ackerman, 1986) were found to have 
been cited in 1,658 recent articles, although a number of these records were 
duplicates of each other and of the records identified using approach 1. Finally, 
using approach 3 we identified a small number working / occasional papers that 
had not (yet) been published in peer-review journals and had not been identified 
using approaches 1 and 2. 
Including all of the identified records would have required reviewing up to 2,000 
articles, which was infeasible given the scope of the study. We therefore restricted 
our attention to the first few pages of results from the searches (where the results 
were sorted by relevance). We also refined approach 2 by searching the results for 
the approach 1 keywords to identify the records that were most likely to be 
relevant to the research question. These steps reduced the results to 55 records. 
We then screened each record by examining their titles and abstracts. Records 
were selected for the review if they were deemed to be directly relevant to the 
research question. We considered empirical studies, reviews and theoretical 
papers. Reference lists from included papers were checked to identify further 
relevant studies.  
4.2.3 Findings 
We organised the relevant studies into three broad categories: 
1) studies that focused on or specifically mentioned funding for scientific or 
health-related research; 
2) studies published since 2010 that did not specifically mention research but 
that focused on the relationship between government spending and private 
donations to charitable organisations; and 
3) studies that used laboratory experiments to investigate private charitable 
donation behaviour.  
4.2.3.1 Studies that mention funding for research  
The only study we identified that focused directly on funding for scientific research, 
and had not been included in our earlier review, was that of Diamond (1999). 
Diamond begins by noting evidence (from areas other than scientific research) 
that when the government increases its funding of a given activity, the private 
funding that had been supporting that activity diminishes. He hypothesises that 
the converse would also be true: as the government withdraws from funding an 
activity, private money will enter to partially fill the gap.  
Diamond examines 43 years of US data on spending on basic research from four 
funding sources: the federal government, industry, universities and non-profit 
institutions. He finds evidence of crowding in, although the economic magnitude of 
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the effect is small, suggesting that donors view federal and private spending on 
basic research as complements rather than substitutes. If this is true both when 
the government increases and when it reduces spending levels, Diamond suggests 
that “private funding could not be expected to replace lost federal funding of 
science”. 
We also identified an empirical study that distinguished health-related charities 
from other types of charities. In an examination of panel data covering all 
registered charities in Sweden between 1989 and 2003, Breman (2006) reported 
results that overall reject the crowding out hypothesis. She categorised the 
organisations depending on whether they are related to health (including health 
research), social services, international aid, or “other”; finding that for health and 
international aid organisations, zero crowding out cannot be rejected; whereas for 
social services and other organisations, zero crowding out can be rejected and 
there is evidence of crowding in. 
4.2.3.2 Studies published since 2010  
In a review of empirical studies of philanthropy, Bekkers and Wiepking (2011) 
identified eight factors driving charitable giving: awareness of need, solicitation, 
costs, benefits, altruism, reputation, psychological benefits, values, and efficacy. 
In the context of the impact of changes in government funding, altruism and 
psychological benefits are of particular interest. Purely altruistic motivation would 
lead to a crowding out effect, as donors reduce their own contributions as they 
learn about increases in contributions by others. However, there is evidence that 
charitable giving produces positive psychological consequences for the donor, 
often labelled “warm glow” or “joy of giving” effects. 
In a UK study based on interviews with 60 “committed donors”, in general i.e. not 
limited to medical research charities, Breeze (2010) found that people tend not to 
give to the most urgent needs but rather to support causes that mean something 
to them. She reports the following criteria that commonly influence donors‟ 
decision-making: their tastes, preferences and passions; their personal and 
professional backgrounds; their perceptions of charity competence; and their 
desire to have a personal impact. Regarding the fourth criterion, Breeze notes that 
the interviewees were “keen to avoid their donations becoming a substitute for 
government spending”, particularly in the area of welfare spending. Rather, they 
were keen for their contributions to complement rather than to replace the funding 
available for a particular cause – donors have “higher expectations for their 
contributions than „gap plugging‟”.  
Garrett and Rhine (2010) claim that the relationship between government 
spending and charitable giving depends on the specific categories of spending 
being studied. This suggests that it is difficult to make inferences about medical 
research funding using data that is not concerned primarily with medical research 
funding. The authors also note that no statistical relationship between government 
spending and charitable contributions would be expected if people are “rationally 
ignorant” about government activities, which is often likely to be the case. 
Andreoni and Payne (2011) distinguish between “classic” and “fundraising” 
crowding out. Classic crowding out occurs when government grants to charities 
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lead donors to reduce their donations because the donors treat their voluntary 
private contributions as a substitute for their involuntary contributions through 
taxation. Fundraising crowding out occurs when the charities receiving the grants 
reduce their fundraising efforts, which results in reduced private donations. The 
latter is a feasible explanation for crowding out in situations where donors are 
largely unaware of changes in funding levels. Using a panel of charities in the US, 
the authors find that “crowding out attributable to classic crowd-out ranges from 
30% to a slight crowd-in effect, while fundraising crowd-out ranges from 70% to 
over 100% of all crowd-out” (the percentages can be interpreted as follows: 30% 
crowd-out indicates that every $1,000 government grant reduces private giving by 
$300). This suggests that the actions of charities themselves are responsible for a 
large proportion of all observed crowding out.  
A more recent study by Andreoni et al. (2013) examines the effect of grants on 
charities‟ incomes in the UK. The authors use a sample of charities that applied for 
a grant from a National Lottery-funded programme. They find that grants do not 
crowd out other income, with evidence of crowd in for some of the smaller 
charities.  
In an empirical study examining panel data from almost 30,000 charities in the 
US, Heutel (2012) reports the government grants to charities lead to a crowding in 
effect, with “a dollar increase in government grants leading to an increase in 
private donations between 10 and 30 cents”. He also finds that the rate of 
crowding in is larger for younger charities (the effect disappears for the oldest 
charities). This suggests the existence of a signalling effect as younger charities 
are less likely to be known by donors, so the signal value of a grant is higher. 
Heutel calls for further research on signalling effects. 
In an empirical study examining the determinants of private donations to US-
based non-government organisations engaged in international development 
cooperation, Herzer and Nunnenkamp (2012) find that government grants crowd 
in private donations in the long run. However, the authors note that private donors 
tend to be more familiar with local charities, whereas information asymmetries are 
likely to exist in the context of large and/or international organisations.   
4.2.3.3 Experimental economics literature 
An alternative approach to testing the crowding out hypothesis is to use laboratory 
experiments. Eckel et al. (2005) conducted one such study in which respondents 
were randomly assigned to an allocation of real money (for example, US$15 to the 
respondent and US$5 to a charity chosen by the respondent from a list). 
Respondents were then invited to voluntarily allocate additional money to their 
chosen charity. One group of respondents was simply informed of the initial 
allocations between themselves and the charity. The other group was told that 
their initial allocation had been, say, US$20 but that a tax had been levied on this, 
with the tax revenue being allocated to the charity. In the first group, the size of 
respondents‟ voluntary contributions increased as the size of the initial allocation 
to the charity fell. In the second group, in which “fiscal illusion is eliminated”, the 
size of the voluntary contributions was not found to vary with the size of the initial 
allocation to the charity. Eckel et al. conclude that “forced contributions crowd out 
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private giving when the source of the funding of the forced transfers is apparent to 
the subjects”. 
In another experimental study, Crumpler and Grossman (2008) allocated an 
endowment of US$10 to respondents and asked them how they wished to divide 
the amount between themselves and a charity (again, chosen by the respondent 
from a list). The respondents were also told that the experimenter would be 
making a donation to the charity, but that the size of this donation would be 
reduced by however much the respondent chooses to allocate to the charity. 
Hence, the charity would receive US$10 in all cases, so the respondents‟ donations 
would be completely crowded out and a pure altruist would have no incentive to 
donate. The authors report that over half of the respondents made a donation, 
which indicates the existence of “warm glow” giving. 
4.2.3.4 Summary of the literature 
In summary, a number of recent studies have reported evidence of the crowding 
in effect, which suggests that an increase in government spending in a particular 
area may result in increased private donations to charities operating in that area. 
However, the majority of studies report US data and may not be relevant to the 
UK context. With their US focus, most of the studies examine the impact of direct 
government grants to charities themselves. There are very few studies that 
specifically examine funding for research, let alone medical research. Furthermore, 
most of the studies focus on increases in government spending, whereas given the 
current economic climate it would be more appropriate to consider the impact of 
cuts in spending. The lack of relevant UK evidence means that experimental or 
stated preference studies may be useful in terms of understanding the potential 
impact of cuts in government funding for cancer research. 
4.3 Stated preference survey 
4.3.1 Objective 
The aim of this stated preference study was to elicit the views of the general public 
about how a change in government spending on cancer research might affect 
people‟s willingness to donate to cancer research charities. We sought to address a 
number of gaps in the existing literature on charitable behaviour, which lacks 
studies that use a stated preference design, and which contains no studies that 
focus specifically on medical research and charitable giving in the UK. 
The survey was designed so as to answer the following key research questions: 
 If given the opportunity to allocate £100 of the income tax they pay this 
year to one or more medical research charities, how would people choose 
to distribution the £100 between cancer research and other medical 
research charities? 
 Would being given the opportunity to allocate £100 of their income tax to 
cancer and other medical research charities lead people to change their 
existing personal out-of-pocket donations to those types of charities? 
 Would people‟s preferred allocations of funds change if they were to learn 
that the government was cutting or increasing funding for cancer and/or 
other medical research? 
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4.3.2 Methods 
4.3.2.1 Survey instrument 
The main part of the survey comprised five hypothetical scenarios. In each 
scenario, respondents were asked to imagine that they had the opportunity to 
allocate £100 of the income tax they paid this year to one or more medical 
research charities. They were asked how they wished to allocate the £100 between 
cancer research charities and medical research charities concerned with diseases 
other than cancer. The recipients of the allocation would be unnamed charities of 
the respondents‟ choosing. The idea behind the scenarios was loosely based on the 
situation in Italy, where since 2006 taxpayers have been offered the opportunity 
to donate 0.5% of their income tax they pay to non-profit organisations of their 
choosing (Agenzia delle Entrate, n.d.).   
After having been given the opportunity to allocate £100 in this way, the 
respondents were then asked if they would want to reduce or increase any 
personal donations that they already make out of their own pocket to cancer 
research and non-cancer medical research charities; and if so, by how much. 
Respondents were only asked about changes to their out-of-pocket personal 
donations if they had earlier claimed to have made financial donations to one or 
more medical research charities in the previous year (see below). These questions 
allowed us to test the extent to which having the opportunity to allocate some of 
their income tax to medical research charities might affect people‟s willingness to 
donate from their own (post-tax) resources.   
Table 4.1 summarises the information provided to respondents in the five 
scenarios. The full survey is reproduced in the Appendix. 
In scenario 1, no information was provided about research funding levels. In 
scenario 2, respondents were presented with rounded estimates of how much the 
government and charities actually spend on medical research in the UK each year 
(figures based on data in: NCRI, 2011; UKCRC, 2012). The actual levels of 
spending on medical research may be very different from what respondents would 
have been expecting. Comparing scenarios 1 and 2 allows us to test the 
hypothesis that some respondents would revise their choices of allocations when 
they become better informed about research funding levels. 
In scenario 3, respondents were asked to imagine a hypothetical situation where 
the government has reduced its annual spending on cancer research from 
£150million (as in scenario 2) to £50million, and has spent the £100million 
difference on more research into diseases other than cancer. The crowding out 
hypothesis suggests that respondents would seek to make up the gap by 
increasing the amount they give to cancer research charities. Alternatively, 
respondents may view the government‟s decision to redirect resources away from 
cancer research towards other areas of medical research as a signal that cancer 
research is a relatively low priority for society (hence comparing scenarios 2 and 3 
allows us to test the signalling hypothesis). If so, they may follow suit by reducing 
the amount they give to cancer research charities. 
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Table 4.1: Summary of scenarios used in the survey 
Scenario 
Spend on medical research in the UK each year 
Description 









1 No information provided to respondent 
Scenario included to capture 
respondents‟ preferences in 
absence of information about 
medical research funding levels 
2 £150m £2,350m £350m £650m 
Realistic estimates of actual 
spending on medical research 
3 £50m £2,450m £350m £650m 
Government reduces its spending 
on cancer research and spends 
that money instead on other 
medical research 
4 £50m £2,350m £350m £650m 
Government reduces its spending 
on cancer research; spending on 
other medical research remains 
unchanged 
5 £250m £2,250m £350m £650m 
Government increases its spending 
on cancer research and reduces its 
spending on other medical 
research by the same amount 
 
Scenario 4 replicates scenario 3 except that the government does not increase its 
spending on other areas of medical research, so total annual government spending 
on medical research has been reduced by the same £100million that has been cut 
from spending on cancer research. 
Finally, in scenario 5 the government has increased its annual spending on cancer 
research by £100million and has found that money by reducing its spending on 
research into diseases other than cancer by £100million. It was hypothesised that 
if a respondent reacts to hearing that the government has reduced its spending on 
cancer research by increasing (reducing) the share of the £100 allocation they give 
to cancer research charities, then they may react to hearing the government has 
increased its spending on cancer research by reducing (increasing) the share for 
cancer research charities.  
Information about the levels of funding for research from charities remained 
constant throughout the scenarios, and was included to provide some context to 
the respondents. 
The questions relating to the five scenarios were preceded by a small number of 
preliminary questions. First, respondents were presented with a list of well-known 
cancer research charities and were asked to indicate which of those charities, if 
any, they had given money to in the past year. An “Other” option was included to 
allow respondents to specify the name of a cancer research charity that they had 
given money to and was not included in the list. Respondents were then asked a 
similar question but about medical research charities focusing on diseases other 
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than cancer. When later faced with the five scenarios, respondents were only 
asked the questions about whether they would change their personal out-of-
pocket donations to cancer research and/or other medical research charities if they 
had already claimed to give money to the relevant types of charities in these 
preliminary questions. 
The respondents were then asked to guess: (1) how much the UK government 
currently spends on medical research each year, in millions of pounds; and (2) the 
percentage of total UK government spending on medical research each year that is 
on cancer research. It was assumed that respondents would not know the answers 
to either of these questions, but having information on their best guesses helps us 
to interpret any changes in their responses when moving from scenario 1 (no 
information on government spending provided) to scenario 2 (realistic estimates of 
government spending levels provided).  
The respondents were then asked to indicate whether they thought that 
government funding of medical research had been going up, been going down, or 
remained about the same, over the last three years. They were then asked the 
same question, but focusing specifically on cancer research. 
Following these preliminary questions, the respondents were presented with the 
five scenarios, as described above. Once they had completed the questions for 
these scenarios, they were invited to provide comments to support their answers if 
they so wished. Respondents who had claimed not to have given money to any 
cancer research charities in the previous year were asked what, if anything, might 
encourage them to donate to a cancer research charity. 
The next question sought to elicit respondents‟ views more directly, asking them 
whether hearing that the government has reduced its spending on cancer research 
would make them more or less likely to donate to a cancer research charity, or to 
donate more or less than they already do. Alternatively, respondents could 
indicate that government spending decisions make no difference to their donation 
decisions. 
Finally, the respondents were asked some background questions about the types 
of charity donations they had made in the last year (to any kind of charity, medical 
or otherwise); whether the level of their charity donations had been going up, 
been going down or remained about the same; and whether they had any personal 
experience of cancer. 
4.3.2.2 Administration of survey 
The questions were included in a self-completion web-based survey. The survey 
was administered on a sample of adult members of the UK general public, all of 
whom were members of a panel managed by Aurora MR, with whom the market 
research agency Accent partnered for this component of the research. We sought a 
sample that was representative of the general population in terms of age and 
gender. We also sought respondents from different socioeconomic grades, 
choosing to oversample those from the very highest grades (A and B) in order to 
obtain a large subsample comprising individuals who might be expected a priori to 
be more likely than average to be regular givers of large charity donations (or to 
become such givers in the future). Screen-in questions, combined with a 
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“minimum quota” approach, were used to ensure that the sample comprised 
individuals with the appropriate characteristics. Respondents were compensated 
for taking part by way of “reward points” which can be redeemed for gift vouchers. 
Information about the scenarios was presented using a combination of text 
descriptions and diagrams (see Appendix). All responses were recorded via the 
web-based survey. In order to control for potential ordering effects, the 
respondents were randomly assigned to one of two blocks that determined the 
order in which the scenarios were presented to them. Respondents in the first 
block faced the scenarios in the same order as described above (12345); 
respondents in the second block were presented with the scenario describing an 
increase in the government‟s funding for cancer research before proceeding to the 
scenarios describing reductions in the government‟s funding for cancer research 
(12534). 
4.3.2.3 Piloting 
The study design was informed by a focus group, which was used to pilot a draft 
version of the survey and to seek feedback from general public participants. The 
focus group took place in Hammersmith, London in May 2013. It was moderated 
by a focus group leader from Accent, with assistance from a member of the study 
team (KS). Nine members of the general public took part, all of whom claimed to 
support the principle of giving to charity. The sample was well-balanced with 
respect to age (three participants under 30 years; three between 30 and 60 years; 
and three over 60 years) and gender (four males; five females).   
The topic was introduced by the focus group leader. This was followed by a group 
discussion about different reasons for giving to charity, including medical research 
charities. The participants were then each handed a paper copy of the draft survey 
and were asked to complete it by hand without conferring with each other. All but 
one of the participants completed the survey within 15 minutes; the majority 
required less than 10 minutes. Feedback was sought on all aspects of the survey. 
The entire session was video recorded. 
The comments were largely favourable, with participants describing the scenarios 
as interesting and easy to understand; and claiming that the survey was 
straightforward to complete without assistance. However, the participants also 
criticised the survey for being overly “wordy” and repetitive; and some participants 
questioned the plausibility of some of the scenarios.   
The findings from the focus group informed the design of the final survey in a 
number of ways, in particular: the reduction of wordiness throughout the survey, 
with less repetition from scenario to scenario; the use of diagrams (rather than 
tables) to demonstrate the key pieces of information in the scenarios; the focus on 
financial donations only, rather than all types of giving (unpaid time, for example); 
the provision of examples of cancer and other medical research charities at the 
start of the survey; survey routing based on answers to previous question (e.g. 
only ask about changes to the respondent‟s out-of-pocket donations to cancer 
research charities if the respondent has already claimed to give money to cancer 
research charities); removal of specific reference to the policy in Italy; and the use 
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of features to make the web-based survey more user-friendly than its pen-and-
paper counterpart. 
4.3.3 Results 
The survey was carried out in July 2013. Respondents who completed the survey 
in less than 3.5 minutes were excluded from the sample due to concerns about 
data quality (n=74), leaving a sample of 401 respondents. The median time taken 
by these 401 respondents to complete the survey was 6.025 minutes. Table 4.2 
presents the background characteristics of the sample. By design, the sample was 
broadly representative of the general population with respect to age and gender 
(Office for National Statistics, 2011a), and comprised a larger proportion of 
individuals in the highest socioeconomic grades (National Readership Survey, 
2013). 
Table 4.2: Sample background characteristics 
 Freq % 
Total 401 100 
Gender 
  Male 








  18 to 29 
  30 to 39 
  40 to 49 
  50 to 59 













Social grade (refers to the occupation/responsibilities of the chief wage earner of 
the respondent’s household) 
  A (higher managerial, administrative or professional) 
  B (intermediate managerial, administrative or professional) 
  C1 (supervisory or clerical and junior managerial, administrative or professional)  
  C2 (skilled manual workers) 
  D (semi-skilled and unskilled manual workers) 

















Types of charity donations made in the last year   
  Money – regular donation 
  Money – one-off donation 
  Money – other (charity events, auctions, etc.) 
  Non-financial (donation of unwanted goods, volunteering, etc.) 













Over the last three years, what has happened to the level of your charity 
donations(s)? 
  Going up 
  Going down 











Personal experience of cancer (respondents could tick multiple boxes) 
  Yes, self 
  Yes, close friend or relative 
  No 












Just over half of the respondents (53.4%) said they had given money to Cancer 
Research UK in the previous year. Donations to Cancer Research UK were more 
common amongst respondents with personal experience of cancer and those from 
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the lower socioeconomic grades (although the question did not specify the size or 
regularity of the donations). 
Figure 4.1 shows the distribution of answers given by respondents when asked: 
(1) how much the UK government spends on medical research each year, in 
millions of pounds; and (2) what proportion of the total UK government spending 
on medical research each year is spent on cancer research. The vast majority 
(96.3%) of respondents underestimated the total government spending on medical 
research (median guess = £24million; actual figure ≈ £2,500million), and a 
similarly large majority overestimated the proportion of government spending on 
medical research that is spent on cancer research (median guess ≈ 30%; actual 
figure ≈ 6%) (actuals based on NCRI, 2011 and UKCRC, 2012). Over four-fifths of 
the respondents (82.5%) guessed that total government spending on medical 
research was less than or equal to £100million, with three evident peaks at 
£10million (12.9%), £50million (9.0%) and £100million (12.2%). The majority of 
respondents guessed that government funding of cancer research had either been 
going down (33.7%) or remained about the same (35.2%) over the past three 
years, with most of the remainder selecting the “don‟t know” option. 
Figure 4.1: Distribution of guesses of levels of government spending 
 
Table 4.3 reports the aggregate response data for the five scenarios. In scenario 
1, in which no information about actual levels of medical research funding was 
provided, the respondents were fairly equally split between giving the majority of 
the £100 allocation to cancer research charities (38.2%), giving the majority to 
non-cancer medical research charities (27.9%), and splitting the allocation equally 
between cancer research and non-cancer medical research charities (33.9%). In 
all of the subsequent scenarios, the proportion of respondents giving the majority 
of the allocation to cancer research charities was greater than in scenario 1. 
Respondents were mostly likely to give the majority of the allocation to cancer 
research charities in scenarios 3 and 4, when they were asked to imagine that the 
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government had reduced its spending on cancer research. One hundred and fifty-
three respondents (38.2%) opted for the same split between cancer research and 
other medical research charities in all five scenarios, including 48 respondents 
(12.0%) who chose a 50:50 split on every occasion. 
Table 4.3: Aggregate response data for scenarios 1-5 
 Scenario 
 1 

























Allocation to cancer research charities 
(out of notional £100 tax deducted 
sum) 
  <£50 
  =£50 


























Mean allocation to cancer research 
charities 
£53.60 £58.19 £63.15 £62.35 £56.47 
Change in personal out-of-pocket 
donations to cancer research charities1 
  Would reduce 
  Would increase 


























Mean change in personal out-of-pocket 
donation to cancer research charities2 -£0.10 +£1.12 +£1.54 +£1.51 -£0.21 
Change in personal out-of-pocket 
donations to other medical research 
charities3 
  Would reduce 
  Would increase 


























Mean change in personal out-of-pocket 
donations to other medical research 
charities -£0.52 -£0.78 -£0.37 +£0.09 +£0.02 
1 Questions asked only to respondents who had given money to one or more cancer research charities in the previous 
year 
2 Excludes outlier (individual who claimed that they would increase their personal donations by £250) 
3 Questions asked only to respondents who had given money to one or more non-cancer medical research charities in 
the previous year 
 
On average, from the £100 of income tax they were able to allocate to medical 
research, respondents chose to give £58.19 to cancer research charities and 
£41.81 to other medical research charities in scenario 2, in which they were 
presented with realistic estimates of government spending levels. In the scenarios 
in which the government had reduced its spending on cancer research, the 
average amount from within the £100 of income tax to be allocated to medical 
research that would be given to cancer research charities increased by £4.96 and 
£4.16 (scenarios 3 and 4, respectively). In the scenario in which the government 
had increased its spending on cancer research, the average amount given to 
cancer research charities from within the £100 of income tax to be allocated fell by 
£1.72 per person, on average (scenario 5). 
In all five scenarios, of the respondents who had earlier claimed to have given 
money to medical research charities in the previous year, the vast majority 
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(ranging from 88.2% in scenario 3 to 92.2% in scenario 1) said that they would 
not change the level of their personal out-of-pocket charity donations even after 
being given the opportunity to give an extra £100 out of their income tax. These 
respondents were most likely to increase their out-of-pocket donations to cancer 
research charities in scenarios 3 and 4, when they were asked to assume that the 
government had reduced its spending on cancer research; and were most likely to 
increase their out-of-pocket donations to non-cancer medical research charities in 
scenario 5, when they were asked to assume that the government had increased 
its spending on cancer research and had found that money by reducing its 
spending on research into diseases other than cancer. 
Sixty-eight point three per cent (274/401) of respondents said they had donated 
to cancer research charities in the last year. Among that group of respondents, 
Table 4.3 shows that the mean personal out-of-pocket donation to cancer research 
charities would be greater in scenario 4 than in scenario 2, but by just £0.39 per 
existing donor. If replicated across 68.3% of the total 50million UK adult 
population this would amount to extra out-of-pocket donations totalling 
£13million. Relative to the hypothetical £100m cut in government spending on 
cancer research in this scenario, this would imply a net £87million reduction in 
combined government and charity annual spending on cancer research. 
Figure 4.2 shows the distributions of the allocations given to cancer research 
charities in each of the five scenarios. The tendency to choose an even split 
between cancer research and other medical research charities in greatest in 
scenario 1. After being provided with information about the levels of government 
spending on medical research (scenarios 2 to 5), many respondents switch to 
giving the entire allocation to cancer research charities. This tendency is strongest 
in the scenarios that describe cuts in government spending on cancer research. It 
is notable that the distributions for scenarios 2 and 5 are near-identical. 
Across all scenarios, respondents with personal experience of cancer were less 
likely to choose even splits than those without personal experience of cancer. The 
differences in the population means between the experience/no experience groups 
are statistically significant in four of the five scenarios (ANOVA analysis). The 
differences in the distributions of the allocations between these groups are 
statistically significant in scenarios 3 and 4 (Kolmogorov-Smirnov test), where 
respondents with personal experience of cancer are more likely than those without 
personal experience of cancer to give a larger share of the allocation to cancer 
research. No statistically significant differences were found between the allocations 
of respondents in the highest socioeconomic grades and those of respondents in 
the lower grades.  
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Figure 4.3 shows the extent to which respondents changed their allocation choices 
from one scenario to another (for selected pairs of scenarios). Compared to 
scenario 2 (the scenario presenting realistic government spending estimates), 
respondents were more likely to give an increased share of the allocation to cancer 
research charities in scenarios 3 and 4 (the scenarios describing cuts to 
government funding for cancer research); and were slightly more likely to give a 
reduced share in scenario 5 (the scenario describing an increase in government 
funding for cancer research). 
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Figure 4.3: Changes in allocations from one scenario to another (for 
selected pairs of scenarios) 
 
 
Comparing the preferred allocations in scenarios 2, 3 and 5: over three-quarters of 
the respondents either gave the same amount to cancer research charities in all 
three scenarios (49.4%) or gave a larger amount to cancer research charities in 
scenario 3 than in scenarios 2 or 5 (28.2%). This is shown in Table 4.4. 
Table 4.4: Comparison of scenarios 2, 3 and 5 – in which was the largest 
amount allocated to cancer research charities?  
Scenario(s) in which the largest amount was given to cancer research charities Freq % 
Same allocation in all three scenarios 198 49.4% 
Scenario 2 20 5.0% 
Scenario 3 113 28.2% 
Scenario 5 18 4.5% 
Scenarios 2 and 3 30 7.5% 
Scenarios 2 and 5 7 1.7% 
Scenarios 3 and 5 15 3.7% 
 
Figure 4.4 shows, for each of the five scenarios, the relationship between 
respondents‟ preferred allocations of the £100 of their income tax and the amount 
they say that being given the opportunity to allocate that £100 of their income tax 
would cause them to  reduce or increase their personal out-of-pocket donations to 
cancer research charities (excluding those who would not change their personal 
donations and a small number of outliers who claimed that they would increase 
their personal donations by more than £100). Figure 4.5 shows the stated changes 
in personal out-of-pocket donations to non-cancer medical research charities. 
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Figure 4.4: Relationship between allocation and change in personal out-
of-pocket donation to cancer research charities 
 
Figure 4.5: Relationship between allocation and change in personal out-
of-pocket donation to non-cancer medical research charities 
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The linear trend lines in Figures 4.4 and 4.5 respectively indicate that the larger a 
respondent‟s allocation to cancer research charities, the more likely that 
respondent is to increase their personal out-of-pocket donations to cancer 
research charities as a result of being given the opportunity to allocate some of 
their income tax; and the more likely they are to reduce their personal out-of-
pocket donations to non-cancer medical research charities. The relationship 
between respondents‟ preferred allocations and the changes in their personal 
donations to cancer research charities appears to be strongest in scenarios 3 and 
4. 
The order in which the scenarios are presented in the survey appears to affect the 
way in which respondents‟ preferred allocations of the £100 of income tax vary 
across the scenarios. Figure 4.6 shows that respondents who were presented with 
scenario 5 prior to scenarios 3 and 4 (order 2) were more likely to choose the 
same allocation in scenarios 2 and 5 than those who were presented with scenario 
5 last (order 1). 
Figure 4.6: Order effects  
 
When asked directly if they were to hear that the government had reduced its 
spending on cancer research whether that would make them more or less likely to 
donate to a cancer research charity (or to donate more or less than they already 
do), the majority of respondents (70.8%) claimed that government spending 
decisions make no difference to their decision about whether or not (or how much) 
to donate to a cancer research charity. Of the remainder, most claimed that it 
would make them more likely to donate, whereas only eight respondents (2.0%) 
claimed that it would make them less likely to donate. Table 4.5 provides a cross-
tabulation of respondents‟ answers to this question and their answers to the 
question regarding scenario 4 when they were asked if they would change the 
level of their personal out-of-pocket donations to cancer research charities when 
faced with a situation whereby the government had reduced its spending on 
cancer research by £100million (the wording of this scenario most closely matches 
the wording of the direct attitudinal question). 
The majority of respondents who claimed that government spending decisions 
make no difference to their decision about whether to donate to a cancer research 
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charity also stated that they would not wish to change the level of their existing 
out-of-pocket donations to cancer research charities were they to hear that the 
government had reduced its spending on cancer research.  
Table 4.5: Cross tabulation – question regarding scenario 4 about impact 
on personal out-of-pocket donations vs. direct attitudinal question 
 
Direct attitudinal question 















0 2 4 6 
Would not 
change 
6 171 65 242 
Would 
increase 
1 8 17 26 
Total 7 181 86 274 
Note: Table refers only to the 274 respondents who had given money to cancer research charities in the previous 
year. 
All respondents were invited to leave comments about their answers to scenario 
questions. The comments were coded and organised into categories by Accent. 
Table 4.6 shows the proportion of respondents who made each type of comment. 
Note that some respondents made comments that belong to multiple categories, 
so the numbers sum to more than 100%. 
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Table 4.6: Summary of comments made by respondents about their 
answers 
Category of comment % 
No comment 80.5% 
Other charities are just as important (general) 0.5% 
Other medical research is just as/more important 3.0% 
Surprised/disgusted at how little cancer research receives from government 2.2% 
My personal donations would not be affected by changes to government policy/funding 3.0% 
The government should prioritise funding for education/preventative measures 0.7% 
People/I tend to donate to a cause they're connected to (e.g. family members affected) 2.2% 
Would support a campaign for increased government funding for medical research 0.7% 
Government funding for medical research should be as transparent as possible 0.5% 
Ability to donate to charity is affected by low income/current economic climate 1.2% 
My preference is to support lesser known charities 0.7% 
Concerns over how funding for research is spent (e.g. ineffective, bureaucracy, poor results) 0.7% 
The government allocations look out of proportion (unspecified) 0.5% 
Generally critical of all cancer treatment/mainstream medicine 0.5% 
Strongly opposed to animal testing 0.5% 
Problems with the form of the survey - confusing, complicated, repetitive 2.7% 
Lack of information/specialist knowledge to provide meaningful responses 1.2% 
Other 1.7% 
 
Respondents who had not earlier claimed to have given money to cancer research 
charities in the previous year were asked what might encourage them to do so. 
The responses were coded and organised into categories by a member of the 
study team (KHV). Table 4.7 shows the proportion of respondents who gave each 
type of response. Responses that suggested that having a larger disposable 
income would encourage donations to a cancer research charity were made 
predominantly by respondents in the lower socioeconomic grades, while responses 
that mentioned personal experience of cancer were made predominantly by those 
in the highest grades. None of the respondents who were asked this question gave 
a response that mentioned the level of government funding for cancer (or any 
other type of) research. 
Table 4.7: Summary of responses made by respondents when asked what 
would encourage them to donate to a cancer research charity 
Category of response % 
No response 56.7% 
Personal experience of cancer (self, friends or family) 11.8% 
Larger disposable income 10.2% 
Greater levels of information and transparency  8.7% 
Nothing (would encourage me to donate to a cancer research charity)  7.1% 
Other 5.5% 
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4.3.4 Discussion 
This study has elicited the views of a sample of the UK general public about how 
(hypothetical) changes in government spending on cancer research might affect 
people‟s willingness to donate to cancer research charities. The main findings are 
as follows:  
 Almost all respondents (96.3%) underestimate the amount that the 
government spends on medical research, and most overestimate the 
proportion of government spending on medical research that is for cancer 
research. When presented with actual government spending figures, the 
overall tendency is to give a larger share of the allocation (£100 of their 
income tax) to cancer research charities (at the expense of medical 
research charities concerned with diseases other than cancer). 
 When respondents are asked to suppose that the government has cut 
funding for cancer research, the overall tendency is to give a larger share 
of the allocation to cancer research charities.  
 When respondents are asked to suppose that the government has 
increased funding for cancer research, the overall tendency is to give a 
smaller share to the allocation to cancer research charities, although the 
impact is somewhat smaller than that of when the government has cut 
funding for cancer research. 
 Notwithstanding the above findings, most respondents‟ preferred allocation 
splits did not vary much from scenario to scenario; and a sizeable minority 
(38.2%) of respondents chose the same allocation split in all five scenarios.  
 In all five scenarios, the vast majority (88.2-92.2%) of respondents said 
that they would not take the opportunity to change the levels of their 
existing personal out-of-pocket donations to cancer research and/or other 
medical research charities, despite the fact that these charities would be 
receiving additional funding by way of the £100 allocation. For those 
respondents who said that they would change their personal donations, the 
larger their preferred allocation to cancer research charities, the more likely 
they are to increase their personal donations to cancer research charities.  
Overall, the results from the scenario questions suggest that most people‟s private 
donation decisions are not (or only slightly) affected by information about 
government spending. This finding is further supported by the responses to the 
direct attitudinal question, in which approximately two-thirds of respondents 
claimed that hearing that the government had reduced its spending on cancer 
research would not affect their decision about whether to donate to a cancer 
research charity, or the size of their donation.  
The open-ended comments made by respondents paint a similar picture. Few of 
the comments mentioned government funding for research as a factor affecting 
their decisions, with respondents claiming that personal experience of cancer, or 
increases in their disposable income, would be the main drivers behind any future 
decision to donate to a cancer research charity. Of the respondents who left a 
comment about their answers to the scenario questions, 15% took the opportunity 
to reiterate the fact their personal donations would not be affected by changes in 
government policy or funding levels. 
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Nevertheless, there are some respondents whose preferred allocations varied 
substantially from scenario to scenario. Overall, the results suggest that crowding 
out effects outweigh any possible crowding in or signalling effects. Of the 
respondents who amended their allocation splits upon being given new information 
about government spending levels, the majority tended to move in the opposite 
direction to the government – increasing the share for cancer research charities 
when government funding for cancer research is cut, and reducing the share for 
cancer research charities when government funding for cancer research is 
increased.  
On average, when moving from scenario 2 (realistic estimates of government 
spending) to scenario 4 (£100million cut to in government funding for cancer 
research with no increase in government funding for other medical research), 
respondents increased the share of the £100 of income tax allocated to cancer 
research by £4.16. Given that the adult population of the UK is approximately 
50million (Office for National Statistics, 2011b) and assuming that the wider 
population would behave in accordance with the stated preferences elicited in this 
study, then if the government were to cut funding for cancer research by 
£100million and gave each individual £100 of income tax to allocate to cancer 
research and other medical research charities of their choosing, then cancer 
research charities would between them receive £208million from such a policy. In 
other words the general public would rebalance tax spending back to cancer 
research, given the chance, if government were to cut its planned spending on 
cancer research. The direction of intent is clear. However not much can be read 
into the magnitude of the additional allocation to cancer research owing to the 
hypothetical nature of the exercise and the fact that the magnitude is likely to be 
strongly affected by the size of the amount that the individual is given discretion 
over to allocate. 
In addition, since the mean change in personal out-of-pocket donation to cancer 
research charities is greater in scenario 4 than in scenario 2, cancer research 
charities might also expect to receive a small amount of further donations from the 
pockets of individuals who already give money to these types of organisations, 
should the government cut its spending on cancer research. Comparing scenario 4 
with scenario 2, the additional £0.39 per person saying they already donate to 
cancer research charities, who make up 68.3% of our survey respondents 
(274/401), suggests that if replicated across 68.3% of the 50million UK adult 
population this would amount to extra out-of-pocket donations of £13million. This 
would not go far towards offsetting the hypothetical £100million cut in government 
spending on cancer research. 
However, we would urge caution when scaling up in this way: in reality, even the 
better-informed members of the public would be unlikely to have access to 
information about government spending levels as presented in the scenarios. 
Furthermore, means tend to be skewed by extreme values (such as respondents 
who claim that they would give an additional £100 to cancer research charities 
after already having been given the opportunity to allocate £100 of income tax to 
those charities) that may not accurately reflect what would happen if the scenario 
were actually to occur. It is perhaps more telling that the median change in 
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personal out-of-pocket donations to both cancer research and other medical 
research charities was zero in all five scenarios. 
It is not surprising that the respondents were largely uninformed about current 
levels of government spending on medical research. A recent survey of public 
views about science and biomedical research reported that, when asked which 
groups they are aware of that carry out medical research in the UK, only 6% 
mentioned the government, 18% the NHS, and 23% mentioned universities; and 
16% said that they did not know (48% mentioned medical research charities) 
(Clemence et al., 2013).  
Most respondents guessed that government spending on medical research is far 
more concentrated on cancer research than is actually the case. This may explain 
the large shares of the allocations given to cancer research at the expense of other 
medical research (in each of the scenarios, the mean amount given to cancer 
research charities was greater than £50 of the £100 to be allocated). However, the 
fact that cancer research was clearly the main subject of the survey (and the fact 
that respondents were informed that the study was funded by Cancer Research 
UK) is likely to have resulted in a focusing effect whereby respondents placed 
more importance on cancer than they otherwise might have done. In terms of the 
purpose of this study, however, the actual amounts given to cancer research 
charities in any given scenario are less important than the ways in which those 
amounts change from scenario to scenario.  
After having been given the opportunity to allocate £100 of income tax to medical 
research charities of their choosing, very few respondents then said that they 
would take the opportunity to reduce the size of their existing personal out-of-
pocket donations. Most existing donors to medical research charities said that they 
would not change the size of their personal donations. This is particularly the case 
in scenario 1, in which respondents were not given any information about 
government funding levels. This means that their answers regarding personal 
donations under scenario 1 would not have been driven by concerns that the 
government is spending too little (or too much) on medical research. 
However, a drawback of stated preference studies is that they only elicit data on 
what respondents say that they would do/prefer – we do not know whether they 
would behave in the same way if the hypothetical scenarios were to actually 
happen. Survey respondents may exaggerate claims about their positive behaviour 
(i.e. giving to charity) either to appease or impress the researcher, or because 
they have a deluded view of themselves. Future research could combine the stated 
preference design with an experimental lab-based study in order to test whether 
people act on their claims when given real money to allocate. 
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APPENDIX TO CHAPTER 3 
A1.1 Identification of the publication sample 
To map the UK cancer funding landscape it is necessary to take a snapshot of the 
research and funder organisational „ecosystem‟ as a whole. To ensure 
comprehensive coverage a window of one full calendar year was selected based on 
the assumption that research active scientists would author at least one published 
paper per year and that even relatively small funding organisations would have 
been likely to have publications stemming from their work published during a 
given year. The year 2011 was selected so that at the outset of the project (in 
early 2013) the lag between publication of papers in journals and complete 
indexing by publication databases would minimally affect data collection, whilst 
allowing the study to be as up-to-date as possible. The sample aims to capture all 
papers with an electronic publication date for 2011.11   
Delineating a broad topic such as cancer for scientometric analysis from first 
principles, without creating biases in data collection, is often challenging. In 
particular, approaches using ad hoc searches for keywords (e.g. in titles and 
abstracts of papers) or those that rely on author-defined keywords will often yield 
many false positives and false negatives (Leydesdorff et al. 2012). In order to 
benefit from prior expertise in building the sample, the Medical Subject Headings 
(MeSH) controlled vocabulary indexing system was used. MeSH classification is the 
basis of the US National Library of Medicine (NLM) of the National Institutes for 
Health (NIH) PubMed/MEDLINE collection where papers are classified in a 
standardised process by indexers according to the main themes and subject 
matter of the paper.12 The coding system allows each paper to be categorised 
using sets of terms drawn from over 26,000 MeSH descriptors organised in a tree 
like branching structure.13 The descriptors describe the disease and anatomical 
focus, the techniques used and any drugs or other molecules discussed in the 
paper. This coding system is such that very specific terms are located within 
broader topics.  
To capture the study of cancer – itself a broad set of diseases – the highest 
available level in the tree-like MeSH coding system was used: “C04 – Neoplasms”. 
MeSH notes the scope of the term neoplasm as: “New abnormal growth of tissue. 
Malignant neoplasms show a greater degree of anaplasia and have the properties 
of invasion and metastasis, compared to benign neoplasms”. The search therefore 
includes benign and malignant neoplasms. Table A2 (at the end of this section) 
shows a full list of the disease sub-categories captured within C04. 
PubMed/MEDLINE returned 115,101 publications, to which examiners at NLM 
assigned as descriptor “Neoplasms” or relative sub-levels in the tree structure of 
the coding system, globally for year 2011.  
                                           
11 The electronic date provided by PubMed/MEDLINE was used. 
12 For further details see www.nlm.nih.gov/mesh  
13 The tree is organized in 16 branches reported in the followings: “Anatomy”, “Organisms”, “Diseases”, 
“Chemical and Drugs”, “Analytical, Diagnostics and Therapeutic Techniques and Equipment”, 
“Psychiatry and Psychology”, “Phenomena and Processes”, “Disciplines and Occupations”, 
“Anthropology, Education, Sociology and Social Phenomena”, “Technology, Industry and Agriculture”, 
“Humanities”, “Information Science”, “Named Groups”, “Health Care”, “Publication Characteristics”, and 
“Geographicals”. 
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A1.2. Data on authors’ addresses and identification of UK publications 
Although PubMed/MEDLINE provides the MeSH indexing system to retrieve papers, 
it does not provide the full data on affiliations or full addresses of all authors 
involved on a given publication. However this data is required to fulfil the aims of 
this study. We therefore matched the data from PubMed/MEDLINE in the above 
step with data from SCOPUS. The match was performed by using the 
PubMed/MEDLINE publication unique identifier, namely “PMID”, and the publication 
DOI. This match covered 98.1% of the global publication production.14 All the data 
were then arranged into a relational database. We identified UK publications as 
those involving at least one author affiliated to a UK organisation. We specifically 
searched for UK in the “Affiliation” field provided by SCOPUS.15 Records from 
PubMed/MEDLINE that were unmatched with SCOPUS records using PMID (1.9%) 
were manually screened and added to the dataset when a UK organisation was 
found involved in the given publication. The final dataset includes 7,922 UK 
publications. 
A1.3. Data sample and scientific discipline coverage 
The 7,922 UK publications composing our sample were distributed across 1,480 
journal titles. Due to publisher restrictions in electronic access to journal titles we 
were not able to access publications from 130 journals. However, access to full 
text of 7,510 publications was obtained. This provides coverage of 94.8% of the 
initial publication sample. 
Figure A1 depicts a web of 224 scientific disciplines (shown as nodes) as defined 
by ISI Web of Science (WoS) „Subject Categories‟ (SCs).16 The network structure 
reflects the propensity of publications in the journals that make up each subject 
category to cite publications in journals in other subject categories (see Rafols, 
Porter, Leydesdorff 2010). The size of each node is proportional to the number 
publications that are published within each subject category. Leading nodes only 
are labelled. The smallest node size depicts nodes with no publications.  
The broad range of scientific disciplines (135 of 224) demonstrates that the use of 
the C04 search does not exclude research in relevant domains.17 Table 3.1 reports 
                                           
14 The lag in the indexing process of the two databases does not allow for a full match of the records. 
For example, when the matched was performed, SCOPUS did not provide the PMID for some of the 
records listed in PubMed/MEDLINE while the latter did not provide the DOI for of some records for 
which SCOPUS did.   
15 We build a query that searched for: “%United Kingdom%”, “% UK;”, “ U.K.;”, “ U.K.,”, “U.K.”, “% 
UK,”, “% UK.”, “%Scotland%”, “%England%”, “%Wales%”, “%Great Britain%”, “%Northern 
Ireland%”. The “%” represents the wild card/ jolly characters. The query returned a sample of 8,347 
publications. Yet, this sample still included false positives (e.g. articles by authors at the “University of 
New South Wales”). These records were eliminated by manual screening returning a sample of 7,922 
publications. 
16 The map was produced by using VOSviewer Version 1.5.4. 
17 The SCs not covered by the publication sample are reported in the followings: Agricultural Economics 
& Policy; Agricultural Engineering; Agriculture, Dairy & Animal Science; Agriculture, Multidisciplinary; 
Agronomy; Anthropology; Area Studies; Astronomy & Astrophysics; Automation & Control Systems; 
Business; Business, Finance; Computer Science, Cybernetics; Computer Science, Hardware & 
Architecture; Computer Science, Software Engineering; Construction & Building Technology; 
Criminology & Penology; Crystallography; Cultural Studies; Demography; Electrochemistry; Energy & 
Fuels; Engineering, Aerospace; Engineering, Chemical; Engineering, Civil; Engineering, Geological; 
Engineering, Industrial; Engineering, Marine; Engineering, Mechanical; Engineering, Ocean; 
Engineering, Petroleum; Entomology; Environmental Studies; Ergonomics; Fisheries; Forestry; 
Geochemistry & Geophysics; Geography; Geography, Physical Geology; Geosciences, Multidisciplinary; 
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the top-20 SCs in terms of number of publications. These SCs represent ~80% of 
the publication sample. Table 3.1 reveals that 33% of the sampled publications are 
published in specialist oncology journals. The other major categories are closely 
associated with clinical disciplines led by Surgery (2nd), Haematology (3rd), 
Radiology (4th), and Gastroenterology and Hepatology (7th), although basic 
sciences are well represented too such as Cell biology (5th), Biochemistry and 
Molecular Biology (6th) and Genetics and Heredity (11th).     
Using the MeSH categorisation „neoplasms‟ will inevitably miss some of those 
publications that might be deemed by researchers or funders to be associated with 
neoplasms. Coding is a subjective process and opinions may differ on whether a 
paper should be included or excluded. For example, a funder or researcher may 
consider studies of angiogenesis in healthy tissue to be relevant for understanding 
how tumours develop a blood supply, but if these papers are not considered to 
actually study cancerous tissue they may not be understood as within the study of 
neoplasms per se, and they will not be coded using the MeSH term „C04‟. The 
publications recovered by the searches employed in this study are therefore 
referred to as a „sample‟, reflecting the fact that the search is exhaustive within 
the C04 field, but not comprehensive of neoplasms by other definitions. 
Table A1: ISI WoS Subject Categories (SCs) representing ~80% of the 
publication sample. 
 ISI WoS Subject Categories Number of publications 
1) Oncology 2,405 
2) Surgery 669 
3) Hematology 432 
4) Radiology, Nuclear Medicine and Medical Imaging 412 
5) Cell Biology 405 
6) Biochemistry and Molecular Biology 369 
7) Gastroenterology and Hepatology 295 
8) Medicine, General and Internal 287 
9) Public, Environmental and Occupational Health 272 
10) Pathology 247 
11) Genetics and Heredity 242 
12) Obstetrics and Gynecology 227 
13) Clinical Neurology 203 
14) Urology and Nephrology 193 
15) Pharmacology and Pharmacy 169 
16) Health Care Sciences and Services 163 
17) Medicine, Research and Experimental 146 
18) Endocrinology and Metabolism 136 
19) Biology 129 
20) Dermatology 125 
Note. A journal can be assigned to more than one SC. 
                                                                                                                          
History; History Of Social Sciences; Horticulture; Hospitality, Leisure, Sport & Tourism; Industrial 
Relations & Labour; Information Science & Library Science; International Relations; Law; Limnology; 
Management; Marine & Freshwater Biology; Materials Science, Ceramics; Materials Science, 
Characterization & Testing; Materials Science, Coatings & Films; Materials Science, Composites; 
Materials Science, Paper & Wood; Materials Science, Textiles; Mathematics; Mathematics, Applied; 
Mechanics; Metallurgy & Metallurgical Engineering; Meteorology & Atmospheric Sciences; Mineralogy; 
Mining & Mineral Processing; Oceanography; Operations Research & Management Science; Ornithology; 
Palaeontology; Physics, Fluids & Plasmas; Physics, Mathematical; Physics, Multidisciplinary; Physics, 
Nuclear; Physics, Particles & Fields; Planning & Development; Plant Sciences; Political Science; 
Psychology, Applied; Psychology, Educational; Psychology, Mathematical; Psychology, Psychoanalysis; 
Public Administration; Remote Sensing; Robotics; Social Sciences, Mathematical Methods; Soil Science; 
Spectroscopy; Telecommunications; Thermodynamics; Transportation; Transportation Science & 
Technology; Urban Studies; Water Resources; Women. 
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Figure A1: Distribution of the publication sample over the ISI WoS SC – size of each node equal to log2 of the number of 
publications in each SC; the map is based on 7,260 out 7,510 publications for which a SC can be identified. 
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A1.4 Extraction of information on acknowledgements  
The study relies on searches undertaken using automated software routines to read from 
the html code of publishers‟ web pages and where necessary to selectively download 
PDFs of the publications. The routines were designed to extract information under the 
following headings: (i) “Acknowledgements”, (ii) “Funding”, (iii) “Conflicts of Interest”, 
(iv) “Financial Disclosure”, (v) “Role of Funding Sources”, (vi) “Financial Supports”, (vii) 
“Competing Financial Interests”, and (ix) “Statement of interests”. We refer to all of the 
above wordings as „acknowledgements‟ henceforth. The automated searches allowed the 
collection of acknowledgements from the majority of publications with manual checks of 
remaining papers. At completion the acknowledgements sections from ~83% of the 
publications in the sample were found, while the remaining ~17% of papers had no 
acknowledgement sections (see Figure A2). 
A1.5 Identification of funders from acknowledgements in publications  
Acknowledgements were manually read by the research team to establish whether they 
mentioned the support of funders. A detailed protocol established guidelines for 
interpretation and coding of funding data, which was undertaken manually by a team of 
coders. 
All sources of funding were recorded where authors indicated financial support for work 
leading to a publication. Other forms of support (colleagues reading drafts, helpful 
comments) were not coded. Declarations of conflicts of interest stemming from historic 
support, unrelated to the current publication, were excluded where possible. 
These searches revealed 3,914 publications (52.1%) that disclosed at least one funder in 
an acknowledgements section, and 2,286 (30.4%) that did not acknowledge funding 
support but did make other forms of acknowledgement. A further 1,310 (17.4%) of 
publications had no acknowledgement sections (see Figure A2). 
A1.6 Why do so many publications not acknowledge research funding? 
Around 48% of the 7510 publications in the sample do not directly disclose a source of 
funding. Prior studies of funding acknowledgements in UK biomedical research have 
found 39% of papers have no acknowledgement to a funder (Lewison et al. 1995), so 
this figure is high, but it is not unexpected for a large proportion of papers not to have 
acknowledgements to funders. There are several possible explanations for this: 
a) The publications required little or no financial support to produce. 
b) The publication required research funding but these details were omitted from the 
publication either by the author(s) or the publisher.  
c) The publications were supported by the author(s) employer, who is acknowledged 
indirectly through the author(s) affiliation. 
Reseach by Lewison et al. (1995) would lead us to expect that in the majority of 
casesreason (c) would be the most common explanation. 
Figure A2 shows of the sample of 7,510 publications divided according to their disclosure 
or funders as well as by publication type. Publication type is an important distinction to 
make since some publications rely on more laboratory work or other research-intensive 
activity than others. SCOPUS makes the distinction between “Articles” and what are 
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often less cost intensive publications to produce, such as “Reviews”, “Letters”, 
“Editorials” and “Notes”.  
The categorisation of publications by SCOPUS definition provides some evidence 
supporting explanation (a) as a higher proportion of publications with acknowledgements 
but no named funders are less cost intensive (37%) than is the case for those with 
acknowledgements (17%).   
The NLM‟s MeSH descriptors for publication types allow further more detailed 
classification within the category of publications that SCOPUS defines as „articles‟. Again 
we searched for those publications that were perceived to be less cost intensive - such 
papers defined by MeSH descriptors as “Comments”, “Case Reports”, “Reviews”, 
“Comparative Study”, “Editorials”, “Consensus Development Conferences”, “Practical 
Guidelines”, “English Abstract”, and “Introductory Journal Articles”. As with the SCOPUS 
typology above, the proportion of less cost intensive publications differs significantly 
between the subsamples of publications where acknowledgements contain funders and 
those that do not contain funders, with 27% of SCOPUS defined “Articles” with funding 
acknowledgements being classified as less cost intensive by MeSH descriptors while 67% 
of SCOPUS defined “Articles” without acknowledgement sections were of the less cost 
intensive types. This provides further evidence to support the high relevance of 
explanation (a). 
To establish whether publications were omitting acknowledgements to funding sources 
due to explanations (b) and (c), it was necessary to directly investigate a sample of 
publications in more detail. 
2,286/7,510 or 30.44% of the sample‟s publications have acknowledgements but no 
stated funders. Of these, 69% explicitly state they did not benefit from financial support. 
Of the remaining 31%, 89 were selected at random for investigation (over 10%). Of 
these, 14/89 (~16%) were deemed to be case reports and therefore it was assumed no 
funding (beyond the author‟s employer) was necessary to fund the publication. No 
further investigation was carried out for these publications. The remaining 75 were 
queried by e-mail to the corresponding author, and 28 responses obtained (37% 
response rate). Only 4/28 (14% of respondents) revealed contribution by funders other 
than authors‟ employers in publications. However 14/28 respondents suggested the 
research had been supported by their employer. We therefore cautiously conclude that 
explanation (c) is more frequently accurate than explanation (b).  
Further enquires were needed for the distinct subset of publications in formats where 
some publishers do not permit author acknowledgements or in cases where authors may 
omit an acknowledgement section. 1,310/7,510 or 17.44% of the sample‟s publications 
contained no acknowledgement sections. Of these, 208 (~16%) were selected at 
random for investigation. 79/208 (38%) were classified as case reports and therefore it 
was assumed no funding (beyond the author‟s employer) was necessary to fund the 
publication. The remaining 129 were queried via email to the corresponding author, and 
49 replies obtained (38% response rate). In 9/49 responses (18%), a funding 
contribution to the publication other than the authors‟ employers was revealed, although 
it is notable that 30/40 revealed a contribution by their employer. Again this suggests 
that explanation (b) is less frequently accurate while explanation (c) is more commonly 
accurate. This is consistent with the findings of Lewison et al. (1995).  
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A1.7 Assumptions on funding disclosures and analytical implications 
A high-level quantitative analysis such as that described here will necessarily make 
strong assumptions about the consistency of the data.   
From the above investigations it is concluded that in the vast majority of cases UK-based 
authors are disclosing external funders appropriately and therefore that the majority of 
publications resulting from cost intensive research acknowledge external funding.   
Publications that do not contain acknowledgements are likely to be the result of less 
costly research and/or paid for by the author(s) host institution or employer. It is also 
important to note (as discussed above) that when prompted by email, authors frequently 
acknowledge the financial contribution of their employer, but it is clearly not an 
established practice to acknowledge the host organisation in an acknowledgement 
section. One interviewee gave some insight into this norm: “I think in general the 
acknowledgements, as I‟m sure you know... if your employer mostly fund[s] your work it 
seems a bit strange to thank them for giving you a job, which in a sense is true but it 
sounds a bit odd.” 
Where a paper contains no funding acknowledgements, it is therefore appropriate to 
assume that the authors‟ employer or host organisation is funding the work. Indeed even 
where there is an external funder acknowledged, the employer (or otherwise host) 
institution should be thought of, if not acknowledged, as a funder because, as explained 
in Chapter 2, the costs of research are borne by external funders and host organisations 
albeit to different extents. For example UK research councils reimburse research grant 
holders 80% of the full economic cost of research they undertake, while charities 
reimburse typically around 60%, with HEI support in England topping this up to 80% 
FEC (UKCRC 2012 p.20). 
One major exception is that contributions by HEFCE, which distributes funding to 
researchers via their universities on the basis of quality performance of researchers in 
each institution as measured by exercises such as the Research Excellence Framework. 
Outputs stemming from HEFCE funding are not recorded because researchers rarely 
acknowledge this source of funding (even though 40 universities receive HEFCE funding 
for biological sciences alone). 18 
Taking the above limitations into account it is theoretically possible to undertake three 
analytical perspectives for the analysis of outputs from research funding support: 
1) Publications supported fully or partially by one or more external funders 
2) Publications fully or partially supported by one or more host organisations 
3) Publications supported by a combination of host organisations and external 
funders 
However, given that in some substantial cases external funders also fund host 
organisations, the third perspective is likely to produce results that are less robust and 
transparent than (1) and (2) individually. An exception is the case where industrial 
funding is concerned, due to higher transparency in the UK over recent years in the 
disclosure of industry support for research. The analysis presented in this study has for 
                                           
18 http://www.hefce.ac.uk/whatwedo/rsrch/howfundr/mainstreamqr/  
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the most part therefore will focused on either the contributions of host organisations, or 
the contributions of external funders.  
A1.8 Standardisation of funders names, author affiliations and aggregation of 
related organisations 
Where funders are acknowledged, this may often be directly by name of organisation (in 
full or abbreviated form), section, funding scheme or even by grant number alone. To 
address the three above-discussed analytical perspectives, it was necessary to 
harmonise all funder names.19 All funders were also geographically coded.   
The same process was followed for the authors‟ affiliations (research host organisations). 
All authors routinely report at least one affiliation and related address details in each 
publication. This information allows publications to be organisationally and 
geographically classified. However, to count data consistently it is necessary to 
harmonise organisations‟ names and relative addresses. This is often challenging given 
that address details may describe teams/groups, departments, sites, organisations and 
clusters of organisations. Some detail levels may also be missing. For example, a 
researcher at the “Royal Free Hospital in London” may describe their affiliation as such 
or use the higher level affiliation, “University College London Hospitals NHS Trust”. 
Furthermore individuals may not be consistent and individuals within the same 
organisation will often observe different practices. It is therefore appropriate to use 
higher level affiliation details for consistency, even though this results in the loss of 
some granularity of the data. 
Manual identification of organisational linkages and aggregation to the highest level of 
organisational group was undertaken using Google-based web searches as well as the 
Cancer Research UK list of organisational groups for clusters of UK research institutions. 
 
Table A2: MeSH Descriptors 2013 (source: PubMED/MEDLINE) 
Note: Each band denotes a distinct 3rd level heading. Codes within a band are 
subsections of the first code in the band 
MeSH Heading Tree Number 
Neoplasms C04 
Cysts C04.182 
Arachnoid Cysts C04.182.044 
Bone Cysts C04.182.089 
Bone Cysts, Aneurysmal C04.182.089.265 
Jaw Cysts C04.182.089.530 
Nonodontogenic Cysts C04.182.089.530.660 
Odontogenic Cysts C04.182.089.530.690 
Basal Cell Nevus Syndrome C04.182.089.530.690.150 
Dentigerous Cyst C04.182.089.530.690.310 
Odontogenic Cyst, Calcifying C04.182.089.530.690.605 
Periodontal Cyst C04.182.089.530.690.790 
Radicular Cyst C04.182.089.530.690.790.820 
Branchioma C04.182.117 
Breast Cyst C04.182.156 
Bronchogenic Cyst C04.182.195 
Chalazion C04.182.197 
Choledochal Cyst C04.182.198 
Colloid Cysts C04.182.199 
Dermoid Cyst C04.182.201 
Epidermal Cyst C04.182.254 
Esophageal Cyst C04.182.281 
Follicular Cyst C04.182.300 
                                           
19 The harmonisation process was manually conducted with the support of “The Vantage Point” software. 
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Ganglion Cysts C04.182.347 
Lymphocele C04.182.430 
Mediastinal Cyst C04.182.444 
Mesenteric Cyst C04.182.473 
Mucocele C04.182.511 
Ovarian Cysts C04.182.612 
Polycystic Ovary Syndrome C04.182.612.765 
Pancreatic Cyst C04.182.640 
Pancreatic Pseudocyst C04.182.640.692 
Parovarian Cyst C04.182.668 
Pilonidal Sinus C04.182.710 
Ranula C04.182.766 
Synovial Cyst C04.182.867 
Popliteal Cyst C04.182.867.500 
Tarlov Cysts C04.182.872 
Thyroglossal Cyst C04.182.902 
Urachal Cyst C04.182.946 
Hamartoma C04.445 
Hamartoma Syndrome, Multiple C04.445.435 
Proteus Syndrome C04.445.435.500 
Pallister-Hall Syndrome C04.445.622 
Tuberous Sclerosis C04.445.810 
Neoplasms by Histologic Type C04.557 
Histiocytic Disorders, Malignant C04.557.227 
Dendritic Cell Sarcoma, Follicular C04.557.227.190 
Dendritic Cell Sarcoma, Interdigitating C04.557.227.199 
Histiocytic Sarcoma C04.557.227.380 
Langerhans Cell Sarcoma C04.557.227.500 
Leukemia C04.557.337 
Enzootic Bovine Leukosis C04.557.337.100 
Leukemia, Experimental C04.557.337.372 
Avian Leukosis C04.557.337.372.216 
Leukemia L1210 C04.557.337.372.594 
Leukemia L5178 C04.557.337.372.602 
Leukemia P388 C04.557.337.372.782 
Leukemia, Feline C04.557.337.385 
Leukemia, Hairy Cell C04.557.337.415 
Leukemia, Lymphoid C04.557.337.428 
Leukemia, B-Cell C04.557.337.428.080 
Leukemia, Lymphocytic, Chronic, B-Cell C04.557.337.428.080.125 
Leukemia, Prolymphocytic, B-Cell C04.557.337.428.080.562 
Leukemia, Biphenotypic, Acute C04.557.337.428.100 
Leukemia, Prolymphocytic C04.557.337.428.565 
Leukemia, Prolymphocytic, B-Cell C04.557.337.428.565.745 
Leukemia, Prolymphocytic, T-Cell C04.557.337.428.565.750 
Leukemia, T-Cell C04.557.337.428.580 
Leukemia, Large Granular Lymphocytic C04.557.337.428.580.049 
Leukemia-Lymphoma, Adult T-Cell C04.557.337.428.580.100 
Leukemia, Prolymphocytic, T-Cell C04.557.337.428.580.125 
Precursor Cell Lymphoblastic Leukemia-Lymphoma C04.557.337.428.600 
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma C04.557.337.428.600.600 
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma C04.557.337.428.600.620 
Leukemia, Mast-Cell C04.557.337.440 
Leukemia, Myeloid C04.557.337.539 
Leukemia, Myelogenous, Chronic, BCR-ABL Positive C04.557.337.539.250 
Blast Crisis C04.557.337.539.250.100 
Leukemia, Myeloid, Accelerated Phase C04.557.337.539.250.300 
Leukemia, Myeloid, Chronic-Phase C04.557.337.539.250.400 
Leukemia, Myeloid, Acute C04.557.337.539.275 
Leukemia, Basophilic, Acute C04.557.337.539.275.125 
Leukemia, Eosinophilic, Acute C04.557.337.539.275.300 
Leukemia, Erythroblastic, Acute C04.557.337.539.275.325 
Leukemia, Mast-Cell C04.557.337.539.275.440 
Leukemia, Megakaryoblastic, Acute C04.557.337.539.275.450 
Leukemia, Monocytic, Acute C04.557.337.539.275.484 
Leukemia, Promyelocytic, Acute C04.557.337.539.275.700 
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative C04.557.337.539.300 
Leukemia, Myelomonocytic, Acute C04.557.337.539.520 
Leukemia, Myelomonocytic, Chronic C04.557.337.539.522 
Leukemia, Myelomonocytic, Juvenile C04.557.337.539.525 
Sarcoma, Myeloid C04.557.337.539.775 
Leukemia, Plasma Cell C04.557.337.595 
Leukemia, Radiation-Induced C04.557.337.650 
Lymphatic Vessel Tumors C04.557.375 
Lymphangioma C04.557.375.450 





Composite Lymphoma C04.557.386.150 
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Hodgkin Disease C04.557.386.355 
Immunoproliferative Small Intestinal Disease C04.557.386.390 
Lymphoma, Non-Hodgkin C04.557.386.480 
Burkitt Lymphoma C04.557.386.480.100 
Lymphoma, B-Cell C04.557.386.480.150 
Burkitt Lymphoma C04.557.386.480.150.165 
Lymphoma, AIDS-Related C04.557.386.480.150.450 
Lymphoma, B-Cell, Marginal Zone C04.557.386.480.150.570 
Lymphoma, Large B-Cell, Diffuse C04.557.386.480.150.585 
Lymphoma, Primary Effusion C04.557.386.480.150.592 
Lymphomatoid Granulomatosis C04.557.386.480.150.600 
Lymphoma, Follicular C04.557.386.480.350 
Lymphoma, Large-Cell, Anaplastic C04.557.386.480.487 
Lymphoma, Large-Cell, Immunoblastic C04.557.386.480.493 
Lymphoma, Mantle-Cell C04.557.386.480.525 
Lymphoma, T-Cell C04.557.386.480.750 
Enteropathy-Associated T-Cell Lymphoma C04.557.386.480.750.099 
Lymphoma, Extranodal NK-T-Cell C04.557.386.480.750.199 
Lymphoma, Large-Cell, Anaplastic C04.557.386.480.750.399 
Lymphoma, T-Cell, Cutaneous C04.557.386.480.750.800 
Lymphoma, Primary Cutaneous Anaplastic Large Cell C04.557.386.480.750.800.507 
Lymphomatoid Papulosis C04.557.386.480.750.800.528 
Mycosis Fungoides C04.557.386.480.750.800.550 
Pagetoid Reticulosis C04.557.386.480.750.800.550.600 
Sezary Syndrome C04.557.386.480.750.800.775 
Lymphoma, T-Cell, Peripheral C04.557.386.480.750.825 
Neoplasms, Complex and Mixed C04.557.435 
Adenolymphoma C04.557.435.075 




Carcinoma, Adenosquamous C04.557.435.250 
Carcinosarcoma C04.557.435.290 
Carcinoma 256, Walker C04.557.435.290.210 
Composite Lymphoma C04.557.435.295 
Hepatoblastoma C04.557.435.380 
Mesenchymoma C04.557.435.500 
Mixed Tumor, Malignant C04.557.435.525 
Mixed Tumor, Mesodermal C04.557.435.530 
Mixed Tumor, Mullerian C04.557.435.540 
Myoepithelioma C04.557.435.585 
Wilms Tumor C04.557.435.595 
Denys-Drash Syndrome C04.557.435.595.220 
WAGR Syndrome C04.557.435.595.950 
Nephroma, Mesoblastic C04.557.435.600 
Pulmonary Blastoma C04.557.435.675 
Rhabdoid Tumor C04.557.435.710 
Sarcoma, Endometrial Stromal C04.557.435.775 
Thymoma C04.557.435.850 
Neoplasms, Connective and Soft Tissue C04.557.450 






Liposarcoma, Myxoid C04.557.450.550.420.425 
Myelolipoma C04.557.450.550.710 





Chondrosarcoma, Mesenchymal C04.557.450.565.280.280 
Endometrial Stromal Tumors C04.557.450.565.325 
Gastrointestinal Stromal Tumors C04.557.450.565.370 
Giant Cell Tumors C04.557.450.565.380 
Giant Cell Tumor of Bone C04.557.450.565.380.380 
Mastocytosis C04.557.450.565.465 
Mast-Cell Sarcoma C04.557.450.565.465.124 
Mastocytoma C04.557.450.565.465.249 
Mastocytoma, Skin C04.557.450.565.465.249.500 
Mastocytosis, Cutaneous C04.557.450.565.465.500 
Mastocytoma, Skin C04.557.450.565.465.500.500 
Urticaria Pigmentosa C04.557.450.565.465.500.850 
Mastocytosis, Systemic C04.557.450.565.465.750 
Leukemia, Mast-Cell C04.557.450.565.465.750.500 
Myofibroma C04.557.450.565.540 
Myxoma C04.557.450.565.550 
Carney Complex C04.557.450.565.550.312 
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Neurothekeoma C04.557.450.565.550.625 
Myxosarcoma C04.557.450.565.560 
Neoplasms, Bone Tissue C04.557.450.565.575 
Fibroma, Ossifying C04.557.450.565.575.400 




Exostoses, Multiple Hereditary C04.557.450.565.575.610.615.325 
Osteoma C04.557.450.565.575.625 
Osteoma, Osteoid C04.557.450.565.575.625.625 
Osteosarcoma C04.557.450.565.575.650 
Osteosarcoma, Juxtacortical C04.557.450.565.575.650.655 
Sarcoma, Ewing C04.557.450.565.575.650.800 
Neoplasms, Fibrous Tissue C04.557.450.565.590 
Fibroma C04.557.450.565.590.340 
Fibroma, Desmoplastic C04.557.450.565.590.340.345 
Fibroma, Ossifying C04.557.450.565.590.340.360 
Fibromatosis, Abdominal C04.557.450.565.590.340.400 





Histiocytoma, Benign Fibrous C04.557.450.565.590.425.350 
Histiocytoma, Malignant Fibrous C04.557.450.565.590.425.360 
Myofibromatosis C04.557.450.565.590.550 
Neoplasms, Fibroepithelial C04.557.450.565.590.595 
Adenofibroma C04.557.450.565.590.595.050 
Cystadenofibroma C04.557.450.565.590.595.050.500 
Brenner Tumor C04.557.450.565.590.595.150 
Fibroadenoma C04.557.450.565.590.595.350 
Solitary Fibrous Tumors C04.557.450.565.590.797 
Solitary Fibrous Tumor, Pleural C04.557.450.565.590.797.750 
Sarcoma, Clear Cell C04.557.450.565.800 
Sarcoma, Small Cell C04.557.450.565.825 
Sarcoma, Synovial C04.557.450.565.835 
Neoplasms, Muscle Tissue C04.557.450.590 
Granular Cell Tumor C04.557.450.590.350 
Leiomyoma C04.557.450.590.450 
Angiomyoma C04.557.450.590.450.125 







Rhabdomyosarcoma, Alveolar C04.557.450.590.550.660.665 
Rhabdomyosarcoma, Embryonal C04.557.450.590.550.660.675 
Sarcoma, Alveolar Soft Part C04.557.450.590.775 
Smooth Muscle Tumor C04.557.450.590.800 






Carcinoma 256, Walker C04.557.450.795.290.210 
Chondrosarcoma C04.557.450.795.300 
Chondrosarcoma, Mesenchymal C04.557.450.795.300.280 
Desmoplastic Small Round Cell Tumor C04.557.450.795.315 
Endometrial Stromal Tumors C04.557.450.795.332 





Histiocytoma, Malignant Fibrous C04.557.450.795.400 
Leiomyosarcoma C04.557.450.795.455 
Liposarcoma C04.557.450.795.465 
Liposarcoma, Myxoid C04.557.450.795.465.425 
Lymphangiosarcoma C04.557.450.795.480 
Mixed Tumor, Mesodermal C04.557.450.795.530 
Myosarcoma C04.557.450.795.550 
Rhabdomyosarcoma C04.557.450.795.550.660 
Rhabdomyosarcoma, Alveolar C04.557.450.795.550.660.665 
Rhabdomyosarcoma, Embryonal C04.557.450.795.550.660.675 
Myxosarcoma C04.557.450.795.560 
Osteosarcoma C04.557.450.795.620 
Osteosarcoma, Juxtacortical C04.557.450.795.620.655 
OHE and SPRU Report for Cancer Research UK 
March 2014 
 
 131  
Sarcoma, Ewing C04.557.450.795.620.800 
Phyllodes Tumor C04.557.450.795.650 
Sarcoma, Alveolar Soft Part C04.557.450.795.775 
Sarcoma, Clear Cell C04.557.450.795.800 
Sarcoma, Experimental C04.557.450.795.830 
Sarcoma 37 C04.557.450.795.830.760 
Sarcoma 180 C04.557.450.795.830.780 
Sarcoma, Avian C04.557.450.795.830.800 
Sarcoma, Yoshida C04.557.450.795.830.850 
Sarcoma, Kaposi C04.557.450.795.850 
Sarcoma, Myeloid C04.557.450.795.853 
Sarcoma, Small Cell C04.557.450.795.870 
Sarcoma, Synovial C04.557.450.795.875 
Neoplasms, Germ Cell and Embryonal C04.557.465 







Endodermal Sinus Tumor C04.557.465.510.350 
Neuroectodermal Tumors C04.557.465.625 
Craniopharyngioma C04.557.465.625.200 





Optic Nerve Glioma C04.557.465.625.600.380.080.667 
Ependymoma C04.557.465.625.600.380.290 





Optic Nerve Glioma C04.557.465.625.600.380.795 
Neurocytoma C04.557.465.625.600.580 
Neuroectodermal Tumors, Primitive C04.557.465.625.600.590 
Medulloblastoma C04.557.465.625.600.590.500 
Neuroectodermal Tumors, Primitive, Peripheral C04.557.465.625.600.590.650 
Neuroblastoma C04.557.465.625.600.590.650.550 




Neuroectodermal Tumor, Melanotic C04.557.465.625.630 
Neuroendocrine Tumors C04.557.465.625.650 
Adenoma, Acidophil C04.557.465.625.650.025 
Adenoma, Basophil C04.557.465.625.650.075 
Adenoma, Chromophobe C04.557.465.625.650.095 
Apudoma C04.557.465.625.650.135 
Carcinoid Tumor C04.557.465.625.650.200 
Malignant Carcinoid Syndrome C04.557.465.625.650.200.500 
Carcinoid Heart Disease C04.557.465.625.650.200.500.205 
Carcinoma, Neuroendocrine C04.557.465.625.650.240 
Carcinoma, Medullary C04.557.465.625.650.240.315 




Hutchinson's Melanotic Freckle C04.557.465.625.650.510.385 
Melanoma, Amelanotic C04.557.465.625.650.510.515 
Melanoma, Experimental C04.557.465.625.650.510.525 
Neurilemmoma C04.557.465.625.650.595 
Neuroma, Acoustic C04.557.465.625.650.595.610 
Neurofibromatosis 2 C04.557.465.625.650.595.610.500 
Paraganglioma C04.557.465.625.650.700 
Paraganglioma, Extra-Adrenal C04.557.465.625.650.700.705 
Carotid Body Tumor C04.557.465.625.650.700.705.220 
Glomus Jugulare Tumor C04.557.465.625.650.700.705.340 




Dermoid Cyst C04.557.465.910.250 
Struma Ovarii C04.557.465.910.850 
Trophoblastic Neoplasms C04.557.465.955 
Choriocarcinoma C04.557.465.955.207 
Choriocarcinoma, Non-gestational C04.557.465.955.207.750 
Trophoblastic Tumor, Placental Site C04.557.465.955.207.875 
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Gestational Trophoblastic Disease C04.557.465.955.416 
Choriocarcinoma C04.557.465.955.416.202 
Trophoblastic Tumor, Placental Site C04.557.465.955.416.202.875 
Hydatidiform Mole C04.557.465.955.416.812 
Hydatidiform Mole, Invasive C04.557.465.955.416.812.500 
Neoplasms, Glandular and Epithelial C04.557.470 
Adenoma C04.557.470.035 
ACTH-Secreting Pituitary Adenoma C04.557.470.035.012 
Adenoma, Acidophil C04.557.470.035.025 
Adenoma, Basophil C04.557.470.035.075 
Adenoma, Bile Duct C04.557.470.035.085 
Adenoma, Chromophobe C04.557.470.035.095 
Adenoma, Islet Cell C04.557.470.035.100 
Insulinoma C04.557.470.035.100.852 
Adenoma, Liver Cell C04.557.470.035.120 
Adenoma, Oxyphilic C04.557.470.035.140 
Adenoma, Pleomorphic C04.557.470.035.155 





Adenoma, Villous C04.557.470.035.185 
Adenomatoid Tumor C04.557.470.035.200 
Adenomatosis, Pulmonary C04.557.470.035.210 
Adenomatous Polyps C04.557.470.035.215 
Adenomatous Polyposis Coli C04.557.470.035.215.100 
Gardner Syndrome C04.557.470.035.215.100.500 
Adrenal Rest Tumor C04.557.470.035.232 
Apudoma C04.557.470.035.250 
Cystadenoma C04.557.470.035.320 
Cystadenoma, Mucinous C04.557.470.035.320.225 
Cystadenoma, Papillary C04.557.470.035.320.230 
Cystadenoma, Serous C04.557.470.035.320.240 
Growth Hormone-Secreting Pituitary Adenoma C04.557.470.035.415 
Mesothelioma C04.557.470.035.510 




Adenocarcinoma, Bronchiolo-Alveolar C04.557.470.200.025.030 
Adenocarcinoma, Clear Cell C04.557.470.200.025.045 
Adenocarcinoma, Follicular C04.557.470.200.025.060 
Carcinoma, Papillary, Follicular C04.557.470.200.025.060.225 
Adenocarcinoma, Mucinous C04.557.470.200.025.075 
Adenocarcinoma, Papillary C04.557.470.200.025.085 
Carcinoma, Papillary, Follicular C04.557.470.200.025.085.225 
Adenocarcinoma, Scirrhous C04.557.470.200.025.095 
Linitis Plastica C04.557.470.200.025.095.410 
Adenocarcinoma, Sebaceous C04.557.470.200.025.105 
Adrenocortical Carcinoma C04.557.470.200.025.152 
Carcinoid Tumor C04.557.470.200.025.200 
Malignant Carcinoid Syndrome C04.557.470.200.025.200.500 
Carcinoid Heart Disease C04.557.470.200.025.200.500.205 
Carcinoma, Acinar Cell C04.557.470.200.025.215 
Carcinoma, Adenoid Cystic C04.557.470.200.025.220 
Carcinoma, Ductal C04.557.470.200.025.232 
Carcinoma, Ductal, Breast C04.557.470.200.025.232.500 
Carcinoma, Pancreatic Ductal C04.557.470.200.025.232.750 
Carcinoma, Endometrioid C04.557.470.200.025.240 
Carcinoma, Hepatocellular C04.557.470.200.025.255 
Carcinoma, Intraductal, Noninfiltrating C04.557.470.200.025.275 
Paget's Disease, Mammary C04.557.470.200.025.275.625 
Carcinoma, Islet Cell C04.557.470.200.025.290 
Gastrinoma C04.557.470.200.025.290.500 
Glucagonoma C04.557.470.200.025.290.750 
Carcinoma, Lobular C04.557.470.200.025.305 
Carcinoma, Mucoepidermoid C04.557.470.200.025.340 
Carcinoma, Neuroendocrine C04.557.470.200.025.370 
Carcinoma, Medullary C04.557.470.200.025.370.315 
Carcinoma, Merkel Cell C04.557.470.200.025.370.325 
Somatostatinoma C04.557.470.200.025.370.695 
Vipoma C04.557.470.200.025.370.847 
Carcinoma, Renal Cell C04.557.470.200.025.390 
Carcinoma, Signet Ring Cell C04.557.470.200.025.415 
Krukenberg Tumor C04.557.470.200.025.415.410 
Carcinoma, Skin Appendage C04.557.470.200.025.420 
Cholangiocarcinoma C04.557.470.200.025.450 
Choriocarcinoma C04.557.470.200.025.455 
Choriocarcinoma, Non-gestational C04.557.470.200.025.455.750 
Trophoblastic Tumor, Placental Site C04.557.470.200.025.455.875 
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Cystadenocarcinoma C04.557.470.200.025.480 
Cystadenocarcinoma, Mucinous C04.557.470.200.025.480.225 
Cystadenocarcinoma, Papillary C04.557.470.200.025.480.230 
Cystadenocarcinoma, Serous C04.557.470.200.025.480.240 
Eccrine Porocarcinoma C04.557.470.200.025.500 
Klatskin's Tumor C04.557.470.200.025.540 
Paget Disease, Extramammary C04.557.470.200.025.660 
Pulmonary Adenomatosis, Ovine C04.557.470.200.025.715 
Carcinoma, Adenosquamous C04.557.470.200.150 
Carcinoma, Basal Cell C04.557.470.200.165 
Basal Cell Nevus Syndrome C04.557.470.200.165.150 
Carcinoma, Basosquamous C04.557.470.200.170 
Carcinoma, Ehrlich Tumor C04.557.470.200.200 
Carcinoma, Giant Cell C04.557.470.200.220 
Carcinoma in Situ C04.557.470.200.240 
Cervical Intraepithelial Neoplasia C04.557.470.200.240.250 
Prostatic Intraepithelial Neoplasia C04.557.470.200.240.500 
Carcinoma, Krebs 2 C04.557.470.200.255 
Carcinoma, Large Cell C04.557.470.200.260 
Carcinoma, Lewis Lung C04.557.470.200.280 
Carcinoma, Papillary C04.557.470.200.360 
Carcinoma, Small Cell C04.557.470.200.380 
Carcinoma, Squamous Cell C04.557.470.200.400 
Bowen's Disease C04.557.470.200.400.130 
Carcinoma, Transitional Cell C04.557.470.200.430 
Carcinoma, Verrucous C04.557.470.200.450 
Buschke-Lowenstein Tumor C04.557.470.200.450.500 
Neoplasms, Adnexal and Skin Appendage C04.557.470.550 
Adenocarcinoma, Sebaceous C04.557.470.550.105 





Carcinoma, Skin Appendage C04.557.470.550.420 
Neoplasms, Basal Cell C04.557.470.565 
Carcinoma, Basal Cell C04.557.470.565.165 
Basal Cell Nevus Syndrome C04.557.470.565.165.150 
Carcinoma, Basosquamous C04.557.470.565.170 
Pilomatrixoma C04.557.470.565.625 
Neoplasms, Cystic, Mucinous, and Serous C04.557.470.590 
Adenocarcinoma, Mucinous C04.557.470.590.075 
Carcinoma, Mucoepidermoid C04.557.470.590.340 
Carcinoma, Signet Ring Cell C04.557.470.590.415 
Krukenberg Tumor C04.557.470.590.415.410 
Cystadenocarcinoma C04.557.470.590.480 
Cystadenocarcinoma, Mucinous C04.557.470.590.480.225 
Cystadenocarcinoma, Papillary C04.557.470.590.480.230 
Cystadenocarcinoma, Serous C04.557.470.590.480.240 
Cystadenofibroma C04.557.470.590.482 
Cystadenoma C04.557.470.590.485 
Cystadenoma, Mucinous C04.557.470.590.485.225 
Cystadenoma, Papillary C04.557.470.590.485.230 
Cystadenoma, Serous C04.557.470.590.485.240 
Mucoepidermoid Tumor C04.557.470.590.580 
Pseudomyxoma Peritonei C04.557.470.590.782 
Neoplasms, Ductal, Lobular, and Medullary C04.557.470.615 
Carcinoma, Ductal C04.557.470.615.132 
Carcinoma, Ductal, Breast C04.557.470.615.132.500 
Carcinoma, Pancreatic Ductal C04.557.470.615.132.750 
Carcinoma, Intraductal, Noninfiltrating C04.557.470.615.275 
Paget's Disease, Mammary C04.557.470.615.275.625 
Carcinoma, Lobular C04.557.470.615.305 
Carcinoma, Medullary C04.557.470.615.315 
Paget Disease, Extramammary C04.557.470.615.660 
Papilloma, Intraductal C04.557.470.615.670 
Neoplasms, Fibroepithelial C04.557.470.625 
Adenofibroma C04.557.470.625.050 
Cystadenofibroma C04.557.470.625.050.500 
Brenner Tumor C04.557.470.625.150 
Fibroadenoma C04.557.470.625.350 
Neoplasms, Mesothelial C04.557.470.660 
Adenomatoid Tumor C04.557.470.660.200 
Mesothelioma C04.557.470.660.510 
Mesothelioma, Cystic C04.557.470.660.510.515 





Optic Nerve Glioma C04.557.470.670.380.080.667 
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Ependymoma C04.557.470.670.380.290 





Optic Nerve Glioma C04.557.470.670.380.795 
Neurocytoma C04.557.470.670.580 
Neuroectodermal Tumors, Primitive C04.557.470.670.590 
Medulloblastoma C04.557.470.670.590.500 
Neuroectodermal Tumors, Primitive, Peripheral C04.557.470.670.590.650 
Neuroblastoma C04.557.470.670.590.650.550 




Neoplasms, Squamous Cell C04.557.470.700 
Acanthoma C04.557.470.700.040 
Carcinoma, Papillary C04.557.470.700.360 
Carcinoma, Squamous Cell C04.557.470.700.400 
Bowen's Disease C04.557.470.700.400.130 
Carcinoma, Verrucous C04.557.470.700.450 
Buschke-Lowenstein Tumor C04.557.470.700.450.500 
Papilloma C04.557.470.700.600 
Papilloma, Inverted C04.557.470.700.600.610 
Neoplasms, Gonadal Tissue C04.557.475 
Gonadoblastoma C04.557.475.395 
Sex Cord-Gonadal Stromal Tumors C04.557.475.750 
Granulosa Cell Tumor C04.557.475.750.656 
Luteoma C04.557.475.750.751 
Sertoli-Leydig Cell Tumor C04.557.475.750.847 
Leydig Cell Tumor C04.557.475.750.847.249 
Sertoli Cell Tumor C04.557.475.750.847.500 
Thecoma C04.557.475.750.875 
Neoplasms, Nerve Tissue C04.557.580 
Meningioma C04.557.580.520 
Nerve Sheath Neoplasms C04.557.580.600 
Neurilemmoma C04.557.580.600.290 
Neurofibroma C04.557.580.600.580 
Neurofibroma, Plexiform C04.557.580.600.580.585 
Neurofibromatoses C04.557.580.600.580.590 
Neurofibromatosis 1 C04.557.580.600.580.590.650 





Neuroma, Acoustic C04.557.580.600.610.595.610 
Neurofibromatosis 2 C04.557.580.600.610.595.610.500 
Neurothekeoma C04.557.580.600.625 
Neuroectodermal Tumors C04.557.580.625 
Craniopharyngioma C04.557.580.625.200 





Optic Nerve Glioma C04.557.580.625.600.380.080.667 
Ependymoma C04.557.580.625.600.380.290 





Optic Nerve Glioma C04.557.580.625.600.380.795 
Neurocytoma C04.557.580.625.600.580 
Neuroectodermal Tumors, Primitive C04.557.580.625.600.590 
Medulloblastoma C04.557.580.625.600.590.500 
Neuroectodermal Tumors, Primitive, Peripheral C04.557.580.625.600.590.650 
Neuroblastoma C04.557.580.625.600.590.650.550 




Neuroectodermal Tumor, Melanotic C04.557.580.625.630 
Neuroendocrine Tumors C04.557.580.625.650 
Adenoma, Acidophil C04.557.580.625.650.025 
Adenoma, Basophil C04.557.580.625.650.075 
Adenoma, Chromophobe C04.557.580.625.650.095 
Apudoma C04.557.580.625.650.135 
Carcinoid Tumor C04.557.580.625.650.200 
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Malignant Carcinoid Syndrome C04.557.580.625.650.200.500 
Carcinoid Heart Disease C04.557.580.625.650.200.500.205 
Carcinoma, Neuroendocrine C04.557.580.625.650.240 
Carcinoma, Medullary C04.557.580.625.650.240.315 
Carcinoma, Merkel Cell C04.557.580.625.650.240.325 
Melanoma C04.557.580.625.650.510 
Hutchinson's Melanotic Freckle C04.557.580.625.650.510.385 
Melanoma, Amelanotic C04.557.580.625.650.510.515 
Melanoma, Experimental C04.557.580.625.650.510.525 
Neurilemmoma C04.557.580.625.650.595 
Neuroma, Acoustic C04.557.580.625.650.595.610 
Paraganglioma C04.557.580.625.650.700 
Paraganglioma, Extra-Adrenal C04.557.580.625.650.700.705 
Carotid Body Tumor C04.557.580.625.650.700.705.220 
Glomus Jugulare Tumor C04.557.580.625.650.700.705.340 
Glomus Tympanicum Tumor C04.557.580.625.650.700.705.360 
Pheochromocytoma C04.557.580.625.650.700.725 
Neoplasms, Plasma Cell C04.557.595 
Multiple Myeloma C04.557.595.500 
Leukemia, Plasma Cell C04.557.595.500.500 
Plasmacytoma C04.557.595.600 
Waldenstrom Macroglobulinemia C04.557.595.925 
Neoplasms, Vascular Tissue C04.557.645 
Angiofibroma C04.557.645.100 
Angiokeratoma C04.557.645.115 
Glomus Tumor C04.557.645.350 
Hemangioma C04.557.645.375 
Central Nervous System Venous Angioma C04.557.645.375.185 
Hemangioendothelioma C04.557.645.375.370 
Hemangioendothelioma, Epithelioid C04.557.645.375.370.380 
Hemangioma, Capillary C04.557.645.375.380 
Hemangioblastoma C04.557.645.375.380.370 
Hemangioma, Cavernous C04.557.645.375.385 
Hemangioma, Cavernous, Central Nervous System C04.557.645.375.385.500 
Kasabach-Merritt Syndrome C04.557.645.375.617 




Sarcoma, Kaposi C04.557.645.750 
Nevi and Melanomas C04.557.665 
Melanoma C04.557.665.510 
Hutchinson's Melanotic Freckle C04.557.665.510.385 
Melanoma, Amelanotic C04.557.665.510.515 
Melanoma, Experimental C04.557.665.510.525 
Nevus C04.557.665.560 
Dysplastic Nevus Syndrome C04.557.665.560.260 
Nevus, Halo C04.557.665.560.580 
Nevus, Intradermal C04.557.665.560.590 
Nevus, Pigmented C04.557.665.560.615 
Mongolian Spot C04.557.665.560.615.530 
Nevus, Blue C04.557.665.560.615.550 
Nevus of Ota C04.557.665.560.615.585 
Nevus, Spindle Cell C04.557.665.560.615.625 
Nevus, Epithelioid and Spindle Cell C04.557.665.560.615.625.585 
Nevus, Sebaceous of Jadassohn C04.557.665.560.700 
Odontogenic Tumors C04.557.695 
Ameloblastoma C04.557.695.065 
Cementoma C04.557.695.210 
Odontogenic Cyst, Calcifying C04.557.695.605 
Odontogenic Tumor, Squamous C04.557.695.607 
Odontoma C04.557.695.610 
Neoplasms by Site C04.588 
Abdominal Neoplasms C04.588.033 
Peritoneal Neoplasms C04.588.033.513 
Retroperitoneal Neoplasms C04.588.033.731 
Sister Mary Joseph's Nodule C04.588.033.740 
Anal Gland Neoplasms C04.588.083 
Bone Neoplasms C04.588.149 
Adamantinoma C04.588.149.030 
Femoral Neoplasms C04.588.149.276 
Skull Neoplasms C04.588.149.721 
Jaw Neoplasms C04.588.149.721.450 
Mandibular Neoplasms C04.588.149.721.450.583 
Maxillary Neoplasms C04.588.149.721.450.601 
Palatal Neoplasms C04.588.149.721.450.692 
Nose Neoplasms C04.588.149.721.600 
Orbital Neoplasms C04.588.149.721.656 
Skull Base Neoplasms C04.588.149.721.828 
Spinal Neoplasms C04.588.149.828 
Breast Neoplasms C04.588.180 
OHE and SPRU Report for Cancer Research UK 
March 2014 
 
 136  
Breast Neoplasms, Male C04.588.180.260 
Carcinoma, Ductal, Breast C04.588.180.390 
Hereditary Breast and Ovarian Cancer Syndrome C04.588.180.483 
Inflammatory Breast Neoplasms C04.588.180.576 
Digestive System Neoplasms C04.588.274 
Biliary Tract Neoplasms C04.588.274.120 
Bile Duct Neoplasms C04.588.274.120.250 
Common Bile Duct Neoplasms C04.588.274.120.250.250 
Gallbladder Neoplasms C04.588.274.120.401 
Gastrointestinal Neoplasms C04.588.274.476 
Esophageal Neoplasms C04.588.274.476.205 
Intestinal Neoplasms C04.588.274.476.411 
Cecal Neoplasms C04.588.274.476.411.184 
Appendiceal Neoplasms C04.588.274.476.411.184.290 
Colorectal Neoplasms C04.588.274.476.411.307 
Adenomatous Polyposis Coli C04.588.274.476.411.307.089 
Gardner Syndrome C04.588.274.476.411.307.089.393 
Colonic Neoplasms C04.588.274.476.411.307.180 
Adenomatous Polyposis Coli C04.588.274.476.411.307.180.089 
Gardner Syndrome C04.588.274.476.411.307.180.089.500 
Sigmoid Neoplasms C04.588.274.476.411.307.180.800 
Colorectal Neoplasms, Hereditary Nonpolyposis C04.588.274.476.411.307.190 
Rectal Neoplasms C04.588.274.476.411.307.790 
Anus Neoplasms C04.588.274.476.411.307.790.040 
Anal Gland Neoplasms C04.588.274.476.411.307.790.040.040 
Duodenal Neoplasms C04.588.274.476.411.445 
Ileal Neoplasms C04.588.274.476.411.501 
Jejunal Neoplasms C04.588.274.476.411.523 
Stomach Neoplasms C04.588.274.476.767 
Liver Neoplasms C04.588.274.623 
Adenoma, Liver Cell C04.588.274.623.040 
Carcinoma, Hepatocellular C04.588.274.623.160 
Liver Neoplasms, Experimental C04.588.274.623.460 
Pancreatic Neoplasms C04.588.274.761 
Adenoma, Islet Cell C04.588.274.761.249 
Insulinoma C04.588.274.761.249.500 





Carcinoma, Pancreatic Ductal C04.588.274.761.750 
Peritoneal Neoplasms C04.588.274.780 
Endocrine Gland Neoplasms C04.588.322 
Adrenal Gland Neoplasms C04.588.322.078 
Adrenal Cortex Neoplasms C04.588.322.078.265 
Adrenocortical Adenoma C04.588.322.078.265.500 
Adrenocortical Carcinoma C04.588.322.078.265.750 
Multiple Endocrine Neoplasia C04.588.322.400 
Multiple Endocrine Neoplasia Type 1 C04.588.322.400.500 
Multiple Endocrine Neoplasia Type 2a C04.588.322.400.505 
Multiple Endocrine Neoplasia Type 2b C04.588.322.400.510 
Ovarian Neoplasms C04.588.322.455 
Granulosa Cell Tumor C04.588.322.455.398 
Hereditary Breast and Ovarian Cancer Syndrome C04.588.322.455.431 
Luteoma C04.588.322.455.464 
Meigs Syndrome C04.588.322.455.531 
Sertoli-Leydig Cell Tumor C04.588.322.455.648 
Thecoma C04.588.322.455.765 
Pancreatic Neoplasms C04.588.322.475 
Adenoma, Islet Cell C04.588.322.475.249 
Insulinoma C04.588.322.475.249.500 





Carcinoma, Pancreatic Ductal C04.588.322.475.750 
Paraneoplastic Endocrine Syndromes C04.588.322.490 
Parathyroid Neoplasms C04.588.322.525 
Pituitary Neoplasms C04.588.322.609 
ACTH-Secreting Pituitary Adenoma C04.588.322.609.145 
Nelson Syndrome C04.588.322.609.145.500 
Growth Hormone-Secreting Pituitary Adenoma C04.588.322.609.292 
Prolactinoma C04.588.322.609.792 
Testicular Neoplasms C04.588.322.762 
Sertoli-Leydig Cell Tumor C04.588.322.762.500 
Leydig Cell Tumor C04.588.322.762.500.249 
Sertoli Cell Tumor C04.588.322.762.500.500 
Thyroid Neoplasms C04.588.322.894 
Thyroid Nodule C04.588.322.894.800 
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Eye Neoplasms C04.588.364 
Conjunctival Neoplasms C04.588.364.235 
Orbital Neoplasms C04.588.364.659 
Paraneoplastic Syndromes, Ocular C04.588.364.738 
Retinal Neoplasms C04.588.364.818 
Retinoblastoma C04.588.364.818.760 
Uveal Neoplasms C04.588.364.978 
Choroid Neoplasms C04.588.364.978.223 
Iris Neoplasms C04.588.364.978.400 
Head and Neck Neoplasms C04.588.443 
Esophageal Neoplasms C04.588.443.353 
Facial Neoplasms C04.588.443.392 
Eyelid Neoplasms C04.588.443.392.500 
Mouth Neoplasms C04.588.443.591 
Gingival Neoplasms C04.588.443.591.402 
Leukoplakia, Oral C04.588.443.591.545 
Leukoplakia, Hairy C04.588.443.591.545.500 
Lip Neoplasms C04.588.443.591.550 
Palatal Neoplasms C04.588.443.591.692 
Salivary Gland Neoplasms C04.588.443.591.824 
Parotid Neoplasms C04.588.443.591.824.695 
Sublingual Gland Neoplasms C04.588.443.591.824.882 
Submandibular Gland Neoplasms C04.588.443.591.824.885 
Tongue Neoplasms C04.588.443.591.925 
Otorhinolaryngologic Neoplasms C04.588.443.665 
Ear Neoplasms C04.588.443.665.312 
Laryngeal Neoplasms C04.588.443.665.481 
Nose Neoplasms C04.588.443.665.650 
Paranasal Sinus Neoplasms C04.588.443.665.650.693 
Maxillary Sinus Neoplasms C04.588.443.665.650.693.575 
Pharyngeal Neoplasms C04.588.443.665.710 
Hypopharyngeal Neoplasms C04.588.443.665.710.485 
Nasopharyngeal Neoplasms C04.588.443.665.710.650 
Oropharyngeal Neoplasms C04.588.443.665.710.684 
Tonsillar Neoplasms C04.588.443.665.710.684.800 
Parathyroid Neoplasms C04.588.443.680 
Thyroid Neoplasms C04.588.443.915 
Thyroid Nodule C04.588.443.915.800 
Tracheal Neoplasms C04.588.443.925 
Hematologic Neoplasms C04.588.448 
Bone Marrow Neoplasms C04.588.448.200 
Mammary Neoplasms, Animal C04.588.531 
Mammary Neoplasms, Experimental C04.588.531.500 
Nervous System Neoplasms C04.588.614 
Central Nervous System Neoplasms C04.588.614.250 
Brain Neoplasms C04.588.614.250.195 
Cerebral Ventricle Neoplasms C04.588.614.250.195.205 
Choroid Plexus Neoplasms C04.588.614.250.195.205.200 
Papilloma, Choroid Plexus C04.588.614.250.195.205.200.500 
Infratentorial Neoplasms C04.588.614.250.195.411 
Brain Stem Neoplasms C04.588.614.250.195.411.100 
Cerebellar Neoplasms C04.588.614.250.195.411.211 
Neurocytoma C04.588.614.250.195.648 
Pinealoma C04.588.614.250.195.766 
Supratentorial Neoplasms C04.588.614.250.195.885 
Hypothalamic Neoplasms C04.588.614.250.195.885.500 
Pallister-Hall Syndrome C04.588.614.250.195.885.500.299 
Pituitary Neoplasms C04.588.614.250.195.885.500.600 
Central Nervous System Cysts C04.588.614.250.387 
Arachnoid Cysts C04.588.614.250.387.100 
Colloid Cysts C04.588.614.250.387.200 
Meningeal Neoplasms C04.588.614.250.580 
Meningeal Carcinomatosis C04.588.614.250.580.150 
Meningioma C04.588.614.250.580.500 
Spinal Cord Neoplasms C04.588.614.250.803 
Epidural Neoplasms C04.588.614.250.803.342 
Cranial Nerve Neoplasms C04.588.614.300 
Optic Nerve Neoplasms C04.588.614.300.600 
Optic Nerve Glioma C04.588.614.300.600.600 
Paraneoplastic Syndromes, Nervous System C04.588.614.550 
Anti-N-Methyl-D-Aspartate Receptor Encephalitis C04.588.614.550.112 
Lambert-Eaton Myasthenic Syndrome C04.588.614.550.225 
Limbic Encephalitis C04.588.614.550.450 
Myelitis, Transverse C04.588.614.550.550 
Opsoclonus-Myoclonus Syndrome C04.588.614.550.600 
Paraneoplastic Cerebellar Degeneration C04.588.614.550.650 
Paraneoplastic Polyneuropathy C04.588.614.550.700 
Peripheral Nervous System Neoplasms C04.588.614.596 
Cranial Nerve Neoplasms C04.588.614.596.240 
Neuroma, Acoustic C04.588.614.596.240.015 
Optic Nerve Neoplasms C04.588.614.596.240.240 
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Optic Nerve Glioma C04.588.614.596.240.240.500 
Pelvic Neoplasms C04.588.699 
Skin Neoplasms C04.588.805 
Acanthoma C04.588.805.040 
Sebaceous Gland Neoplasms C04.588.805.578 
Muir-Torre Syndrome C04.588.805.578.500 
Sweat Gland Neoplasms C04.588.805.776 
Soft Tissue Neoplasms C04.588.839 
Muscle Neoplasms C04.588.839.500 
Vascular Neoplasms C04.588.839.750 
Splenic Neoplasms C04.588.842 
Thoracic Neoplasms C04.588.894 
Heart Neoplasms C04.588.894.309 
Carney Complex C04.588.894.309.500 
Mediastinal Neoplasms C04.588.894.479 
Respiratory Tract Neoplasms C04.588.894.797 
Lung Neoplasms C04.588.894.797.520 
Bronchial Neoplasms C04.588.894.797.520.109 
Carcinoma, Bronchogenic C04.588.894.797.520.109.220 
Carcinoma, Non-Small-Cell Lung C04.588.894.797.520.109.220.249 
Small Cell Lung Carcinoma C04.588.894.797.520.109.220.624 
Multiple Pulmonary Nodules C04.588.894.797.520.237 
Pancoast Syndrome C04.588.894.797.520.734 
Pulmonary Blastoma C04.588.894.797.520.867 
Pulmonary Sclerosing Hemangioma C04.588.894.797.520.933 
Solitary Pulmonary Nodule C04.588.894.797.520.966 
Pleural Neoplasms C04.588.894.797.640 
Pleural Effusion, Malignant C04.588.894.797.640.700 
Solitary Fibrous Tumor, Pleural C04.588.894.797.640.800 
Tracheal Neoplasms C04.588.894.797.760 
Thymus Neoplasms C04.588.894.949 
Thymoma C04.588.894.949.500 
Urogenital Neoplasms C04.588.945 
Genital Neoplasms, Female C04.588.945.418 
Fallopian Tube Neoplasms C04.588.945.418.365 
Uterine Neoplasms C04.588.945.418.948 
Endometrial Neoplasms C04.588.945.418.948.585 
Carcinoma, Endometrioid C04.588.945.418.948.585.124 
Uterine Cervical Neoplasms C04.588.945.418.948.850 
Vaginal Neoplasms C04.588.945.418.955 
Vulvar Neoplasms C04.588.945.418.968 
Genital Neoplasms, Male C04.588.945.440 
Penile Neoplasms C04.588.945.440.715 
Prostatic Neoplasms C04.588.945.440.770 
Testicular Neoplasms C04.588.945.440.915 
Sertoli-Leydig Cell Tumor C04.588.945.440.915.500 
Leydig Cell Tumor C04.588.945.440.915.500.249 
Sertoli Cell Tumor C04.588.945.440.915.500.500 
Urologic Neoplasms C04.588.945.947 
Kidney Neoplasms C04.588.945.947.535 
Carcinoma, Renal Cell C04.588.945.947.535.160 
Wilms Tumor C04.588.945.947.535.585 
Denys-Drash Syndrome C04.588.945.947.535.585.220 
WAGR Syndrome C04.588.945.947.535.585.950 
Nephroma, Mesoblastic C04.588.945.947.535.790 
Ureteral Neoplasms C04.588.945.947.940 
Urethral Neoplasms C04.588.945.947.945 
Urinary Bladder Neoplasms C04.588.945.947.960 
Venereal Tumors, Veterinary C04.588.945.956 
Neoplasms, Experimental C04.619 
Carcinoma 256, Walker C04.619.045 
Carcinoma, Brown-Pearce C04.619.124 
Carcinoma, Ehrlich Tumor C04.619.169 
Carcinoma, Krebs 2 C04.619.214 
Carcinoma, Lewis Lung C04.619.230 
Leukemia, Experimental C04.619.531 
Avian Leukosis C04.619.531.216 
Leukemia L1210 C04.619.531.594 
Leukemia L5178 C04.619.531.602 
Leukemia P388 C04.619.531.782 
Liver Neoplasms, Experimental C04.619.540 
Mammary Neoplasms, Experimental C04.619.590 
Melanoma, Experimental C04.619.600 
Sarcoma, Experimental C04.619.857 
Sarcoma 37 C04.619.857.573 
Sarcoma 180 C04.619.857.656 
Sarcoma, Avian C04.619.857.800 
Sarcoma, Yoshida C04.619.857.822 
Tumor Virus Infections C04.619.935 
Avian Leukosis C04.619.935.120 
Epstein-Barr Virus Infections C04.619.935.313 
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Burkitt Lymphoma C04.619.935.313.165 
Marek Disease C04.619.935.489 
Sarcoma, Avian C04.619.935.800 
Neoplasms, Hormone-Dependent C04.626 
Neoplasms, Multiple Primary C04.651 
Hamartoma Syndrome, Multiple C04.651.435 
Proteus Syndrome C04.651.435.500 
Multiple Endocrine Neoplasia C04.651.600 
Multiple Endocrine Neoplasia Type 1 C04.651.600.500 
Multiple Endocrine Neoplasia Type 2a C04.651.600.505 
Multiple Endocrine Neoplasia Type 2b C04.651.600.510 
Tuberous Sclerosis C04.651.800 
Neoplasms, Post-Traumatic C04.666 
Neoplasms, Radiation-Induced C04.682 
Leukemia, Radiation-Induced C04.682.512 
Neoplasms, Second Primary C04.692 
Neoplastic Processes C04.697 
Anaplasia C04.697.045 
Cell Transformation, Neoplastic C04.697.152 
Blast Crisis C04.697.152.110 
Cell Transformation, Viral C04.697.152.160 
Cocarcinogenesis C04.697.160 
Neoplasm Invasiveness C04.697.645 
Leukemic Infiltration C04.697.645.500 
Neoplasm Metastasis C04.697.650 
Lymphatic Metastasis C04.697.650.560 
Neoplasm Micrometastasis C04.697.650.695 
Neoplasm Seeding C04.697.650.830 
Neoplasms, Unknown Primary C04.697.650.895 
Neoplastic Cells, Circulating C04.697.650.900 
Neoplasm Recurrence, Local C04.697.655 
Neoplasm Regression, Spontaneous C04.697.670 
Neoplasm, Residual C04.697.700 
Neoplastic Syndromes, Hereditary C04.700 
Adenomatous Polyposis Coli C04.700.100 
Gardner Syndrome C04.700.100.392 
Basal Cell Nevus Syndrome C04.700.175 
Birt-Hogg-Dube Syndrome C04.700.212 
Colorectal Neoplasms, Hereditary Nonpolyposis C04.700.250 
Lynch Syndrome II C04.700.250.500 
Muir-Torre Syndrome C04.700.250.500.500 
Dysplastic Nevus Syndrome C04.700.305 
Exostoses, Multiple Hereditary C04.700.330 
Hamartoma Syndrome, Multiple C04.700.435 
Hereditary Breast and Ovarian Cancer Syndrome C04.700.517 
Li-Fraumeni Syndrome C04.700.600 
Multiple Endocrine Neoplasia C04.700.630 
Multiple Endocrine Neoplasia Type 1 C04.700.630.500 
Multiple Endocrine Neoplasia Type 2a C04.700.630.505 
Multiple Endocrine Neoplasia Type 2b C04.700.630.510 
Tuberous Sclerosis C04.700.632 
Wilms Tumor C04.700.635 
Denys-Drash Syndrome C04.700.635.220 
WAGR Syndrome C04.700.635.950 
Neurofibromatoses C04.700.645 
Neurofibromatosis 1 C04.700.645.650 
Neurofibromatosis 2 C04.700.645.655 
Peutz-Jeghers Syndrome C04.700.705 
Paraneoplastic Syndromes C04.730 
Paraneoplastic Endocrine Syndromes C04.730.713 
ACTH Syndrome, Ectopic C04.730.713.317 
Zollinger-Ellison Syndrome C04.730.713.988 
Paraneoplastic Syndromes, Nervous System C04.730.856 
Anti-N-Methyl-D-Aspartate Receptor Encephalitis C04.730.856.112 
Lambert-Eaton Myasthenic Syndrome C04.730.856.225 
Limbic Encephalitis C04.730.856.437 
Myelitis, Transverse C04.730.856.543 
Opsoclonus-Myoclonus Syndrome C04.730.856.596 
Paraneoplastic Cerebellar Degeneration C04.730.856.650 
Paraneoplastic Polyneuropathy C04.730.856.700 
Paraneoplastic Syndromes, Ocular C04.730.900 
Precancerous Conditions C04.834 
Aberrant Crypt Foci C04.834.020 
Erythroplasia C04.834.288 
Keratosis, Actinic C04.834.450 
Leukoplakia C04.834.512 
Leukoplakia, Oral C04.834.512.513 
Leukoplakia, Hairy C04.834.512.513.500 
Lymphomatoid Granulomatosis C04.834.567 
Preleukemia C04.834.770 
Uterine Cervical Dysplasia C04.834.818 
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Xeroderma Pigmentosum C04.834.867 
Pregnancy Complications, Neoplastic C04.850 
Trophoblastic Neoplasms C04.850.908 
Gestational Trophoblastic Disease C04.850.908.416 
Choriocarcinoma C04.850.908.416.186 
Trophoblastic Tumor, Placental Site C04.850.908.416.186.875 
Hydatidiform Mole C04.850.908.416.750 
Hydatidiform Mole, Invasive C04.850.908.416.750.500 
Tumor Virus Infections C04.925 
Avian Leukosis C04.925.120 
Carcinoma, Merkel Cell C04.925.216 
Epstein-Barr Virus Infections C04.925.313 
Burkitt Lymphoma C04.925.313.165 
Marek Disease C04.925.489 
Sarcoma, Avian C04.925.700 
Warts C04.925.744 
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Appendix to Chapter 4 - Screenshots from survey 
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